Towards the total synthesis of thiopeptide antibiotics by Glover, Christian
Towards the total synthesis 
of thiopeptide antibiotics
A thesis submitted to Cardiff University 
By
Christian Glover 
BSc (Hons.), MRSC
In Candidature of 
Doctor of Philosophy
July 2006
School of Chemistry 
Cardiff University
UMI Number: U584849
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U584849
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
<P(u<D. ‘Jfiesis 2006
DECLARATION
This work has not previously been accepted in substance for any degree and is not being 
concurrently submitted in candidature of any degree.
Signed ........................
D «te ..2 i . z £ : L r . £ . £ ...........
STATEMENT ONE
This thesis is the result of my own investigations, except where other wise stated. Other sources 
are acknowledged by footnotes giving explicit references.
Signed .^ tt ... ^  t-. TfrT....
2 . 1  - © T  ~ g G>Date.
STATEMENT TWO
I herby give my consent for my thesis, if accepted, to be available for photocopying and for inter- 
library loan, and for the title and summary to be made available to outside organisations.
Signed TT...........
Date........
(pfL<D. Thesis 2006
This thesis is dedicated to Arron.
<Ph.<D. Thesis 2006
ABSTRACT
The Bohlmann-Rahtz intermediates (aminodienones) have provided a viable route to 2,3,6- 
trisubstituted and 2,3,5,6-tetrasubstituted pyridines (a substitution pattern hitherto unreported for 
Bohlmann-Rahtz intermediates), using new mild facile reaction conditions. These new methods 
provide the potential for both complimentary and independent pathways to access many of the 
thiopeptide antibiotics as well as other pyridine containing natural products. Degradation studies 
of thiopeptide antibiotics have led to the isolation of fragments that help in the structural 
elucidation of the parent molecules. Our efforts to synthesize degradation fragments from 
thiopeptide antibiotics have led to the total synthesis of the methyl sulfomycinate 39 in 9 steps 
from H-Thr-OMe and 15% overall yield, sulfomycinic amide 38, sulfomycinine 37 and the 
synthesis of saramycetic acid I 47, the latter in 9 steps and 11% overall yield. Furthermore 
progress towards the total synthesis of micrococcin Pi has demonstrated that enamine and 
alkynone precursors to the Bohlmann-Rahtz pyridine synthesis are viable intermediates en route 
to the core of micrococcin Pi.
iii
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/>-TsOH p~T oluenesulphonic acid
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RT Room Temperature
Ser Serine
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Subsp. Sub species
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1 The Bohlmann-Rahtz pyridine synthesis
1.1 Discovery
Many different methods for the synthesis of pyridines are available, encompassing a number of
prominent procedures that have earned their inventors great recognition in tribute to the discoveiy 
of useful heterocyclic methodology. Invariably these procedures are judged on a number of 
familiar criteria: efficiency, selectivity (including regio-, chemo- and even stereoselectivity), 
substrate tolerance, opportunities for diversity, atom economy, ecological value, etc. However, 
inevitably, with so many varied routes to these targets being unearthed throughout the years, some 
transformations following their discoveiy, in spite of having the potential to satisfy most if not all 
of the criteria, become largely forgotten. The Bohlmann-Rahtz pyridine synthesis, first reported 
in 1957,1 until very recently was one such procedure.
Trisubstituted pyridines are synthesized in a two-step procedure by the reaction of enamines 1 
and alkynyl ketones or aldehydes, 2, (Scheme 1). Note that throughout this document the R group 
number system corresponds to the final position that a given R group is located around the 
pyridine ring. Bohlmann and Rahtz observed that the condensation of ethyl (3-aminocrotonate la, 
2-aminopent-2-ene-4-one lb, or (3-aminocrotonitrile lc  and l-phenylprop-2-yn-l-one 2a, 
but-3-yn-2-one 2b, or propargylic aldehyde 2c is completely regioselective and proceeds by 
Michael addition and enamine C-alkylation to give an aminodiene intermediate 3 that can be 
isolated in high yield. In a subsequent procedure, heating intermediates 3 to a temperature of 
120-170 °C, induces spontaneous cyclodehydration (presumably via isomerisation of double 
bond geometry) to give 2,3,6-trisubstituted pyridines I-VI in excellent overall yield and with 
total regiocontrol. Although it is related to the corresponding reaction of enamines with enones 
and hence to the well-known Hantzsch dihydropyridine synthesis,2 the use of ynones leads to an 
heteroaromatic product directly thus obviating the need for a final aromatizing oxidative step.3
Scheme 1. The traditional Bohlmann-Rahtz pyridine synthesis
EtOH O
50 °C, 5 h 120-170 °C
Neat
1a-c 3 l-VII
I, R2=Me, R3=COMe, Re=H; II, R2=Me, R3=COMe, R*=Me;
HI, R2=Me, R3=CN, R®=Me; IV, R2=Me, R3=CN, R®=H;
V, R^Ph, R3=CN, R6=Me; VI, R2=Me, R3=C02Et, R®=H;
1
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1.2 Recent improvements in methodology
Within the last decade the potential of the Bohlmann-Rahtz pyridine synthesis has began to be 
unravelled. Bagley and co-workers have published numerous works regarding methodology 
improvement, including a range of cataylsis and solvent effects, tandem processes and microwave 
technology. The immediate result of these works is the identification of modified Bohlmann- 
Rahtz procedures that offer a growing range of tri— and tetrasubstituted pyridines that are regio-, 
chemo- and even stereospecific. Moreover the modified procedures offer the potential for greater 
application in synthetic chemistry due to milder, improved reaction conditions compared to the 
original Bohlmann-Rahtz pyridine synthesis. This chapter will review the contributions made 
from the literature since Bohlmann-Rahtz first discovered the reaction in 1957 (including much 
of the authors findings for completeness).
1.2.1 Use of catalysts and solvents
Avoiding the use of high cyclodehydration temperatures, extending this protocol for use in the 
synthesis of tetrasubstituted pyridines and developing a single one-step experimental procedure 
would increase the scope and utility of the Bohlmann-Rahtz reaction.4 In order to investigate 
these improvements, intermediate aminodienone 3a was prepared by standard Bohlmann-Rahtz 
conditions,1,4 from ethyl p-aminocrotonate la  and but-3-yn-2-one 2a in ethanol (EtOH) at 50 
°C, to give the pure cyclodehydration precursor in 98% yield following purification. However, 
due to shortages in the availability of butynone 2a, concerns about its volatility and in order to 
expand the scope of viable substrates, an alternative route to intermediate 3a was sought. To that 
end a mixture of ethyl p-aminocrotonate la  and 4-(trimethylsilyl)but-3-yn-2-one 2d, which was 
cheaper than 2a, more readily available and less volatile, was heated to 50 °C in a range of 
different solvents (Table l).4
Table 1. Michael addition of la  and 2d in various solvents at 50 °C
Solvent Result Solvent Result
Acetone No reaction Diethyl ether No reaction
Toluene No reaction Neat No reaction
Dichlorom ethane No reaction Dimethylsulphoxide Product 3a (59%)
Chloroform No reaction Ethanol Product 3a (98%)
In most cases only unreacted starting materials were isolated from the reaction mixture. 
However, when a solution of crotonate la  and butynone 2d was stirred in ethanol (the original 
solvent of choice from Bohlmann-Rahtz conditions) or dimethylsulphoxide (DMSO) at 50 °C for
2
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5 hours, aminodienone 3a was produced in 98 or 59% yield, respectively, after purification. 
Clearly the reaction favours the use of polar solvents, although ethanol, a protic solvent gave 
better yields over DMSO, an aprotic solvent In both of these solvents protodesilylation occurred 
spontaneously under the reaction conditions, and, in view of the improvements that this 
transformation offered over the original procedure, this became the method of choice for the 
synthesis of aminodienone 3a (Scheme 2).
Scheme 2. Synthesis of aminodiene 3a using a modified alkynone 2d
o
H2N C02Et II EtOH
^  + ~ X/  IMS 50 °C, 5 h, (98%) H2N ' ^
1a 2d 3a
In view of the fact that the Bohlmann-Rahtz synthesis requires a Michael donor (enamine) and a 
Michael acceptor (alkynone), it was postulated that the use of a Bronsted5 (namely acetic acid, 
AcOH) or Lewis acid6 may promote the conjugate addition as well as double bond isomerisation 
of the intermediate aminodienone 3a, thus facilitating spontaneous cyclodehydration to pyridine 
4a. Furthermore the presence of an acid could enable the reaction to proceed at lower temperature 
than traditional Bohlmann-Rahtz conditions, by acid catalysed protonation of double bonds 
present in the intermediate 3a thus obviating the need to isolate the conjugate addition product 
Validation of this hypothesis was achieved by stirring aminodienone 3a in toluene (PhMe) and 
acetic acid (5:1) to generate pyridine 4a in excellent yield and without need for further 
purification (Scheme 3). After verifying the potential for Bronsted acid catalysis from the
Scheme 3. Pyridine formation from aminodienone by Bronsted acid catalysis
o
Et02C . ^ ^ X ^  PhMe, AcOH Et02c
H N 50 °C (100%)
3a 4a
aminodienone to the corresponding pyridine, a range of enaminoesters la , c -f  was prepared 
according to a modified literature procedure.7 These were reacted with alkynones 2b, d -f  at 50 
°C in toluene-acetic acid (5:1) to provide highly functionalised pyridines 4b-g in a single step in
3
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good to excellent yield (Bagley, Dale and Bower. Scheme 4, Table 2).5 Only pyridines 4h-j 
failed to form, which in examples 4h and 4j was attributed to acid catalyzed decomposition of the 
starting enamine. In the case of 4i the reaction is likely to have failed due to the lack of an ethyl 
ester/electron withdrawing group in the R6 position of the alkynone, which clearly enhances the 
formation of 4d (95% yield).
Table 2. Synthesis of functionalised 
pyridines 4b-j
Scheme 4. Synthesis of functionalised pyridines 
4b-g
H2N R3 2  PhMe, AcOH r3
r 2 r 4 ^  50 °C (65- 95%) R2A N^ k R6
1a, c-4 2b, d-f 4b-g
R2 R3 R4 R6 Product Yield%
Me Et02C Me3Si Me 4b 79
Me Et02C Et Me 4c 85
Me Et02C Ph EtOzC 4d 95
Ph Et02C Et Me 4e 65
Ph Et02C H Me 4f 73
2-furyl Et02C Me3Si Me 4g 80
Me NC Et Me 4h 0
Me Et02C Ph Me 4i 0
Me ' Bu02C Me3Si Me 4i 0
Investigations by the Bagley research group during 2001 and 2002 using Lewis acid catalysis as 
an alternative to Bronsted acids have been shown to be largely successful. Aminodiene 3a was 
treated with various Lewis acids at low temperature, but the use of BF3*OEt2 failed to generate 
even a trace of pyridine 4a, whereas zinc(II) bromide (15 mol%) or ferric chloride (10 mol%) in 
dichloromethane (CH2CI2) did promote the cyclodehydration. Full conversion was achieved 
when a solution of aminodienone 3a and zinc(II) bromide (15 mol%) in toluene was heated at 
reflux for 5 hours, to give pyridine 4a as the only product in 59% yield (Scheme 5,6 Table 34).
Scheme 5. Pyridine formation from 
aminodienone by Lewis acid catalysis
H2N
PhMe, (59%)
3a
Table 3. Lewis acid catalysed cyclodehydration 
of aminodiene 3a
Lewis acid Conditions Compound
°  ZnBr2(15 mol%) E tO ^ ^ / s . BF3.OEt2 CH2C12, reflux, 4 h 3a
FeCI2 (10 mol%) CH2C12, reflux, 3.5 h 3a, 4a (3:2)
Sc(OTf)3 (100 mol%) CH2C12, reflux, 24 h 3a, 4a (3:2)
ZnBr2 (100 mol%) CH2C12, reflux, 24 h 4a (46%)
ZnBr2 (15 mol%) PhMe, reflux, 5 h 4a (59%)
Since it was clear that Lewis acid catalysis had the potential to generate the pyridine at relatively 
low temperatures from the corresponding aminodienone, a range of different Lewis acids was 
screened in a known Bohlmann-Rahtz heteroannelation reaction in an effort to provide an
4
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alternative one step procedure. A solution of ethyl (3-aminocrotonate la  and 4— 
(trimethylsilyl)but-3-yn-2-one 2d in either dichloromethane or toluene was heated at reflux 
overnight in the presence of 10-100 mol% of a Lewis acid. No reaction occurred in die absence 
of a Lewis acid catalyst, but in all other experiments pyridine 4a was formed, showing that Lewis 
acid catalysis promotes both the Michael addition and subsequent spontaneous cyclodehydration. 
The best conditions found used either ytterbium(III) triflate (20 mol%), refluxing in toluene for 18 
hours (90% yield) or zinc(II) bromide (15 mol%), refluxing in toluene for 5 hours (90% yield). 
Neither the aminodienone intermediate 3a or its trimethylsilyl derivative were isolated from any 
of these reactions, leading to the conclusion that, in the presence of a Lewis acid, 
cyclodehydration occurred spontaneously under the reaction conditions. It is worthy noting 
however, mechanistic studies for the use of Lewis acids were not undertaken and it is assumed 
that Lewis acid catalysis is facilitated by co ordination to any of the heteroatoms present in the 
reactant material resulting in isomerisation and cyclodehydration.
In order to extend the scope of this methodology a series of enamines la,c,f,g and alkynones 2b, 
d-g was submitted to the Lewis acid catalyzed heteroannelation conditions (Scheme 6), in toluene 
in the presence of either zinc(II) bromide or ytterbium(III) triflate (Table 4).
Scheme 6. Lewis acid catalysed procedure for the one step synthesis 
of tri- or tetra-substituted pyridines
o r4
H2N R3 II Yb(OTf)3orZnBr2 (15 mol%)
- ^ r ' R 6 ----------------------------------------
R R4 PhMe, reflux, 5-24 h (32-90%) R2'  "NT 'R e
1a,b,f,g 2b, d-g 4b-f, n>-p
Table 4. Heteroannelation catalysed by Yb(OTF)3 or ZnBr2
R2 R3 R4 R6 Product
Yb(OTf)3 ZnBr2 
Yield% Yield%
Me Et02C Me3Si Me 4b 90“ 90
Me Et02C Et Me 4c 83 67
Me Et02C Ph Et02C 4d 55 85b
Me Et02C Me3Si Et02C 4m 33 44°
Ph Et02C Et Me 4e 32 72
Ph Et02C Ph Me 4n 68 62
Ph Et02C Ph Et02C 4o 44 65
Ph EtOzC H Me 4f 58 70
2-Pyridyl Et02C Et Me 4P 68 62
a20 moI% catalyst was used. 10 mol% catalyst was used.c protodesilylated 
pyridine (R4 = H) was also isolated.
5
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In general, reactions catalyzed by zinc(II) bromide were faster (complete after 5 hours as opposed 
to 24 hours) and more efficient than those conducted in the presence of ytterbium(III) triflate, 
with a few notable exceptions (such as the synthesis of pyridine 4c, 4n and 4p). It is noteworthy 
to consider that in the case of zinc(II) bromide it transpires that protodesilylation occurs giving 
rise to the trisubstituted pyridine (entry 4m) in one step from the enamine and alkynone rather 
than two steps in accordance with the traditional Bohlmann-Rahtz procedure. Furthermore 
control over the retention of the silyl group in the R4 position could provide a useful synthetic 
strategy to alternative functionality at the R4 position, although methodology to employ this 
feature has not been explored to date. In all cases the Lewis acid catalyzed Bohlmann-Rahtz 
heteroannelation reaction was successful to give tri— and tetrasubstituted pyridines 4b-f, m-p,6 
following spontaneous cyclodehydration.
Bagley, Dale and Bower explored milder conditions for conjugate addition/cyclodehydration that 
would be compatible with acid sensitive substrates, enamines la , c-e and alkynones 2d,e,g were 
stirred in toluene at 50 °C in the presence of amberlyst 15 ion exchange resin for 26 hours 
(Scheme 7). Although reactions involving f3-aminocrotonitrile lc  were unsuccessful, in all other 
experiments pyridines 4g, 1-1 were formed in good yield (Table 5).5 This procedure is a 
compelling alternative to those already discussed due to the simplicity of the purification, 
requiring filtration only to yield the pure product4 It was interesting to note that in the case of 
pyridine 4g, protodesilylation did not occur in the presence of an acidic resin, yet for pyridine 4j, 
protodesilylation was spontaneous under the reaction conditions.
Scheme 7. Synthesis of pyridines using amberlyst 
15 ion exchange resin as the catalyst
h2n r3
>=/
R2
1a, c-e
Me Amberlyst 15 
PhMe, 50 °C 
(71-83%)
Table 5. Synthesis of functionalised 
pyridines using amberlyst 15 ion exchange 
resin
2d,e,g
R2 N Me
4fl,W
R2 R3 R4 Product Yield%
2-Furyl Et02C Me3Si 4g 73
Me Et02C Ph 4i 71
Me 'Bu0 2C MejSi 4j 83a
Me 'Bu0 2C Et 4k 80
Me 'Bu0 2C Ph 41 76
‘Product is the protodesilylated pyridine (R =H).
With the success of these facile one-step cyclodehydration reactions firmly established, it 
remained to investigate the scope and versatility of the Bronsted and Lewis acid catalyzed 
methods and compare these with the original Bohlmann-Rahtz reaction. Ethyl ff-am inocrotonate 
la  was reacted with either but-3-yn-2-one 2a or l-phenylprop-2-yn-l-one 2b using the 
traditional two-step procedure (Method A) and both of the new one-step acid-catalyzed methods
6
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(Methods B and C) (Scheme 8). All three reactions gave the desired products 4a and 4q in 
excellent yield, the least efficient route to pyridine 4q being the traditional two-step procedure 
(Table 6). In contrast the direct study shows that the one-step reactions using but-3-yn-2-one 
2a, although more convenient, were still not as efficient as the traditional Bohlmann-Rahtz 
method for this transformation.4 Clearly the yield of products in the original procedure is equally 
as good as the two catalyzed procedures however, the new methods represented a breakthrough in 
the search for improved Bohlmann-Rahtz methodology. The catalyzed procedures are suitable 
for application in synthesis of tri- and tetrasubstituted pyridines that avoided the very harsh 
conditions of the traditional Bohlmann-Rahtz procedure. More importantly, these new methods 
can be conducted in a single preparative step and combine favourable facile reaction conditions.
Scheme 8. Bohlmann-Rahtz methodology 
comparisons
1a 2a,b 4a,q
Reagents and conditions: (A) EtOH, 50 °C, 5 h; then 140-160 
°C; (B) PhMe-AcOH (5:1), 50 °C, 5.5 h; (C) ZnBr2 (15 mol%). 
PhMe, reflux, 5.5 h.
Table 6. Comparing the three 
Bohlmann-Rahtz heteroannelation methods
Alkynone R Method Catalyst Product Yield%
2a Me A None 4a 85
2a Me B AcOH 4a 77
2a Me C ZnBr2 4a 65
2b Ph A None 4q 80
2b Ph B AcOH 4q 85
2b Ph C ZnBr2 4q 86
In order to overcome problems of poor substrate availability (enamines 1), to improve the facility 
of the whole process and in the discovery of new multiple-component condensation reactions in 
heterocyclic chemistiy, Bagley, Dale and Bower proposed that a three-component condensation 
of a p~keto ester 5, alkynone 2 and ammonia would provide a much more efficient approach 
towards poly-substituted pyridines 4.® To that end ethyl acetoacetate 5a was reacted with either 
one or two equivalents of hex-3-yn-2-one 2e and ammonium acetate in toluene, heated at reflux 
in the presence of either acetic acid or zinc(II) bromide (Scheme 9). In all cases, pyridine 4c was 
formed directly as the only reaction product and isolated in good to excellent yield in a single 
preparative step with total regiocontrol. With two equivalents of alkynone, the zinc(II) bromide 
catalyzed reaction gave the best result (96%), compared to acetic acid (78%), although when 
using one equivalent of alkynone the acetic acid method gave slightly higher yields (68% vs. 
66%).
7
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Scheme 9. Three component condensation reaction
NH4OAc, PhMe Et
O CQ2Et 9 ^  acid cat. 20 h Et02C ^ J L
/  + (67-96%)
5a 2e 4c
The scope of this reaction was established with a range of different (3-keto esters 5a-d and 
alkynones 2b,d,e,g, which were heated at reflux in toluene under different acidic conditions in the 
presence of an excess of ammonium acetate (Scheme 10).
Scheme 10. Three component condensation reaction of [3-keto ester subset 5, alkynone subset 2 
and ammonia under acid conditions
0 0  9  ?h F*
II J f  Et =  f  E tO z C ^ ^ L  E t O z C ^ X  E t O z C ^ ^
M e ^ - ^ O E t  Me J  ]  Y  I  T  1
M e ^ N  Me PhA N Me M e ^ N  Me
4i 4n 4a
TMS Ph Et
EtOzC^A. feuOzC^A. <Bu02CnA .
reflux, acid cat. Me N Me Me N Me Me N Me
j? 9 TMS —
Me/ ^ ' / T>fBu Me 4b 4| 4d
5a 2e,
.00 0 _    / /I I Ph- —  X
P h ^ ^ ^ O E t  Me
5b 2g NH4OAc, PhMe
5C 2d
BocHN s
N Me
BocHN s
5d 2b
In all of the cases that were investigated (Table 7), pyridine 4 or 6 was isolated in good to 
excellent yield (55-96%). Again it was observed that the reaction of 4-(trimethylsilyl)but-3-yn- 
2-one 2d in the presence of zinc(II) bromide resulted in partial protodesilylation to give a mixture 
of pyridine 4a and 4b (entry 5). However, by employing acetic acid as the catalyst, only a single 
pyridine 4a was produced in 75% yield (entry 6). The use of terf-butyl acetoacetate 5c, caused a 
reduction in the efficiency of the process but pyridine 41 was still isolated in moderate yield under 
zinc(II) bromide or Amberlyst 15 ion exchange resin catalyzed conditions (entries 7 and 9). The 
synthesis of the N-terZ-butoxycarbonyl-protected valine derived thiazolyl-pyridine 6, resulted in 
a high degree of racemisation in toluene (entry 11), and is likely due to protonation of the nitrogen
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Table 7. Examining the scope of the three-component heteroannelation reaction
Entry P-Keto ester 5 Alkynone 2 Equivalents of 5 Acid catalyst Product Yield%“
1 5a It 2 ZnBr2 4c 96
2 5a 2g 2 AcOH 4i 80
3 5b 2g 2 AcOH 4n 70
4 5b 2g 2 ZnBr2 4n 88
5 5a 2d 2 ZnBr2 4a,4b (44:56) 55
6 5a 2d 2 AcOH 4a 75
7 5c 2c 3 ZnBr2 41 49
8 5c 2g 2 Amberlyst 15 41 53
9 5c 2g 3 Amberlyst 15 41 60
10 5c 2e 3 Amberlyst 15 4k 55
11 5d 2b 3 AcOH 6 68b
12 5d 2b 3 AcOH 6 71bc
a Isolated yield of product. b Formed in 78% ee (entry 11) or 98% ee (entry 12) by HPLC analysis 
[Chiralpak AD column, hexane-IPA (92:8)].c Reflux in benzene.
atom in the thiazole ring allowing Cl raceimsation however, by switching to benzene these 
problems were reduced (entiy 12).8
Clearly the results from Bagley, Dale and Bower are showing that there is scope to react small, 
cheap and commercially available 1,3 dicarbonyls with alkynones to generate a range of 
differentially substituted pyridines in good yield, using methods developed within the group. 
Furthermore it is remarkable that simple 1,3 dicarbonyl compounds that have potentially 
numerous reactive pathways can undergo Michael addition with an alkynone generating pyridine 
6 in good to excellent yield.
Later in 2004 Bagley, Chapemari and Xiong reacted a range of acid sensitive precursors in order 
to complement the multi-step three-component condensation process described above, for the 
synthesis of pyridine heterocycles. To that end, 1,3-dicarbonyl compounds 7a-c and alkynones 
2a,d,e,g-i were heated in ethanol at reflux for 24 hours in the presence of one or ten equivalents 
of ammonium acetate (Scheme 11).
Scheme 11. Mild acid-free three-component condensation 
reaction
NH4OAc, EtOH r4
o. COR3 II reflux, 24 h R3OC
Me^N'^R6 
4
Me r4 ^  (38-98%)
9
Chapter 1 <Ph.<D. Thesis 2006 Introduction
In most experiments (Table 8), pyridine 4b,c,i-k,q-s,u,x was generated in moderate to excellent 
yield (entries 1-12, 38-98%) as the only regioisomeric product. When 4-{trimethylsilyl)but-3- 
yn-2-one 2d was used, only protodesilylated pyridines 4b and 4j were obtained. It is not clear 
why 10 equivalents of ammonium acetate result in a lower yield of product (entry 10) then when 
using 1 equivalent of the same reagent (entry 9). Clearly pyridine 4u is generated in good yield 
without significant degradation when 10 equivalents of ammonium acetate are used (entry 8). It 
would be worth repeating these reactions comparing in each case the yields obtained when using 
1 or 10 equivalents of ammonium acetate. However reaction was successful for a wide variety of 
substrates and constitutes a mild acid-free method incorporating a protic solvent, for the synthesis 
of poly-substituted pyridines from simple acid sensitive reagents.9
Table 8. Examining the scope of the three-component reaction
Entry _ . _ Alkynone 2 Compound 7 ' R R3 R4 R5
NH,OAc
Equivalents3
Product Yield%b
1 7a 2a Me OEt H Ph 10 4q 95°
2 7a 2h Me OEt H T-CJHUCl 10 4r 84c
3 7a 2i Me OEt H ^-QJ^OMe 10 4s 90c
4 7a 2e Me OEt Et Me 10 4c 38
5 7a 2d Me OEt TMS Me 1 4b 90d
6 7a 2d Me OEt TMS Me 10 4b 90d
7 7a 2g Me OEt Ph Me 1 4i 51
8 7b 2a Me O'Bu H Ph 10 4u 89
9 7b 2e Me O'Bu Et Me 1 4k 71
10 7b 2e Me O'Bu Et Me 10 4k 63
11 7b 2d Me O'Bu TMS Me 1 4j 98d
12 7c 2a Me n h 2 H Ph 1 4x 98
awith respect to 1,3-dicarbonyl compounds. bIsolated yield after purification. cAn excess (1.7 equiv.) of 
1,3-dicarbonyl compound was employed. dOnly protodesilylated pyridine (R4=H) was produced.
1.2.2 Tandem oxidation-heteroannelation Bohlmann-Rahtz reaction
The in situ tandem oxidation-heteroannelation of propargylic alcohols 8 with either o-  
iodoxybenzoic acid (IBX) or manganese dioxide provides a new one-pot tandem route to 
nitrogen-containing heteroaromatic building blocks, affecting up to four separate synthetic 
transformations in a single preparative step. Many of these heteroannelation reactions proceed in 
good yield and with total regiocontrol of the pyridine 4 from either enamine 1 or p-keto ester 5 
precursors.
Optimum conditions involved heating enamine la  and a one-fold excess of both die propargylic 
alcohol 8a and o-iodoxybenzoic acid in dimethylsulphoxide-acetic acid (5:1) at 65 °C overnight 
to give pyridine 4a in 70% isolated yield after purification on silica. With successful conditions
10
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established for the tandem process, a range of propargylic alcohols 8a-e was submitted to in situ 
oxidation-heteroannelation with ethyl P~aminocrotonate la and 0 -iodoxybenzoic acid (Scheme 
12).
Scheme 12. Tandem oxidation-heteroannelation of proparglic alcohols
ov R3 
R2
7a-c
8a-f
nh3
OH IBX or Mn02 
R6 ”
H2N R3 
R2
1a,e,f
R4" 
2a,b,e,h-j
R4
Michael addition R 3 / L
 I ICyclodehydration R2 N R6
4a,q-s,u,y,z
It was found that the efficiency of the reaction was highly dependent upon the nature of the 
propargylic alcohol, generating pyridines 4a,q-s,y in 20-73% yield (Table 9a). It was postulated
Table 9a. In situ tandem oxidation-heteroannelation of propogylic alcohols
Using IBX
p-Keto ester gnamjne j A ^ h ol 8 R2 R3 R4 R6 Pyridine 4 Yield%
— la 8a Me Et02C H Ph 4q 70
- la 8b Me Et02C H 4*-C6H4Cl 4r 73
- la 8c Me Et02C H 4,-C6H4OMe 4s 53
- la 8d Me Et02C H Me 4a 45
— la 8e Me Et02C H Et 4y 20
that the moderate yield of the one-pot process was a consequence of the oxidative degradation of 
ethyl p-aminocrotonate la  under the reaction conditions. When a range of propargylic alcohols 
8a-d,f, p-keto esters 5a-c and ammonium acetate were heated at reflux in toluene-acetic acid 
(5:1) in the presence of manganese dioxide (Scheme 12), pyridines 4a,a’,r,s,u,z were formed 
directly in up to 96% yield and with total regiocontrol (Table 9b). Thus, generating the enamine 
in situ by the condensation of the corresponding p-keto ester 5 and ammonia helped to reduced 
enamine degradation and furthermore establish a new and highly facile 3-component
cyclocondensation route to these targets that affects four transformations in a single preparative
.  10step.
11
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Table 9b. In situ tandem oxidation-heteroannelation of propogylic alcohols
Using MnOz
5a - 8d Me Et02C H Me 4a 66
5a - 8b Me Et02C H 4’-C6H4Cl 4r %
5a - 8c Me Et02C H 4’-C6H4OMe 4s 85
5c - 8f Me 'Bu0 2C Et Me 4z 60
5c - 8a Me 'Bu0 2C H Ph 4u 73
5b — 8b Ph Et02C H 4’-C6H4CI 4a' 63
1.2.3 Microwave synthesis
In recent years, the use of microwave dielectric heating in synthetic chemistry has emerged as a 
valuable alternative to conventional conductive heating methods.11 This field of chemistry is 
known as ‘Microwave-assisted organic synthesis’ (MAOS) and with no direct contact between 
the chemical reactants and the energy source, microwave-assisted chemistry can be more 
efficient, in terms of the energy used, capable of providing faster heating rates and able to 
improve reaction rates and efficiencies. Recent advances in instrumentation, with the introduction 
of dedicated ovens for organic synthesis that focus microwaves in a monomodal cavity, have 
increased the popularity and reproducibility of microwave chemistry, increasing the methodology 
available for the development of new synthetic reactions and optimisation of existing 
procedures.12
In order to expand further the versatility of the Bohlmann-Rahtz reaction and in an effort to 
explore a microwave-assisted process, Bagley, Lunn and Xiong carried out investigations in a 
self-tuning single-mode CEM Discover™ Focused Synthesizer.13 A solution of ethyl p - 
aminocrotonate la  and an excess of phenylpropynone 2a (Scheme 13) was stirred in toluene or
Scheme 13. One-pot heteroannelation of enamine la  with alkynones 
2 under microwave or thermal conditions to yield pyridines 4
O R
H2NI C °2Et + ^ A r6 Solvent, 170 °C Et02C y L
/  R4 ^  microwave or thermal
1a 2a,d,e,g-i 4afcfi,<f-s
dimethylsulphoxide (solvents that have been shown to promote Michael addition in traditional 
Bohlmann-Rahtz reactions in previous studies) at 170 °C by irradiating initially at 150 or 160 W 
(Table 10). The reaction conducted in toluene was found to be sluggish at best, providing
12
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pyridine 4q in 76% yield after 90 min (entry 1). The use of a more polar solvent, 
dimethylsulphoxide that can couple more efficiently with microwave radiation, resulted in a more
Table 10. Reactions in a sealed tube using either 
microwave-assisited conditions or conductive heating
Entry
microwave
yield%“
Thermal
yield%a
Solvent Time (min)
1 76 54 PhMe 90
2 87 80 DMSO 20
3 80 33 PhMe-ZnBr2 (15 mol%) 10
4 98 95 PhMe-AcOH (5:1) 10
5 84 93 Neat 20
‘ Isolated yield after purification on silica
rapid reaction. Michael addition and spontaneous cyclodehydration was complete after 20 
min, to give pyridine 4q in 87% yield (entiy 2). As expected reactions conducted in toluene were 
accelerated dramatically by the presence of zinc(II) bromide (15 mol%) providing the product in 
80% yield after 10 min at 170 °C (entry 3). However, the optimum conditions for this 
transformation employed acetic acid. After stirring for 10 min in a solution of toluene-acetic acid 
(5:1) at 170 °C (initial power 160 W), pyridine 4q was isolated in 98% yield (entry 4). In a bid to 
explore solventless reaction conditions, a mixture of enamine la  and alkynone 2a was irradiated 
at 170 °C (initial power 150 W) for 20 min to give pyridine 4q in 84% yield (entry 5). Although 
this final experiment was not as efficient, the use of solventless reaction conditions does have 
some intrinsic ecological and chemical value by virtue of no waste solvent and thus ultimately no 
direct impact to the environment.
All of the microwave-assisted experiments facilitated both Michael addition and 
cyclodehydration in a single synthetic step and generated the target pyridine 4q as a single 
regioisomer. A further investigation was carried out in order to establish if traditional conductive 
heating methods could also facilitate a similar one-pot transformation. The same range of 
reactions was repeated in a sealed tube using an oil bath as an external heat source and the results 
were compared with the microwave-assisted reactions (Table 10). In almost all of the 
experiments, the microwave-assisted conditions gave the product in a higher yield, in particular 
for the reaction conducted in toluene in the presence of 15 mol% of zinc(II) bromide (entry 3), 
although in many instances comparable yields were obtained (entries 2, 4 and 5). Only the 
solventless reaction (entry 5) gave superior results in a Carius tube, this is likely due to the lack of 
energy transfer when neat reagents were radiated under microwave conditions.
13
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In order to test the scope of the microwave-assisted reaction, ethyl (3-aminocrotonate la  was 
reacted with alkynones 2a,d,e,g-i by irradiating a solution of the reagents in dimethylsulphoxide 
at 170 °C for 20 min (Scheme 13). In all of the experiments, a single regioisomeric pyridine was 
formed (Table 11). Although the efficiency of the reaction of enamine la  and 4-phenylbutynone 
2g was low (entry l),13 this alkynone has been noted to be problematic in similar heteroannelation 
reactions.5
Table 11. Microwave-assisited synthesis of pyridines 4
Entry Alkynone 2 R4 R6 Product 4 Yield%*
1 2g Ph Me 4i 24
2 2d H Me 4a 62
3 2e Et Me 4c 94
4 2a H Ph 4q 87
5 2ta H 4'-C6H4Cl 4r 75
6 2i H 4'-C6H4OMe 4s 66
a Isolated yield after purification on silica
The remaining microwave-assisted reactions gave pyridine products 4a,c,q-s in good yields after 
purification by column chromatography (entries 2-6), illustrating that the one-pot microwave- 
assisted Bohlmann-Rahtz reaction represents a simple and highly-expedient route to tri- and 
tetrasubstituted pyridines. This is a new and extremely simple method to facilitate Michael 
addition and cyclodehydration in only 20 min using microwave irradiation, which proceeds with 
total control of regiochemistry.13 Nonetheless the microwave procedures described are only 
viable to substrates that can tolerate the high temperature conditions and therefore should not be 
considered a general method.
1.2.4 Continuous flow reactors
From the early experiments in domestic ovens to the use of multimodal or monomodal 
instruments designed for organic synthesis, this technology has been implemented worldwide and 
continues to be developed.12 However, although modem monomodal instruments dedicated for 
MAOS are very successful in small scale operations, efforts to process this technology in 
continuous flow (CF) reactors are frustrated by the physical limitations of microwave heating, 
with a penetration depth of only a few centimetres and the limited dimensions of the standing 
wave cavity. Current technology has attempted to overcome these obstacles with conventional 
instruments by the use of CF reactors that pump the reagents through a small heated coil that
14
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winds in and out of the cavity, with external temperature monitoring using a fibre optic sensor, 
although alternative methods, such as using a multimode batch or CF reactor, have also been 
described.
More recently a new method for carrying out MAOS under CF processing using a commercially 
available monomodal microwave synthesizer has been described by Bagley, Jenkins, Lubinu, 
Mason and Wood.14 The flow cell was inserted into the cavity o f a self-tunable monomodal 
microwave synthesizer, irradiated, and stabilized at the required reaction temperature through 
moderation o f microwave power before the introduction of reagents into the reactor (Figure 1). 
The reactant, aminodienone 3b is dissolved in solvent and clearly introduced into the microwave 
through a small tube (~5 mm internal diameter) via the HPLC pump, the solvent/reactant mixture 
passes through a layer o f sand (~10 g) (necessaiy to minimize dispersion and create micro- 
channels) via the small tube and is affected by microwave irradiation in the reaction chamber at 
the bottom of the reaction tube (10 ml volume). As a result o f the continuous pressure exerted by 
the HPLC pump and that o f the back pressure regulator (sand is stopped from escaping the 
reaction tube by the presence of two frits, shown in white) the reacting mixture is forced up the 
reaction tube. The mixture passes through the micro-channels in the sand and is collected in a 
flask and purified initially by column chromatography until the procedure is optimised such that 
the product, pyridine 4q can be isolated as a single product by simply evaporating off the solvent.
Figure 1. Schematic diagram of the CF microwave reactor
HPLC pump Back pressure 
regulatorBohlmann-Rahtz
Frit
Sand
MWMW
Frit ■ 
MW cavil
Reaction
chamber
Et02C.
Ph
Me' Ph
IR Sensor
3b
The development of a new microwave-assisted CF process shown above for the synthesis of 
pyridines based upon the Bohlmann-Rahtz reaction was one o f the first systems to be tested. 
Aminodienone 3b was prepared and cyclodehydrated with CF processing under homogeneous
15
processing rate, mmc
total energy,8 kJ
3 Batch experiment ir
reactor charged wit! 
microwave cavity.
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Additionally, CF reactions run at the same flow rate used less magnetron energy in a glass tube 
(method c) than in the Teflon heating coil (method b) (Table 12), demonstrating that a glass tube 
CF reactor offers (i) improved heating efficiency, (ii) the potential for operation on a large scale, 
(iii) successful transfer from batch (method a) to CF processing (method c), and (iv) improved 
performance over commercial Teflon heating coils. As a result of these findings based partially 
on the Bohlmann-Rahtz synthesis, the scene has been set to transfer the process technology to 
large-scale operations and ultimately to an industrial based process.
1.3 Applications
As a direct result of the increased awareness of the Bohlmann-Rahtz pyridine synthesis and due 
to improved Bohlmann-Rahtz experimental procedures, the application of this reaction to the 
synthesis of a variety of heterocyclic targets is now in evidence. These heterocycles not only 
include tri— and tetrasubstituted pyridines but also pyrido[2,3-e/Jpyrimidines in combinatorial 
libraries and as building blocks in natural product synthesis. Although the predominant 
contributor to the versatility of the Bohlmann-Rahtz pyridine synthesis remains Bagley and co­
workers, contributions from both Moody and Baldwin must be acknowledged.
1.3.1 Synthesis of pyrido[2,3-</Jpyrimidines and uracil derivatives
Pyrido[2,3-d]pyrimidine heterocycles (also known as 5-deazapteridines) have received much less 
attention in the literature in spite of their structural relationship to both pyridines and pterins, the 
latter isolated from the wing pigments of European butterflies as long ago as the nineteenth 
centuiy.15 Interest in pyrido[2,3-*/]pyrimidine derivatives has increased dramatically in recent 
years, based upon a diverse range of biological properties and the potential for folate antagonists16 
to elicit highly species-specific responses as antitumour,17 antibacterial,18 anti-inflammatory19 
and insecticidal agents.20
To continue interests in the synthesis of nitrogen-containing heterocycles, the development of 
new methods for the synthesis of highly-functionalised 5-deazapterins, by modifying the 
Bohlmann-Rahtz pyridine synthesis has been reported, for die rapid assembly of a targeted library 
of folate antagonists. Central to the approach was the need to develop a novel method, using 
readily available starting materials and simple experimental procedures, for the rapid synthesis of 
structurally diverse heterocycles with complete control of regiochemistry. Following the success 
of a number of modified Bohlmann-Rahtz conditions for the synthesis of pyridines,4"6,8 it was 
proposed by Bagley, Hughes, Lloyd and Powers that similar Michael addition-cyclodehydration 
strategies should be successful for the synthesis of highly functionalised 5-deazapteridine 
heterocycles.21
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Earlier work by Bagley, Dale, Hughes, Ohnesorge, Phillips and Bower showed that Lewis acid 
methodology could be applied to the synthesis of pyrido[2,3-*/Jpyrimidines 11 from the 
corresponding aminodienone pyrimidine derivative 10 or from pyrimidinone 9 and alkynone 
2d,k. The study showed that when a solution of aminodienone pyrimidine 10a or 10b and 
zinc(II) bromide (20 mol%) in dimethylsulphoxide was stirred overnight at 110 °C the 
heteroannelated product, 11a or l ib  respectively, was isolated in quantitative yield (Scheme 15). 
Furthermore when a solution of pyrimidinone 9 and either alkynone 2d or 2k in 
dimethylsulphoxide was stirred at 110 °C for 72 hours in the presence of either zinc(II) bromide 
(20 mol%) or ytterbium(III) triflate (20 mol%), the zinc(II) catalyzed reactions gave pure 
pyrido[2,3-</|pyrimidine lla ,b  in 92 and 89% yield, respectively, whereas the ytterbium(III) 
catalyzed process gave a slightly impure product lla ,b  in 94 and 91% respective yield (Scheme 
15).6
Scheme 15. Synthesis of pyrido[2,3-i/)pyrimidines lla ,b  using Lewis 
acid catalysis
II
h2n ^ n nh2
EtOH, RT, 72 h (99%)
O O
hnX ^ A r
HjN ^ N  NH2
TMS —  {  
R
2d R = Me.
2k R = C02Et
ZnBr2 or YbfOTffe (20 mol%)
DMSO, 110 °C. 72 h, (89-94%)
10a R = Me, 10b R = C02Et
DMSO, 
110 °C, 18 h
ZnBr2 or 
Yb(OTf)3
HX x
H2N N N" 'R
11a R = Me, 11b R = C02Et
The application of Bohlmann-Rathz methodology to the synthesis of pyridopyrimidones was 
expanded further by assessing the treatment of pyrimidinone 9 with one equivalent of alkynone 
(2b) in a range of solvents at room temperature or 50 °C according to standard conditions for 
Bohlmann-Rahtz pyridine synthesis (Table 13). The optimum conditions to facilitate the reaction 
involved stirring at room temperature, where the product yield was equal to (entries 1-3) or better 
than (entries 4-8) the corresponding process run at 50 °C. It is noteworthy that the choice of 
solvent had a large influence upon the course of die reaction. In experiments using acetone, 
acetonitrile or 1,2-dimethoxyethane (DME) at 50 °C, only a trace of Michael addition product
18
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Scheme 16. Summary of conditions to synthesize 11a
Reagents and conditions: (a) EtOH, MeOH or DMSO, 50 °C, 72 h (72- 
95%); (b) 180 °C (100%); (c) AeOH or DMF, 50 °C, 72 h (90-92%).
Bagley and Hughes set out to ascertain whether the methodology could be extended to provide a 
new general route to pyrido[2,3-*/lpyrimidine derivatives, pyrimidinone 9 was treated with a 
range of 4—substituted alkynones 2b,d-g,k at room temperature in a range of different solvents; 
acetic acid, ethanol, A^V-dimethylformamide or dimethylsulphoxide according to a number of 
procedures (A-D) (Scheme 17). Details of the optimum results are shown in Table 14.21
Scheme 17. Reaction of pyrimidinone 9 and alkynone 2c,d-g,k in different solvents by 
method A, B, C or D
V A) i. 72 h; ii. H20
rc, Jp B) i. 72 h; ii. H2 0; iii. 180 °C ^
R2  H2 N ^ S A n h 2  C) i. 72 h; ii. evaporate "  H2 N " S A n ^ R 2
D) i. 72 h; ii. evaporate; iii. 180 °C
2 c,d-f,k 9  1 1 a-d
It was found that the course of the reaction varied with the choice of alkynone and solvent. 
Alkynone substitution appeared to slow down the reaction, as evidenced by the presence of 
starting material after stirring at room temperature for 72 hours in dimethylsulphoxide or NJV- 
dimethylformamide (data not shown). The only reliable method, that tolerated a wide range of 
substituents, was by stirring pyrimidinone 9 with one equivalent of alkynone 2b,d-f,k in 
dimethylsulphoxide for 72 hours at either room temperature or 60 °C, followed by addition of 
water and filtration of the precipitated solid. As before, in cases where cyclodehydration did not 
occur spontaneously under the reaction conditions, pyridine annelation could then be affected by 
heating the resultant solid to 180 °C to give pyrido[2,3-cfJpyrimidine 11a or lib  in excellent yield 
(entries 3, 5-7). The purity of pyrido[2,3-JJpyrimidines lla -d  prepared by method A or B in 
dimethylsulphoxide (>95% by *H NMR) was much higher than similar reactions conducted in 
either ethanol or A^V-dimethylformamide and thus the use of this solvent became the method of 
choice for the synthesis of these heterocycles.
20
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Table 14. Reaction of pyrimidinone 9 with alkynones 2b,d-g,k in various solvents and under 
different reaction conditions
Entry 2 R1 R2 Solvent Method Temperature Product R1 R2 Yield%
1 2e Et Me DMSO A 60 °C 11c Et Me 84
2 2f Ph Et02C DMSO A RT lid Ph Et02C 79
3 2b H Me DMSO B RT 11a H Me 86“
4 2d TMS Me DMSO B RT 11a H Me 96a,b
5 2k TMS Et02C DMSO B 60 °C lib H EtOaC 95a.b
6 2d TMS Me DMF C 60 °C 11a H Me l\%h
7 2d TMS Me EtOH D 60 °C 11a H Me 96a,b
aCyclodehydration was facilitated by heating to 180 °C in a two-step process.b Spontaneous protodesilylation 
accompanied Michael addition.
The Michael addition and subsequent cyclodehydration of pyrimidinone 9 and a range of 
alkynones can generate pyrido[2,3-*/Jpyrimidines in excellent yield (optimum yield for 
preparation of l la -d  varies between 71 and 98%). This method is effective in a number of 
different solvents but is most reliable and versatile in dimethylsulphoxide. The experimental 
procedure is facile and lends itself well to combinatorial methods, requiring no further 
purification and providing the target heterocycles in one or two steps with total regiocontrol.21 
Bagley and Hughes also established successful Bohlmann-Rahtz conditions for the synthesis of 
pyridopyrimidine 13a from 6-aminouracil 12a and 4-(trimethylsilyl)-butynone 2d in 
dimethylsulphoxide at 110 °C for 72 hours in the presence of either zinc(II) bromide or 
ytterbium(III) triflate (20 mol%), to give the products in 60 and 52% yield, respectively (Scheme 
18). Further application of this reaction showed that 5-deazapterin 13b-i was generated in good 
yield from alkynones 2d,e,g,k and 6-aminouracils 12a-c (Scheme 18, Table 15). When 
trimethylsilyl-substituted alkynones 2d,k were reacted with uracils 12a,b (entries 1-4 and 7-10, 
Table 15) spontaneous protodesilylation accompanied Michael addition-cyclodehydration to 
generate pyridopyriinidines 13a,b,d,e (R5 = H). When these reactions were conducted either in 
the absence of a Lewis acid (entry 2 and 8) or at room temperature (entry 9) die efficiency of 
reaction was reduced. The optimum experimental conditions reacted uracils 12a-c with 
alkynones 2,e,g,k at 110 °C in the presence of zinc(II) bromide for 72 h to give products 13d-i in 
good yield (60-75%). Replacing zinc(II) bromide with ytterbium(Ill) triflate (entries 12 and 16) 
caused a small reduction in the efficiency of the cyclocondensation process. It was apparent that 
the Lewis acid catalyzed cyclocondensation was appropriate for a number of different alkynones 
and a range of uracil derivatives 12a-c.22
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Scheme 18. Reaction of 6-aminouracil 12a-c and alkynone 2d,e,g,k in 
DMSO with a Lewis acid catalyst
O O R 5
n< =  ,? r V S ______  ^ so-iio°c’72h___ .
R7 °  N i NH2 ZnBr2 orYb(OTf)3 O N , N R7
R1 R
2d,e,g,k 12a-c 13a-i
Table 15. Reaction of uracil 12a-c with alkynones 2d,e,g,k
Entry 12 R1 R3 2 R5 R7 Lewis acid Product Yield0/®8
1 12a H H 2d TMS Me ZnBr2 13a 60b
2 12b Me H 2d TMS Me None 13b 74b
3 12b Me H 2d TMS Me ZnBr2 13b 94b
4 12b Me H 2d TMS Me Yb(OTf)3 13b 90b
5° 12c Me Me 2d TMS Me ZnBr2 13c 53b
6C 12c Me Me 2d TMS Me Yb(OTf)3 13c 54b
7 12a H H 2k TMS Et02C ZnBr2 13d 60b
8 12b Me H 2k TMS Et02C None 13e 43b
9 12b Me H 2k TMS Et02C ZnBr2 13e 39bd
10 12b Me H 2k TMS Et02C ZnBr2 13e 65b
11 12b Me H 2e Et Me ZnBr2 13f 71
12 12b Me H 2e Et Me Yb(OTf)3 13f 68
13 12b Me H 2g Ph Me ZnBr2 13g 62
14 12c Me Me 2e Et Me None 13h 42
15 12c Me Me 2e Et Me ZnBr2 13h 75
16 12c Me Me 2e Et Me Yb(OTf)3 13h 72
17 12c Me Me 2g Ph Me ZnBr2 131 72
a Isolated yield. b Spontaneous protodesilylation accompanied the reaction (R5 = H). c Reactions were run over 96 
hours, isolating the Bohlmann-Rahtz intermediate only. d Reaction was carried out at room temperature.
The application of a number of modified Bohlmann-Rahtz procedures has led to new general 
methods for the synthesis of a number of potentially biologically active heterocycles based upon 
modified uracil derivatives that could be used for the preparation of diverse 5-deazapterin 
libraries as inhibitors of folate-dependent enzymes. Given the known difficulties surrounding 
these complex heterocycles (synthesis and handling) it is remarkable to see modified Bohlmann- 
Rahtz procedures being applied to the synthesis of these compounds in excellent yields using 
relatively simple methodology.
13.2 Combinatorial library synthesis
The development of new methods for the synthesis of heterocyclic compound libraries, both in 
solution and on solid phase, is an ever-expanding area in combinatorial chemistry. The
22
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application of the Bohlmann-Rahtz heteroannelation reaction has been successful for the 
combinatorial synthesis of a small pyridine library in solution, establishing the potential of this 
methodology in combinatorial chemistry.
In all of the reactions investigated, a complete pyridine libraiy was generated with vaiying 
product ratios (determined by integration of the !H NMR for the pyridine 4-H or 5-H resonances 
compared with the ]H NMR of pure pyridines isolated in previous studies) and high library purity 
(determined by reference to a known quantity of tetramethylsilane as an internal standard 
according to established methodology) using a simple acid-base extraction workup procedure. 
For example, an excess of ethyl [3-aminocrotonate la  was reacted with an equimolar mixture of 
three alkynones 2d,e,g which varied in the nature of the 4-substituent and that have been reported 
to react differently in heteroannelation processes. A small library of pyridines 4a-c,i (Scheme 19) 
was generated using either traditional Bohlmann-Rahtz conditions (method A), stirring in
Scheme 19. Combinatorial synthesis of pyridines 4a-c,i
,  r.4 -rm.o A) EtOH, 50 °C; then 160 °C R4 4aR4 = H
0  2a R = TMS p\ phMp-ArOH °C. FtfUO JL 4b R4 = TMSH2N C02Et + 2b R4  = Et B) PhM^cOH, 50 °C   E102C
/ ~ ^  Me 21R4 = Ph C) PhMe, ZnBr2, reflux " 1
1a
M e^N Me 4iR = Ph
acetic acid-toluene (method B), or the Lewis acid catalyzed heteroannelation process (method C) 
(Table 16). Using the traditional two step procedure (method A), heating the mixture to 50 °C in 
ethanol, isolating the intermediate, and then heating to 160 °C for 3 h to effect cyclodehydration, 
resulted in the isolation of four pyridines 4a-c, i with protodesilylation occurring throughout the 
course of reaction. With this in mind, die product ratio (R) was large and varied between 1 < R < 
25, although the overall yield and product purity were good. Some protodesilylation also 
accompanied the reaction conducted in toluene-acetic acid (method B) and although the product 
ratio (R) improved, varying between 1 < R < 8.3, the overall yield was low (30%). However, the 
Lewis acid-catalyzed conditions (method C) resulted in no protodesilylation and thus gave rise to 
three pyridines 4b,c,i in high purity, good overall yield, and in a product ratio (R) that only varied 
between 1 < R < 2. It was curious to note that the product ratios varied between the different 
heteroannelation procedures, as did the identity of the major product, indicating that the 
alkynones display different reactivity profiles according to the method used. The Lewis acid- 
catalyzed methods appeared to provide the best overall yield, product ratios, and libraiy purity for 
the solution phase combinatorial synthesis of pyridines from ethyl |3-aminocrotonate (la) in the 
Bohlmann-Rahtz synthesis.
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Table 16. Comparison of Bohlmann-Rahtz 
heteroannelation procedures for the combinatorial 
synthesis of pyridines 4a—c,i
Method Products Yield% Ratio Library
purity%
A 4a-c4 62 54:100:65:4 75
B 4a—c4 30 12:52:100:67 80
C 4b,c,i 64 100:73:50 86
This approach has the potential to access highly substituted and heavily functionalized pyridines 
directly from readily available starting materials without any need for subsequent purification and 
so should complement other published procedures for the solution phase combinatorial synthesis 
of pyridine libraries.
Simple low molecular weight heterocyclic molecules make ideal scaffolds on which to base the 
high throughput synthesis of libraries of drug-like compounds. Examples include the use of 
1,2,5-thiadiazolidin-3-one-l,l-dioxide and pyrimidine scaffolds in the synthesis of serine 
proteinase and kinase inhibitors respectively,24 and the use of simple pyridine scaffolds to 
generate libraries of inhibitors of HIV-1 protease and Factor Xa.25 In 2003, Moody and co- 
workers were involved in a programme designed to develop new heterocyclic scaffolds 14 for 
library synthesis, trisubstituted pyridines 15-17 containing two points of potential diversity were 
synthesized using Bohlmann-Rahtz methodology (Figure 2).
Figure 2. Pyridine scaffold 14 and corresponding trisubtituted pyridines 15-17
r2X'l'
EtO
N L' R3
OBn
O
E t0 X f \bochn-^A-nA^
EtO
BocN
14 15 16 17
R1, R2, R3  points of diversity; X = O,
NH; L = Linker
The conditions for the synthesis of pyridine 17 were optimised by the reaction of enamine 18 with 
butynone 2b in boiling ethanol to give product 17 in 77% yield. Hydrolysis of ester 17 gave acid 
19 that was then taken on to scale up. Following a design process directed towards drug-like 
products, acid 19 was coupled to a range of amines to provide 14 protected intermediates in 61-
24
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87% yield on a 100 mmol scale, that were then subjected to reaction with 148 carboxylic acids 
generating 2072 amides for drug screening (Scheme 20). In summary the use of modified 
Bohlmann-Rahtz methodology has been demonstrated in an efficient large scale synthesis of the 
pyridine scaffold 19 containing two points of diversity and applied in library synthesis.26
Scheme 20. Drug design library synthesis applying the Bohlmann-Rahtz pyridine synthesis
2bnh 2  o Further
modificationHO'EtOH EtO' Hydrolysis
'OEt Reflux, (77%)BocN
BocN BocN
drug screening
18 17 19
1 3 3  Natural product chemistry
Baldwin and co-workers previously reported that by stirring bis-acetylenes 20a-c with enamine 
21 in ethanol at reflux afforded the corresponding pyridines 22a-c in good isolated yield (Scheme 
21).
Scheme 21. Bohlmann-Rahtz reaction of bis-acetylenes 20a-c and enamine 21
O emu e k r1H2N C02Me V  EtOH.eh ■ a = Ph (85%)
Me R ' ^ ^ ' C O . E t  re"UX b = C5 H7  (75%)
R C°2 Et c = C4 H9  (78%)
2 1  2 0 a-c 2 2 a-c
The initial studies by Baldwin (shown above) clearly inspired the synthesis of the pyridine 
analogue derived from the natural product, azatyrosine 23. Heterocyclic a-amino acids 
azatyrosine 23, mimosine 24, and lathyrine 25 have been observed to display antibiotic, 
antitumor, wool growth and pollen growth inhibitory activities (Figure 3).27
Figure 3. Heterocyclic a-amino acids, azatyrosine 23, mimosine 24 and lathyrine 25
h° t x  i ° 2h ° n  ** X  co2h
L-Azatyrosine 23 L-Mimosine 24 L-Lathyrine 25
25
Chapter 1 <Ph.<D. Thesis 2006 Introduction
The condensation of alkynone 26 and 3-aminobut-2-enoic acid methyl ester 21 or 4-aminopent- 
3-en-2-one 27, in ethanolic solution at reflux, gave the corresponding trisubstituted pyridine, (3- 
alanines 28 and 29 in 81 and 91% yield respectively. Subsequent deprotection and purification by 
ion exchange chromatography afforded the free amino acids 30 and 31 as analogues of the a -  
amino acid L-azatyrosine (Scheme 22).28
Scheme 22. Bohlmann-Rahtz synthesis of analogues 30 and 31 of L-azatyrosine 23
H2N COzMe 
Me
21
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O'Bu
26
MeOzC 
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28
NHBoc Deprotection HO2 C 
Isolation 1
30
H2 N COMe
)= /Me
NHBoc 
O'Bu
MeOC
reflux, (91%) Me'
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The most significant application of the Bohlmann-Rahtz reaction is in the synthesis of thiopeptide 
antibiotics, a class of naturally occurring sulphur-containing, highly modified, macrocyclic 
peptides, nearly all of which inhibit protein synthesis in bacteria. Structurally, these antibiotics 
consist of a tri— or tetrasubstituted 6-membered nitrogen heterocycle clustered in a central 
polyazole domain in a macrocyclic framework of modified heterocyclic residues, including 
thiazoles, oxazoles, indoles, and dehydroamino acids. Notable examples include; thiostrepton 32, 
Sch 40832 33, micrococcin Pj 34 and nosiheptide 35 (Figure 4).19
These biologically active substances are secondary metabolites produced by actinomycetes, 
Gram-positive mycelial sporulating bacteria, largely of the genus Streptomyces that can be 
subdivided into 29 different antibiotic families containing well over 76 structurally distinct 
entities. Classification of the thiopeptide antibiotic families is achieved according to their 
structure and in particular, in the nature of the central heterocyclic domain. Essentially there are 
five distinct classes of these natural products, assigned based upon the oxidation state of the 
central pyridine/piperidine (Table 17). All of the series a and b thiopeptides can be identified by 
their piperidine or dehydropiperidine central heterocyclic domain, series c represents the smallest 
class of these natural products and to date is made up of only one thiopeptide antibiotic (Sch 
40832), possessing a unique central domain consisting of a frilly saturated piperidine heterocycle 
fused to a imidazoline ring. The series d  family is by far the largest of the series, making up 19 of
26
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Figure 4. Notable examples of the thiopeptide antibiotics representing different families
Sch 40832 33
HO. NH
NHThiostrepton A 32
HN
OHHN
X  / - 7<V  W n H NH /  
J r  H H Me I  H T ?
x P  h h o  o J m ^ h ^S-V .xNH
OH
HN
OHMe
NH
HO" NHHO.
NHMe
“ W
HO
'OH
HN,
HO
HN .OH
.0 o.
HN" "OH HN
HN Nosiheptide 35Micrococcin P1 34
NH
HO'
Table 17. Thiopeptide antibiotic families classified according to their central heterocyclic domain
series a andb series c series d series e
bryamycin (A-8506)* Sch 40832 A10255 promothiocin glycothiohexide a
Sch 18640(68-1147) amythiamicin AN3323 MJ347—81F4
siomycin beminamycin radamycin multhiomycinb
thiactin3 cyclothiazomycin sulfomycin nocathiacin
thiopeptin GE2270 thioactin nosiheptide
thiostrepton GE37468
geninthiocin
methylsulfomycin
micrococcin
promoinducin
thiocillin 
thiotipin 
thioxamycin 
YM-266183-4
S-54832
a Shown to be identical to thiostrepton. b Shown to be identical to nosiheptide.
the 29 different antibiotic families and containing a trisubstituted pyridine central domain. The 
series e thiopeptide antibiotics contain a 2,3,5,6-tetrasubstituted pyridine with a 5-hydroxy
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Scheme 25. Sturcture and degradation products of cyclothiazomycin 45
nh2
nh .oh
\  .NH HN
Cyclothiazomycin 46
6 NHCI, 110 °C, 18 h C02H
^-Lactam hydrolysate 46
°£>V'0"
Saramycetic add 47
The preparation of some of the unusual structural motifs present in cyclothiazomycin has attracted 
synthetic interest,35 but until recently the stereospecific synthesis of its y-amino acid central 
heterocyclic domain had not been addressed. In 2004, Bagley and Xiong approached the 
synthesis of y-lactam 46 by constructing the cyclothiazomycin central domain 52 utilizing a 
Bohlmann-Rahtz reaction to assemble the pyridine from acyclic precursors, starting from the 
corresponding amino acid 48 (Scheme 2G)?6 However, the effectiveness of a Bohlmann-Rahtz 
strategy, in this case relied upon the ready availability of chiral enamine 49, which needed to 
proceed through the heteroannelation without racemization. Reacting the known (/?)-{3-keto ester 
48s7 with ammonium acetate gave enamine 49; however, during its formation or purification, this 
chiral intermediate partially racemized on exposure to heat (ethanol at reflux), Bronsted acid 
(acetic acid), or silica gel and could only be isolated in 70% yield and 92% ee by carrying out the 
reaction at room temperature in ethanol and using the crude material without purification (a). The
Scheme 26. Synthesis of cyclothiazomycin central domain 52
s
Et° 2 Cv. a X 0 2Et b ° V ^ N; W t  Et°2c
BocHN L " 1    a * ™o  NH4 OAc B o c H N ^ k  p  ^  Me -H20
EtOH, 3 h Y  NH2  ==. -.1/ I .  MejJje t , 3 T h^ 1 I
(70%) Me y . s  Et02 C ^ y "
N ^  NH2
NHBoc C02Et
(R>-48(>99% ee) (R)-49(>92% ee) J (Ry-62(>92% ee)
Et02C {Ry- 51
SO
Bohlmann-Rahtz reaction of (/£)-{3-keto ester 48, enamine 49 and readily available propynone 50 
was further investigated by Bagley and Xiong in order to optimise conditions (Scheme 26, Table
30
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procedure, the total synthesis of y-lactam 46 was achieved in a remarkable 4 steps from readily 
available precursors in overall 30% yield and 88% ee.
Retrosynthetic studies of the thiopeptide amythiamicin A 53 provided a further application of the 
Bohlmann-Rahtz reaction by Michael addition-cyclodehydration of enamine 55 and alkynone 56 
(Scheme 27). Utilizing conditions successful for the synthesis of other pyridines, Michael 
addition of enamine 55 and alkynone 56 in ethanol followed by acetic acid-catalyzed 
cyclodehydration at 70 °C, gave the amythiamicin heterocyclic domain 57 with total regiocontrol 
in 85% yield and 93% ee. This work by Bagley, Dale, Jenkins and Bower, represents the first 
synthesis of the heterocyclic cluster of amythiamicin, in protected form, generated in only 9 steps 
and 18% overall yield from 54, and constitutes a rapid route to the amythiamicin antibiotic 
family.38
Scheme 27. Retrosynthetic analysis of amythiamycin A 53 and the forward
synthesis of the target domain 57
MeHN
SEMO'
target domain
HN
Amythiamycin A 53
EtOH, 60 °C, 
PhMe-AcOH, 70 °C, 
(85%) yield (93% ee)
Bohlmann-Rahtz 
pyridine synthesis
SEMO'
8  steps N/ /
21%
54
55
Promothiocin A 58 is a member of the series d  family of thiopeptide antibiotics and is isolated 
from Streptomyces sp. SF2741. Its structure was elucidated in 1994 by Yun, Hidaka, Furihata and 
Seto using NMR spectroscopy39 and although the stereochemistry of the natural product was not 
reported, it was assumed that the three stereogenic centres originated from natural L-amino acids. 
The synthesis of this thiopeptide antibiotic is not only one of the first examples to use a traditional
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oxidation of the aminodienone in order to access the series e core domain directly are not feasible. 
There is some scope to revisit this methodology at a later date particularly in view of the poor 
solvent choice for methods a-c, which is likely to be reacting with the oxidising reagents.
2.4.3 Further investigation of halo pyridines
The lack of promising results to access the series e core domain led us to reinvestigate the 
synthesis of halopyridines. Rather than using bromine as the halogen; we considered synthesizing 
pyridines bearing chlorine or iodine. In order to investigate halogenation, the corresponding N - 
halosuccinimide and aminodienone 3e was stirred in ethanol at 0 °C for 1 hour according to our 
previously reported method for bromocyclization9 (Scheme 43).
Scheme 43. Reaction of A—halosuccimides with aminodienone 3e
3e 89 X -  halogen 3e 4f
Reagents and conditions: (a) EtOH, 0 °C, /V-halosucdnimide, 1 h; (b) EtOH, 0 °C, AModosucdnimide, 1 h (100%).
Reaction of aminodienone 3e with AL-chlorosuccinimide (NCS) (method a) resulted in a complex 
mixture of crude products by *H NMR spectroscopy, no chloropyridine 89 was isolated and after 
purification only trace quantities of trisubstituted pyridine 4f could be identified. Surprisingly the 
same reaction using AModosuccinimide (NIS) (method b) returned only trisubstituted pyridine 4f 
and after purification a quantitative yield was recorded. No halopyridines were isolated using 
either method, however the method using TV-iodosuccinimide revealed an astonishing and 
unexpected result that could be used in the synthesis of the core pyridine domain of the series d  
thiopeptide antibiotics (2.1, Figure 5) and therefore demanded further investigation.
2.5 Series d thiopeptide antibiotics
Series d  thiopeptide antibiotics predominantly contain only one macrocyclic peptide loop centred 
around a 2,3,6-trisubstituted pyridine core domain clustered with thiazole and/or oxazole 
heterocycles with a peptide side chain consisting of heterocyclic or dehydrated amino acid 
residues attached at the 6-position of the pyridine ring. As well as being the dominant class of 
thiopeptide antibiotics they contain 49 distinct entities, which show diversity in structure and 
biological activity. Notable examples include the sulfomycins I—III 36a-c and the first reported
50
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thiopeptide antibiotic to be discovered in 1948, found in the sewage from the city of Oxford, 
micrococcin 34 (Figure 7).1
Figure 7. Examples of series d  thiopeptide antibiotics
Sulfomydn I, R = CH(OH)Me 36a 
Sulfomydn II, R = CH2Me 36b 
Sulfomydn III, R = CH2OH 36c
R
ho" ' \ . . . nh
HN^q
/ V 4 ^ 3 W*!"-■ HN j^P
^N H- yKX^ rfHN
HQ
W W "“o-NH hn—/ '
>->OH
HN
Micrococdn Pi 34
MeO HO
NH
It is noteworthy to discuss the function of the string of dehydroalanine residues (A) attached to the 
6-position of core pyridine domain found in the sulfoymicins 36a-c. So called dehydroalanine 
due to the fact that investigations have shown this string of residues is constructed 
biosynthetically from modified alanine amino acid residues.1 As revealed (Chapter One, 1.3.3) 
thiopeptide antibiotics are secondary metabolites from Actinomycetes, these organisms were once 
thought to be a part of the Fungi kingdom, indicating their need to produce antibiotics. Later it 
became clear that these organisms displayed features that were both eukaryotic (multi cellular 
organism) and prokaiyotic (single cellular organism) and as a result the antibiotics produced in 
defence of bacteria could endanger the Actinomycetes existence. In order to combat this self 
generated threat and regulate thiopeptide production many Actinomycetes exhibit this string of 
dehydroalanine residues. The mechanisms that bring about this resistance and regulation are 
beyond the scope of this work, however, suffice to know that the dehydroalanine residues (A) is 
recognised and docks into specific sites on cell proteins that in turn bring about regulation and 
resistance. Dehydroalanine residues are not exclusive to the series d  thiopeptide antibiotics and 
can be seen in many other thiopeptides. In fact the cell proteins involved in the recognition of the 
dehydroalanine residues are known collectively as TIP (Thiostrepton Induced Proteins). Clearly
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Chapter 2 <Pk<D. Thesis 2006 <R$suks and(Discussion
then thiostrepton a series b, thiopeptide antibiotic contains the dehydroalanine resiudes 
recognition site and work that elucidated the function of this feature was originally carried out on 
thiostrepton.14 The fact that not all the thiopeptide antibiotics contain the dehydroalanine residues 
is a clear indication that mechanisms for antibiotic resistance and regulation in Actinomycetes are 
numerous and complex.1
2.5.1 NIS mediated cydodehydration
In order to investigate the AModosuccinimide mediated cydodehydration, aminodienones 3a-f 
were stirred with 1.2 equivalents of TV-iodosuccinimide in ethanol at 0 °C for one hour. The
reaction was evaporated in vacuo and purified by column chromatography to reveal
cyclodehydrated products 4a,f,q—t in good to excellent yield (Scheme 44).
Scheme 44. NIS mediated cydodehydration
H2N R 3 EtOH, nis, 0  °c. 1 h
r2 \ = ^  (66-98%)
R6
3a-f 4a,f,q-t
Remarkably the lowest yield recorded for these facile reactions was when aminodienone 3a was 
used to generate trisubstituted pyridine 4a in 66% yield (entry 1, Table 23), although when the
Table 23. Cydodehydration of aminodienones 3 mediated by NIS
Entry Dienone 3 R2 R3 R6 Product 4 Yield%“
1 3a Me Et02C Me 4a 66
2 3a Me Et02C Me 4a 71b
3 3a Me Et02C Me 4a 84d
4 3e Ph Et02C Me 4f >98
5 3b Me Et02C Ph 4q >98
6 3b Me Et02C Ph 4q >98°
7 3c Me Et02C 4'-C6H4Cl 4r 97
8 3d Me Et02C 4'-C6H4OMe 4s >98
9 3f Me 'Bu0 2C Me 4t >98
10 3f Me 'Bu0 2C Me 4t >98b
“Isolated yield after purification on silica.b Reactions were run in the presence of NaHC03. c
A catalytic (20 mol%) quantity of NIS was used. d Reaction was run over the course of 4 h 
rather than 1 h.
TXR2 fsT^ R6
52
Chapter2 <PfL<D. Thesis 2006 4(fsu{ts and(Discussion
reaction was run for 4 hours rather than 1 hour the yield increased to 84% (entry 3). Furthermore 
the use of only a catalytic quantity of A-iodosuccinimide (20 mol%) did not adversely affect the 
course or efficiency of reaction, generating pyridine 4q in quantitative yield (entry 6).
It is proposed that the Lewis acidity of A-iodosuccinimide was responsible for this astonishingly 
facile cydodehydration, and this was supported by further experimentation. Repeating the 
process in the absence of A-iodosuccinimide returned unreacted starting material 3 only. When 
A-iodosuccinimide was purified by recrystallization prior to use, or employed in the presence of 
sodium hydrogen carbonate (to remove HI present or generated throughout the course of the 
reaction), this did not adversely affect the yield of pyridine 4 and in some instances improved the 
reaction efficiency (entries 2 & 10). Although no mechanistic studies were performed it is 
hypothesized that NIS is behaving as a Lewis acid and is likely coordinating with oxygen or at 
times with nitrogen at various stages of the transformation simply facilitating geometric bond 
isomerization at low temperature (Scheme 45). The use of A-iodosuccinimide in ethanol 
represents a new mild method for the low temperature cydodehydration of Bohlmann-Rahtz 
intermediates for the synthesis of 2,3,6-trisubstituted pyridines 4 in excellent yield.9
Scheme 45. Proposed mechanism for NIS mediated cydodehydration
n is , o °c
R6 EtOH
NIS
3
R2 R3
NIS
R:
t o .R2 N R6 
4
2.5.2 Iodine mediated cydodehydration
Although it was evident that traces of HI had not catalyzed the NIS process, it could not be ruled 
out that traces of iodine (generated by photochemical decomposition) were mediating the reaction. 
To test this hypothesis aminodienone 3a, the least efficient substrate in the A-iodosuccinimide 
cydodehydration reactions, was reacted with a stoichiometric amount of either iodine or A- 
iodosuccinimide in ethanol at 0 °C for 30 minutes (Scheme 46). Under these conditions both 
reactions gave efficient conversion to pyridine 4a, but the iodine cydodehydration was superior, 
generating the product in quantitative yield after only a simple work up. These transformations
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Scheme 46. Cydodehydration of aminodienone 3a
were then repeated in the presence of two equivalents of sodium thiosulphate, added prior to the 
cyclodehydrating agent, to establish if iodine generated from A-iodosuccinimide was responsible 
for the reaction’s facility (Table 24). As expected, the iodine mediated reaction now failed,
Table 24. Comparing stoichiometic I2 and NIS
Reagent Yield% Yield%“
h >98 9b
NIS
u00OO oO00
‘Reaction was run in the presence on Na2S20 3. b Starting material 3a 
was recovered (91%). “Purification on silica was required.
giving only a 9% yield of product and predominantly returning unreacted starting material 3a 
(91% recovery). In contrast, the cydodehydration mediated by A-iodosuccinimide was chiefly 
unaffected by the presence of sodium thiosulphate and gave pyridine 4a in 80% yield, supporting 
the hypothesis that it was the Lewis acidity of A-iodosuccinimide and not the generation of iodine 
insitu, that was responsible for the reactivity.
Following the success of this study, an alternative aminodienone 3f was reacted with iodine (0.1- 
100 mol%) in ethanol at room temperature for 30 minutes in an effort to establish if a process 
could be developed that was catalytic in reagent. Essentially quantitative conversions to pyridine 
4t were observed under catalytic conditions even at very low iodine concentrations (0.5 mol%, 
Table 25).
Table 25. Room temperature cydodehydration of 3g varying concentration of I2
I2 (mol%)c Yield%
100 >98
50 >98
20 >98
10 >98
1.0 >98
0.5 >98
0.1 18a*b
a From 1H NMR analysis of the crude reaction mixture.b A mixture of 3f:4t (5.3:1) was obtained. c
Reaction was run for 30 minutes
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With conditions established for catalytic cydodehydration, a range of aminodienones 3a-d,f-i 
were reacted with catalytic iodine (20 mol%) in ethanol at room temperature for 30 minutes 
(Scheme 47). After a simple aqueous work up with sodium thiosulphate solution, the 2,3,6- 
trisubstituted pyridines 4a,q-w were obtained in excellent yield (Table 26). Only in case of the 
iodine catalyzed cydodehydration of 3d (entry 4) was any further purification required and this 
was attributed to the poor solubility of the substrate in ethanol.15
Scheme 47. Catalytic cydodehydration of 
aminodienones 3
h2n r 3
R6
3a-d,f-i
l2  ( 2 0  mol%)
EtOH, RT, 30 min 
(92 to >98%)
R3
N RB
4a,q-w
Table 26. Cydodehydration of aminodienones 3 using catalytic 
quantities of iodine (20 mol%)
Entry Dienone 3 R3 R6 Product 4 Yield %a
1 3a Et02C Me 4a >98
2 3b Et02C Ph 4q >98
3 3c Et02C 4'-C6H4Cl 4r >98
4 3d EtOzC 4'-C6H4OMe 4s 92b
5 3f 1 Bu02C Me 4t >98
6 3g /Bu0 2C Ph 4u 97
7 3h ‘ Bu02C 4,-C6H4Cl 4v 92
8 3i ‘ Bu02C 4'-C6H4OMe 4w >98
a Isolated yield of pure 4 after an aqueous work up. b Yield of pyridine 4s from 
analysis of *H NMR spectrum which showed dienone 3d (8%) was also present.
2.6 Conclusion
We have been able to access 5-bromopyridines in excellent yield from the corresponding 
Bohlmann-Rahtz intermediates, a substitution pattern hitherto not accessible from these 
intermediates. Efforts to elaborate the bromopyridines in order to access the core domain found 
in the series e thiopeptide antibiotics were unsuccessful. However methodology originally 
anticipated to be valuable in synthesising the core domain of series e thiopeptide antibiotics has 
been applied to the synthesis of the core domain of the series d  thiopeptide antibiotics. Treatment 
with A-iodosuccinimide represents a new mild method for the synthesis of 2,3,6-trisubstituted
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pyridines at low temperature, whilst iodine can be used to mediate the same transformation at 
ambient temperature with a number of advantages over iV-iodosuccinimide or other Lewis acids. 
The procedure is simple to perform, giving the product in excellent yield, without the need for 
column chromatography and with total regiocontrol.
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3 Synthesis of degradation products from thiopeptide antibiotics
3.1 Sulfomycins
The sulfomycins 36a-c are one class of thiopeptide antibiotic isolated from Streptomyces 
viridochromogenes subsp. sulfomycini ATCC 29776 and MCRL-0368 with strong inhibitory 
activity against Gram-positive bacteria.1 Chemical degradation studies,2,3 in combination with 'H 
and 13C NMR spectroscopic and FAB mass spectrometric data,4,5 elucidated their structure which 
contains an oxazole-thiazole-pyridine series d  domain but differs between factors in the identity 
of one alkenyl substituent (R) located on the cyclic peptide backbone. In these degradation 
experiments, the acid hydrolysis of sulfomycin I in concentrated hydrochloric acid at 110 °C gave 
beminamycinic acid 87 and sulfomycinine hydrochloride 37, both of which have been identified 
by X-ray crystallographic methods and chemical synthesis.6,7 Acidic methanolysis of sulfomycin 
using Amberlyst 15 ion-exchange resin gave dimethyl sulfomycinamate 40, sulfomycinic amide 
38, and methyl sulfomycinate 39, the latter of which was transformed to 37 in order to provide 
corroborating data on the structure (Scheme 48).
Scheme 48. Structure and chemical degradation of the sulfomycins 36a-c
HCI(aq), 110 °C, 6  h
HN
NH
HCI (aq)
HN
OH
Dimethyl sulfomycinamate 40 beminamycinic acid 90
N=< 36a
MeOH 
H+, 20 hHO"\...NH 
. HN^o
Me
HCI (aq) 0 2C ^ A  +-
   T  7 <HN^
NH MeO
COR
MeO
(±)-Sulfomycinine 37.HCIHN Sulfomycinic amide, R = NH2  38 
Methyl sulfomycinate, R = OMe 39MeO
Sulfomycin I, R = CH(OH)Me 36a 
Sulfomycin II, R = CH2Me 36b 
Sulfomycin III, R = CH2OH 36c
HCI (aq), 110 °C, 6  h
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The synthesis of dimethyl sulfomycinamate 40,8 by Bohlmann-Rahtz reaction of an 
oxazolylenamine, further verified the identity of this acidic methanolysis product to complement
the findings of Kelly,9 but the structures of degradation products 38 and 39, which were proposed 
on the basis of IR, UV, NMR spectroscopic and MS data for 39,2 are unconfirmed. In order to
convergent synthesis of methyl sulfomycinate 39, which was then converted to sulfomycinic
fragments 38 and 39 we also treated methyl sulfomycinate with 6N hydrochloric acid, isolating 
sulfomycinine hydrochloride 37 with identical spectroscopic data previously reported.
3.2 Synthesis of degradation products 37,38 and 39 from the sulfomycins
3.2.1 Retrosynthesis of methyl sulfomycinate
Retrosynthesis of methyl sulfomycinate reveals that its structure is a modified tripeptide that 
consists of two fragments: an oxazole-containing dipeptide 106 related to the known (-)- 
muscoride A building block,12 and a 2-formylthiazole-4~carboxylate residue 98 that is also a 
component of the antibiotic althiomycin,13 present as its dimethyl acetal (Scheme 49).
Scheme 49. Retrosynthesis of methyl sulfomycinate
Our convergent strategy assembled each heterocyclic component in turn and then coupled them 
together with subsequent elaboration to give methyl sulfomycinate 39.
validate a route towards the sulfomycins and as part of our interest in the total synthesis10 and 
stereochemistry of thiopeptide antibiotics,11 we set out to address this shortfall and establish a
amide 38 by aminolysis. In order to further confirm Abe’s assignment of the degradation
CO^e C02Me
39 98 106
H2 N .,vC02Me
CbzHN'H2fT C02Me
99 103
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3.2.2 Synthesis of 2-formylthiazole-4—carboxylate residue 98
Starting with 2,2-diethoxyacetamide 91, treatment with phosphorous pentasulphide in 
dichloromethane for 2 hours at 0 °C, according to a modified literature procedure,14 gave 
thioamide 93 in 23% yield. However recent studies within the research group identified the 
effective application of ammonium sulphide in the thionation of nitriles to give thioamides in 
good to excellent yield.15 To test whether this method could be used in the synthesis of residue 
98, 2,2-diethoxyacetonitrile 92 was stirred in methanol and ammonium sulphide either under 
microwave-assisted or traditional thermal conditions. This approach gave thioamide 93 in higher 
yield than the corresponding reaction with phosphorus pentasulphide. Although quicker than 
traditional thermal conditions, the microwave-assisted reaction gave the desired product in 37% 
yield (loss of yield attributed to the solubility of 93 in aqueous phase during aqueous work up), as 
compared to a quantitative yield (no aqueous work up necessary) when run under ambient 
conditions for 18 hours. Both methods are viable, however the method using microwave 
irradiation requires an aqueous work up to purify the reaction mixture, this results in an 
appreciable loss of yield. As a result of a cleaner reaction under ambient conditions, a superior 
yield was observed making this the method of choice for the synthesis of residue 98 (Scheme 50).
Scheme 50. Synthesis of thioamide 93 from the 
corresponding amide or nitrile
EtO^ jO P4S«). CH2 CI2  EtO
EtO NH2  0 °C, 2 h (23%) EtO NH2
91 93
EtO (NH4 )2 S.MeOH EtO S
) —= n -------------------------------------► r~ \
Eto microwave, 80 °C, 15 min (37%) E t 0  NH2
or
9 2  RT, 18 h (100%) 9 3
Ethyl 2-(diethoxymethyl)thiazole-4-carboxylate 94 was prepared by reaction of thioamide 93 
with ethyl bromopyruvate in ethanol in the presence of 4A molecular sieves (to prevent acetal 
deprotection) under Hantzsch conditions. Thiazole 94 was isolated in quantitative yield after 
purification twice by column chromatography. Transacetalization was necessary to facilitate the 
dimethoxy-acetal present in the target compound 39, a feature commercial unavailable in a 
corresponding nitrile. The transformation of 94 occurred under acidic conditions with p -  
toluenesulphonic acid (p-TsOH) in methanol at reflux for 6 hours gave ethyl 2- 
(dimethoxymethyl)thiazole-4-carboxylate 95 in good yield (66%). Saponification of compound
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95 using lithium hydroxide-water gave the desired 2-(dimethoxymethyl)thiazole-4-carboxylic 
acid residue 95 in 64% yield. It is noteworthy to discuss that the transacetalization reaction can 
suffer from the transesterification side reaction, giving a mixture of ethyl and methyl esters, 
compounds 95 and 96 respectively. This makes purification problematic, due to the compounds’ 
similar Rf values, and can cause a reduction in yield. In order to try and mitigate 
transesterification the milder acid catalyst, pyridinium /Moluenesulphonate (PPTS) was 
employed. However when thiazole 94 was stirred in methanol at reflux, with PPTS for 6 or 18 
hours, unreacted starting material was isolated with some acetal deprotection product 97 
(identified by NMR spectroscopy), although no transacetalization appeared to have occurred. 
In an effort to circumvent this problem, reduce the total number of steps to compound 98 and 
improve the yield over the two steps, we decided to perform an intuitive one-pot 
transacetalization and saponification of thiazole 94. The advantage of this procedure would be 
any transesterification that may occur in the first part of the reaction would still yield the desired 
residue 98 upon hydrolysis. Thiazole 94 was stirred in methanol with /Moluenesulphonic acid at 
reflux for 6 hours. After this time an excess of six equivalents of lithium hydroxide monohydrate 
was added and the reaction mixture was stirred for 48 hours at room temperature. After acidic 
work up, the desired compound 98 was isolated in 54% overall yield, an increase of 12% over the 
previous two step method (42%) (Scheme 51).
Scheme 51. Synthesis of residue 98
94 97
93 94 98
e
.C02Me
95 96
Reagents and conditions: (a) ethyl bromopyruvate, EtOH, reflux, 1 h (100%); (b) PPTS, MeOH, reflux, 6  or 18 h; 
(c) p-TsOH, MeOH, reflux, 6  h; LiOH MeOH-H2 0, 48 h (54%); (d) p-TsOH, MeOH, reflux, 6  h (95, 6 6 %); (e) 
LiOH, MeOH-H2 0, rt, 18 h (64%).
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3.2.3 Synthesis of oxazole 106
Oxazole 106 was prepared according to a modified method of Pattendenl2 from an 0-silyl ether 
derivative of L-threonine (Thr) 102. Synthesis of iV-benzyloxycarbonylthreonine (Cbz) ester 100 
was achieved in good yield (93%) from the corresponding amine hydrochloride, HCl.H-L-Thr- 
OMe 99. O-Silyl protection of 100 in dry ACV-dimethylformamide using tert- 
butyldimethylsilyl-(TBS)chloride (TBDMSC1), imidazole and A^-dimethylaminopyridine 
(DMAP), by stirring at room temperature for 36 hours, gave Cbz-L-Thr(TBS)-OMe 101 in 
quantitative yield. Saponification of 101 in methanol-water using lithium hydroxide
monohydrate gave the desired Cbz-L-Thr(TBS)-carboxylic acid 102,16 in 96% yield (Scheme 
52).
Scheme 52. Synthesis of Cbz—L-Thr(TBS)-OMe 102
H O ,,,/ HO,,, /  TBS0,„ /  TBSO,,, /
HCI.H2 N ^ X 0 2Me C bzH N ^X 02Me C bzH N ^C 02Me CbzHN C02H
99 100 101 102
Reagents and conditions: (a) Benzyl chloroformate, NaHC03, H2 0, RT, 72 h (93%); (b) TBDMSCI, 
imidazole, DMAP, DMF, RT, 16 h (98%); (c) LiOH, MeOH-H2 0, RT, 18 h (96%).
Peptide coupling was investigated using three different coupling reagents, l-[3 - 
(dimethylamino)propyl]-3-ethylcarbodiimide (EDCI) (method a), W-methyl morpholine (NMM)
17and isobutylchloroformate (method b) or benzotriazole-l-yloxytripyrrolidinophosphonium 
hexafluorophosphate (pyBOP) (method c)12 (Scheme 53). Cbz-L-Thr(TBS)-OH 102, was 
reacted according to methods a-c and, after purification by column chromatography, the yields 
were compared. Method a provided dipeptide 103 in 23% yield, whilst method b provided a 
much improved yield of 66% in a shorter period of time. However the use of pyBOP furnished a 
superior yield to either methods a or b, giving dipeptide 103 in 83% yield (method c). pyBOP is 
from a class of peptide coupling reagents which burst onto the scene in the very early 1990s, 
championed by Castro, Coste and Le-Nguyen.18 The coupling reagent incorporates the more 
traditional hydroxybenzotriazole functionality as well as a phosphonium cation within its 
structure. Benefits from using pyBOP over hydroxybenzotriazole are measured by the increased 
activation induced by the phosphonium cation, which helps to ensure immediate activation of a 
carboxylic acid functionality to aminolysis of a reacting amino acid. The life time of an activated 
carboxy group is reduced and therefore the common risk associated with coupling amino acid 
(racemization) is reduced. Furthermore the procedure is very simple, allowing all of the reagents
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and substrates to be added to the reaction mixture at the on set of the reaction, purification is 
relatively easy as the side products of this reaction are usually insoluble and/or do not move off 
the base line in thin layer chromatography analysis, in elution solvents used to isolate the product. 
The mechanism for the reaction proceeds via numerous routes and is facilitated by the presence of 
an organic base (triethylamine), however examples of the fundamental processes involved are 
illustrated in Scheme 53.
Scheme 53. Synthesis of dipeptide 103
TBSO,,
CbzHN
fOH
pyBOP 
N-
N'
R = pyrrolidine
N"
TBSO., /  ©O 
CbzHN^2>PR3
Hjf
TBSO,, C°2Me
CbzHN^C'°-N\ / N
M s
TBSO,,,r
C bzH N ^C 02H
102
Method a, b or c 
HCI.H-L-Thr-OMe
TBSO,,,^ 
CbzHNJ v ^ N  ,C02Me %
103
Reagents and conditions: (a) Et3 N, EDCI, CH2 Cl2 , 0 °C, 1 h; then amino add, RT, 16 h (23%); (b) NMM, 
isobutylchtorofbrmate, THF, 0 °C, 30 min, then amino add, 0 °C, 4 h (6 6 %); (c) amino add, pyBOP, Et3 N, CH2 CI2, 0 
°C-RT, 18 h (83%).
Cyclization of dipeptide 103 to oxazoline 104 was attempted according to a number of reported 
procedures. The first method utilized /Moluenesulphonic acid in toluene at reflux over a Dean 
and Stark apparatus,19 and after purification by column chromatography returned predominantly 
starting material (50% yield) and two unidentifiable fractions by \H NMR. Method two used 
thionylchloride in A^/V-dimethylformamide at 0 °C followed by stirring at room temperature 
overnight20 and after purification by column chromatography returned material that made up 30% 
of the original mass, however the mixture was unidentifiable (*H NMR) and did not contain either 
compound 103 or 104. The third method utilized [bis(2-methoxyethyl)amino]sulphur trifluoride 
(DeoxoFluor) with stirring in dichloromethane at -20 °C for 18 hours21 after a basic work up and 
purification by column chromatography gratifyingly the desired oxazoline 104 was isolated in 
65% yield (Scheme 54). The mechanisms surrounding the use of Deoxofluor are discussed later 
in the context of an analogous reagent, diethyl amino sulphur trifluoride (DAST) (Chapter Four- 
4.5).
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Oxidation of oxazoline 104 in dichloromethane using bromotrichloromethane and 1,8- 
diaza[5.4.0]undec-7-ene (DBU),22 gave oxazole 105 in 52% yield. It was observed that the 
NMR spectrum of the crude material from the cyclization step, after work up, contained no 
starting material whereas, in some instances, after further purification by column chromatography 
contamination from dipeptide 103 was observed. This indicated that some hydrolysis of 
oxazoline 104 occurs in the presence of silica. The hypothesis was further supported by the 
difficulty observed when low and high resolution mass spectrometry analysis repeatedly found the 
mass ion (MH+, 483) for dipeptide 103, and only after repeated efforts did we observe the mass 
ion (MH*, 465) for oxazoline 104. In an effort to circumvent the instability of compound 104, 
and in accordance with a reported procedure,21 dipeptide 103 was subjected to cyclization and 
oxidation in one pot giving oxazole 105 in 52% overall yield. A one-pot two-step method not 
only reduces the overall number of synthetic steps but also improves the yield of oxazole 105. 
Hydrogenolysis of the benzyloxycarbonyl protecting group over palladium on carbon in methanol 
gave the target oxazole 106 in 93% yield (Scheme 54).
Scheme 54. Cyclization and modification of dipeptide 103
c
dba
CbzHN’ CbzHN’CbzHN’
'OH
103 104 105 106
Reagents and conditions: (a) DeoxoFluor, CH2 CI2 , -20 °C, 18 h (65%); (b) CBrCI3, DBU, CH2 CI2 , -20 °C, 18 h (52%); (c) 
DeoxoFluor, CH2 Ci2, -20 °C, 18 h; then CBrCI3, DBU, CH2 CI2, -20 °C, 18 h (52%); (d) H2, Pd-C, MeOH, RT, 3 h (98%).
3.2.4 Synthesis of methyl sulfomycinate 39
Residues 98 and 106 were coupled to give tripeptide 107 using either /5 0 -butyl chloroformate or 
pyBOP. As previously observed, when using pyBOP there was a notable increase in yield over 
isobutylchloroformate (88% and 43% respectively). Protodesilylation of 107 by treatment with 
tetra-n-butylammmoniumfluoride (TBAF) in tetrahydrofuran (THF) gave the free alcohol 108 in 
77% yield, which was dehydrated via the corresponding methanesulphonate derivative to give the 
desired methyl sulfomycinate 39 in 60% yield (Scheme 55).
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Scheme 55. Methyl sulfomycinate 39
MeO N-v 'C°2h
H JMeO S '
TBSO/,
H2N ^—CO?Me
°i
106
a orb
,OTBS
MeO
MeO
107
MeO
MeO
C02Me
Reagents and conditions: (a) NMM, isobutylchloroformate, THF, 0 °C, 30 min; then 106,0 °C, 4 h (43%); 
(b) pyBOP, Et3 N, CH^fe, 0 °C-RT, 18 h (8 8 %); (c) TBAF, THF, 0 °C-RT, 5 h (77%); (d) MeS02 CI, 
CH2 CI2, RT, 1 h; Et3 N, CH2 CI2, RT, 18 h (60%).
The physical and spectroscopic data of the synthetic material [mp 122-123 °C; IR (KBr)/cm 1 
1719, 1684; *H NMR (CDC13) 8.65 (1H, bs, NH), 8.14 (1H, s, CH) 6.68 (1H, q, J7.2, CH), 5.55 
(1H, s, CH), 3.82 (3H, s, OMe), 3.41 (6H, s, OMe), 2.57 (3H, s, Me), 1.84 (3H, d, J7.2, CHMe); 
UV (MeOH)/nm Xmax 246 (log s 4.40)] were in excellent agreement with the literature data on 
the degradation product [mp 124-125 °C; IR (KB^/cm1 1715, 1685; ‘H NMR (CDC13) 8.70 (1H, 
bs, NH), 8.20 (1H, s, CH), 6.68 (1H, q, J7.2, CH), 5.58 (1H, s, CH), 3.86 (3H, s, OMe), 3.46 (6H, 
s, OMe), 2.61 (3H, s, Me), 1.87 (3H, d, J  7.2, CHM?); UV (MeOH)/nm Arnax 247 (log e 4.38)],2 
confirming the outcome of Abe’s methanolysis studies2 and providing a viable route to this region 
of the sulfomycin cyclic peptides. Furthermore the geometric stereochemistry of methyl 
sulfomycinate 39 has been assigned as Z based upon 2D NOE analysis;4 by design, anti­
elimination of the precursor 108 would give the desired Z-configuration. In order to verily the 
predicted configuration, 2D NOE was used on our synthetic material and gratifyingly we 
identified a significant correlation between the methyl group of the propene moiety and the NH of 
the amide.
3.2.5 Synthesis of sulfomycinic amide and sulfomycinine
To complement the degradation studies described and to further confirm the validity of our 
synthetic material we carried out both the known ammonolysis and hydrolysis of 39, in 
methanolic ammonia at room temperature for the former or in hydrochloric acid at 110 °C for the
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latter, to obtain sulfomycinic amide 38 and sulfomycinine 37 in moderate yield (24% and 27% 
respectively) (Scheme 56).
Scheme 56. Degradation products from the sulfomycins
MeO n
Methyl sulfomycinate 39
a MeO CONH2
MeO
Sulfomycinic amide 38
V ^N +i\
(±)-Sulfomycinine 37.HCI
Reagents and conditions: (a) NH3, MeOH, RT, 2 d (24%); (b) HCI (aq) 110 °C, 2 h (27%).
0 ^  7The physical properties of compounds 37 and 38 corroborate known data. ’ ’ This convergent 
synthesis thus confirms both the structures of methyl sulfomycinate 39 and the outcome of its 
chemical degradation, as well as providing a method for the preparation of this fragment 
applicable to the total synthesis of the sulfomycin thiopeptide antibiotics in 9 steps from the 
commercially available H-L-Thr-OMe 96 .HCI and 15% overall yield.23
The chemical degradation of compounds 38 or 39 in 6N hydrochloric acid will generate 
sulfomycinine 37, the mechanism by which this is achieved is complex as a consequence of the 
many possible degradation pathways that may occur. The following discussion focuses direct 
mechanistic pathways necessary to form the degradation product, the reader should be aware that 
this is by no means the only mechanistic pathway occurring under the conditions described 
(Scheme 57).
It is evident that the final degradation product 37 must lose the oxazole fragment at some point 
during the reaction, this is a good a place as any to start. The solution is proton rich therefore the 
nitrogen of the oxazole ring may become protonated and thus activated for nucleophilic attack by 
water (a), further hydrolysis will generate compound 109. Protonation of the same nitrogen on 
the ring, in conjunction with the donation of a pair of electrons from one of the two possible 
oxygen atoms (b) will result in formation of intermediate 110. The final step in the removal of
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Scheme 57. Degradation of methyl sulfomycinate 39 to (±)-sulfomycinine 37
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the oxazole (c) requires another molecule of water to attack the activated ester functionality, 
driving off the unwanted fragment generating 111a. It should be noted that step c is not shown in 
equilibrium and would not favour reforming compound 110, effectively making the 
transformation unidirectional. In order to precede compound 111a must undergo geometric 
isomerization about the dehydrothreonine functionality (d) generating a new conformation, 
compound 111b. The a,p unsaturated carbonyl functionality of the compound will now undergo 
attack from the nitrogen in the thiazole ring (e) to form the thiazolium compound 112, this can 
easily reform to the carboxylic acid under the reaction conditions (0 forming compound 113. The 
acetal moiety is not required on the thiazolium ring and through protonation of one the methoxy 
groups and intramolecular attack (g), oxonium ion 114 is generated. Water may now attack (h) to 
form hemiacetal 115, this may now undergo elimination in a process common to thiazolium 
compounds (i), generating a stablized anion adjacent to the cationic nitrogen 116. Finally 
sulfomycinine 37 can be formed by protonation of the anion (j).
3.3 Cyclothiazomycin
Cyclothiazomycin is an unusual series d  thiazolylpeptide that possesses a number of unique 
structural features. It lacks the 2- and 3- azole substituents on the central core domain, a feature 
common to series d  core domains. Instead it contains an alanine derived heterocyclic residue of 
(7?)-configuration, quaternary sulphide, and two macrocyclic loops (Scheme 58).24 Although no
66
Chapter 3 (PfL<D. Thesis 2006 Qtfsu&s and(Discussion
Scheme 58. Cyclothiazomycin 45 and its hydrolysates
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antibacterial data have been associated with cyclothiazomycin, which also lacks the characteristic 
polydehydroalanine side chain, this thiopeptide is still worthy of note as a novel and selective 
inhibitor of human plasma renin with an I C 5 0  of 1.7 pM. First isolated from the fermentation 
broth of Streptomyces sp. NR0516 from a soil sample collected at Kanagawa, Japan, and purified 
first by column chromatography and then by preparative HPLC,25 initial structure determination, 
using high-resolution HR-FAB-MS mass spectrometry, elemental analysis, and lU and 13C NMR 
spectroscopic data, was supported by chemical degradation studies, acidic hydrolysis generating 
an unusual pyridine containing y-amino acid as lactam 46,26 the identity of which has been 
verified by synthesis, and saramycetic acid 147 (Scheme 59).27
Saramycetic acid I 47, also described as 2-(2-acetylthiazol-4-yl)-4-thiazolecarboxylic acid, was 
isolated as long ago as 1967 from saramycetin, an unidentified antifungal antibiotic. It consists 
essentially of a bisthiazole moiety with an acetyl substituent at the 2-position and a carboxylic 
acid in the 4’—position.28 Bisthiazoles are of interest because they are present in many natural 
products with useful biological properties. For example it can be found within the side chain of a 
large number of other thiopeptide antibiotics, including micrococcin, all of die thiocillins (I, 117, 
Figure 8), YM-266183, YM-266184, QN3323A, QN3323B and QN3323Y,1 and in the 
macrocyclic loops of all of the amythiamicins, the GE2270 factors (A, 118, Figure 8) and 
GE37468A.29
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Figure 8. Examples of thiopeptide antibiotics containing a bisthiazole moiety
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3.4 Natural source and uses of bisthiazoles
Over the last two decades, unique natural products containing directly linked thiazoles have been 
isolated from natural sources. Owing to their important biological activities, many of these 
compounds are leads for drug development and have therefore drawn the attention of various 
research groups. Although there are two natural sources of compounds that contain two or more 
2,4-linked azoles, microorganism cultures have predominantly furnished the linked thiazole- 
containing natural products. Isolation of a family of antifungal cystothiazoles including the potent 
cystothiazole A 119 (Figure 9) from the culture broth of myxobacterium Cystobacter fuscus has 
been reported.30 Structurally related to the cystothiazoles and also representative of bisthiazole
Figure 9. Additional natural products containing a bisthiazole moiety
OMeOMe
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families are myxothiazols31 120 and 121 (Figure 9) and melithiazoles.32 Evidently included 
within this family are many of the thiopeptide antibiotics discussed above, along with a group of
bleomycin A2 122 (Figure 9) is the major component of the anticancer drug bleonoxane, which 
has found clinical use in combination chemotherapy for the treatment of a range of cancer related 
illnesses.34
3.5 Synthesis of bisthiazole fragments
3.5.1 Hantzsch cyclization
The Hantzsch synthesis is one of the most utilized approaches to prepare polythiazoles. This one 
pot reaction of a a-haloketone, often ethyl bromopyruvate 123, with a thioamide 124 mediates 
the cyclization and subsequent dehydration to give the corresponding thiazole 125. Once the first 
ring is prepared, derivatization at the C2 or C4 positions can facilitate formation of the bisthiazole 
via an iterative process. The C2 route requires transformation to the corresponding a-haloketone 
126, thus generating one of the substrates required for the Hantzsch. However if the more popular 
C4 route is chosen then transformation to a thioamide 127, often by ester hydrolysis, amide 
formation and thionation by Lawesson’s reagent or phosphorus pentasulphide generates the 
Hantzsch substrate. To demonstrate this principal, if a-haloketone 126 and thioamide 124 or 
thioamide 127 and ethyl bromopyruvate 123 were reacted together then bisthiazole 128 would be 
generated (Scheme 59).
Scheme 59. Hantzsch synthesis of bisthiazoles
glycopeptide antibiotics isolated from the microorganism Streptomyces verticillus 33 In particular,
C2 method
124 123 125 126
2 or 3 steps C4 method
R = alkyl, aryl
123
Although no conditions are shown, yields vary from 35-95% on a range of reactions; it is 
noteworthy that the C2 method has been used to prepare the bisthiazole fragment found in
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bleomycin A2 ,35 whereas C4 methodology has been applied to the synthesis of derivatives of the 
antibiotic GE2270A.36
3.5.2 Formation and oxidation of thiazolines
Inspired by the biosynthesis of thiazoles, several synthetic routes to bisthiazoles employ cysteine 
derivatives. This strategy has also been applied to the synthesis of a bisthiazole fragment of 
bleomycin B2 .37 The procedure is based on sequential formation of thiazoline rings from cysteine 
derived peptides 129 and 130 with hydrochloric acid, followed by oxidation with nickel peroxide 
(Scheme 60).
Scheme 60. Biomimetically inspired synthesis of bisthiazoles
H
Ry N C02Et a FU^Ny-COzEt b 
°  ^SH (77%) (93%)
129
R = BnNH(CH2 ) 2  130
Reagents and conditions: (a) HCI, CHCI3, 0 °C; (b) Ni02, CHCI3; (c) KOH, aq 
dioxane; (d) H-Cys(Trt)-OEt, DCC, THF; (e) AgN03, pyridine, MeOH; (f) H2 S, MeOH.
In addition to sequential strategies employed in bisthiazole formation, a one-pot preparation of a 
thiazole-thiazoline fragment 132 has been reported.38 This relies on the preparation of a protected 
cysteine-cysteine dipeptide 131, and when activated the thiazole-thiazoline is formed by rapid 
oxidation of one ring. Although further oxidation is not described, one could envisage bisthiazole 
formation in one step from compound 132 (Scheme 61).
Scheme 61. Synthesis of thiazole-thiazoline 132
O g-"STrt
phA uJC K ^ C 0 2Me T^ (38%>”  n ^ N  C°2Me
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Furthermore thiazoline formation can be achieved by electrophilic activation of an amide, 
employing triflic anhydride followed by condensation with cysteine. This strategy has been 
employed to generate (+)-cystothiazole A from 133 in excellent overall yield (Scheme 62).39
Scheme 62. Electrophilic activation to give a bisthiazole
co2Et
I  _JL. ?T' _JU
Pr^N H M e <P r^ N M e (90%) . J L « /  (99%)
'Pr &
C02Et CONHMe N - / CC>2Et
5 3  —  i S  —  r y vipr^ S  (92%) i p ^ S  (69%) /pr/ = N  b
133
Reagents and conditions: (a) Tf2 0, Pyridine, Ch^Cfe; (b) H-Cys-OEt.HCI, 
pyridine; (c) CBrCfe, DBU; (d) MeNH2, MeOH.
Combinations of methods discussed above have been utilized to synthesize bisthiazoles. These 
include compound 134 for the use in the synthesis of cystothiazole A and C, the A-C fragment of 
micrococcin Pi and a fragment present in cyclothiazomycin 135 (Figure 10).34
Figure 10. Examples of bisthiazoles prepared by 
Hantzsch or thiazoline chemistry
BnC^C.
NHBoc S
3.5.3 Cross-coupling reactions
Palladium catalyzed cross coupling reactions although useful for ary 1-aryl or aryl-heteroaryl bond 
formation have seen little use in forming 2,4’-bisthiazole bonds probably as a consequence of the 
difficulty in obtaining the required starting materials. Nonetheless with the appropriate starting 
material 2,4’ bond formations have been described in the synthesis of a number of bisthiazoles 
including micrococcinic acid,40 cystothiazole A, B41 and E42 and GE2270D2 43 
The bisthiazole in micrococcinic acid 136 (Scheme 63) was achieved by a Stille cross-coupling 
reaction, whilst a range of 2,4’-thiazole-thiazole bond formations have been achieved in
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moderate to excellent yield, depending on the substitution pattern, by implementing Stille or 
Negishi methods.44 Furthermore this strategy has been applied successfully in the total synthesis 
of cystothiazole A 119, cystothiazole B 137 (Scheme 64), cystothiazole E and also for the 
synthesis of the bisthiazole fragment of the thiopeptide antibiotic GE2270D2.34
Scheme 63. Cross-coupling reactions to form bisthiazoles
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3.5.4 Summary
Of the different polyazole containing natural products with important biological features, the 
bisthiazoles are common structures to be observed. In general Hantzsch cyclization has been the 
preferred method to prepare mono- and bisthiazoles; however commercially available cysteine 
has also been shown worthy as an alternative strategy to these interesting structures. Limitations 
on the use of palladium catalyzed cross-coupling strategies have been attributed to difficulties 
involved in accessing suitable precursors. However there can be no doubt of the effectiveness of 
cross-coupling reactions in the formation of bisthiazoles.
3.6 Synthesis of saramycetic acid 1 47
In order to consolidate the methods described above, and as part of our interest in the total 
synthesislO of thiopeptide antibiotics, we set out to design and implement a route towards 
saramycetic acid I 47, the acid hydrolysate of cyclothiazomycin 45. Due to the plethora of 
methods that could lead to the synthesis of the target molecule we decided to neglect
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organometallic methods favouring instead a range of other methods investigated in parallel in 
order to optimise efficiency to the target molecule.
3.6.1 Cysteine-derived synthesis of saramycetic acid I
The overall aim of this synthesis was to prepare a bisthiazolidine fragment and investigate its 
potential for both rings to undergo oxidation in one step, a method not previously reported 
(Scheme 64).
Scheme 64. Retrosynthesis of a bisthiazolidine fragment
138
In addition we also considered the potential for thiazolidine formation and oxidation followed by 
derivatization and elaboration to give a second thiazoline (Scheme 65).
Scheme 65. Retrosynthesis of an iterative bisthiazole fragment
138
In order to test these hypotheses our initial goal was the synthesis of a thiazolidine ring containing 
a latent aldehyde functionality 139 that could be manipulated towards the target molecule once 
the second thiazolidine ring was successfully incorporated. In addition investigations of the 
susceptibility of thiazolidine 139 by oxidation using manganese dioxide as reported for similar
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structures,45 and its propensity for ester reduction using diisobutylaluminium hydride (DIBAL) 
were undertaken. Thiazolidine 139 was prepared by the condensation of the free base derivative 
of the hydrochloride salt of H-L-cysteine-ethyl ester 138 and dimethoxyacetaldehyde in toluene. 
The compound isolated after evaporation and drying over sodium sulphate in chloroform was 
characterized by 'H NMR spectroscopic analysis and taken on to the next step without further 
purification. The material was reacted according to three procedures using DIBAL as the 
reducing agent (Scheme 66)
Scheme 66. Preparation and reduction of thiazolidine 139
HS
HCI.H2N C O ^t
138
MeO
MeO H
139
C02Et
b, c or d MeO S-^
MeO N - A 0  
H
Reagents and conditions: (a) E^N, RT, 3 h, fitter; then dimethoxyacetaldehyde, RT, 18 h; (b) 1.5 
eq. DIBAL, CH2 CI2, -84 °C, 2.5 h; (c) 1.5 eq. DIBAL, PhMe, -84 °C, 2.5 h, (d) 1.5 eq. DIBAL, 
THF, -84 °C, 2.5 h.
The NMR spectrum showed in each case (methods b-d) that after filtration the presence of 
mostly starting material was observed. There was no significant signal in the spectrum to indicate 
the presence of an aldehyde CH, suggesting that reduction of thiazolidine 139 had been 
unsuccessful. In addition oxidation of 139 was performed in a range of solvents, thermally and 
under microwave irradiation (Scheme 67, Table 27). The results show that when the reaction was
Scheme 67. Oxidation of thiazolidine 139
HS
'I
MeO.
HCI.H2N C O ^t MeO
b or c or d MeO
C02Et MeO
H i> nA C02Et
138 139 95
Reagents and conditions: (a) Et3 N, RT, 3 h, filter, then dimethoxyacetaldehyde, RT, 18 h; (b) 10 
eq. Mn02, PhMe, microwave, 140 °C, 1 h (9%); (c) 10 eq. Mn02, PhMe, microwave, 140 °C, 2 h 
(9%); (c) 4 eq. Mn02, PhMe, reflux, 18 h (11%).
carried out in toluene, oxidation of thiazolidine 139 to the desired compound 95 occurred in low 
yield (entries 3-5). If the solvent was changed for either acetonitrile (MeCN) or dichloromethane 
under microwave irradiation, no oxidation occurred and return of starting material was observed
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with a small loss of yield (entries 1 & 2). Ten equivalents of manganese dioxide and an elevated 
temperature were required for reactions in the microwave to proceed (entries 3 & 4). Under 
thermal conditions the reaction was run for a longer period of time to achieve comparable yields 
to those run in the microwave; however only four equivalents of reagent were required at a lower 
reaction temperature (entry 5).
Table 27. Oxidation of compound 139 using Mn02
Entry Solvent Conditions
Equivalents
Mn02 Compound Yield%8
1 Acetonitrile microwave, 100 °C, 1 h 4 139 95b
2 Dichloromethane microwave, 100 °C, 1 h 4 139 92b
3 Toluene microwave, 140 °C, 1 h 10 95 9
4 Toluene microwave, 140 °C, 2 h 10 95 9
5 Toluene thermal, reflux, 18 h 4 95 11
8 Isolated yield after purification by column chromatography. b Crude recovery of starting material after 
filtration.
We have demonstrated that the reduction of thiazolidine 139 was not possible using DIBAL in a 
range of solvents at -84 °C, although this may be due to the low temperature in which the 
reactions were carried out. More importantly however, is the result showing that oxidation of 
thiazolidine 139 using manganese dioxide is not an effective method to form thiazole 95, which 
therefore undermines this strategy. In contrast, in parallel to the above strategy, preparation of 
thiazolidine 140 according to a modified procedure,47 gave the desired product in excellent yield 
(97%). The second step of the route although apparently relatively straight forward did not give 
good yields of the desired terf-butoxycarbonyl (Boc) protected amine under a range of conditions 
(Scheme 68, Table 28).
Scheme 68. Formation of thiazolidine 140 and Boc protection
s  » y s  ■> y s
i nnoFt M COoEt N r
HS
HCI.H2N C02Et \\ 02 t ' g ^ S x > 2Et
138 140 1 4 1
Reagents and conditions: (a) Et3 N, acetone, RT, 1 h, filter, then 1,3- 
dimethoxypropane, acetone, 60 °C, 2 h (97%); (b) 1.1 eq. DIEA, 1.5 eq. Boc^O, 
MeCN, 50 °C, 2 d (9%).
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Table 28. Methods attempted to protect thiazolidine 140
Entry Solvent Base Equivalents of base
Equivalents 
of Boc
Temperature
/°C
Time
/h Catalyst Compound Yield %a
1 CH2C12 Et3N 2.3 2 25 18 — 140 88
2 MeCN ' Pr2NEt 1.1 1.2 25 48 — 140 77
3 MeCN ' Pr2NEt 1.1 1.5 50 48 — 140/141 63/9
4 MeCN ' Pr2NEt 1.1 1.5 90 60 DMAP 140 53
8 Isolated yield after purification by column chromatogrpahy
All of the attempts to generate compound 141 returned starting material (entries 1-4). By 
increasing the temperature of the reaction to 50 °C we isolated the desired product 141 in low 
yield (9%) along with appreciable starting material (63%) (entiy 3). In an effort to improve the 
yield we increased the reaction temperature to reflux, increased the reaction time and included a 
catalyst in the form of A^iV-dimethylaminopyridine (entry 4), however to our surprise no desired 
product was observed and a lower yield of starting material was returned (53%).
Even though the synthesis of thiazolidine 140 was superior to that of thiazolidine 139, the failure 
of 140 to undergo Boc protection raised some serious doubts about the validity of this strategy. 
This in combination with the lack of susceptibility of thiazolidine 139 to undergo reduction, and 
the poor yields obtained for the oxidation provided early evidence that these strategies were too 
problematic to validate an elegant synthetic approach to saramycetic acid 147.
3.6.2 Tripeptide-based synthesis of saramycetic acid I
Further retrosynthetic analysis of saramycetic acid I led to the hypothesis that it could be prepared 
from a tripeptide made up of serine amino acid residues. Cyclization of the tripeptide using 
diethylaminosulphur-trifluoride (DAST) would give the corresponding oxazoline. Subsequent 
thionation using hydrogen sulphide to give the thioamide tripeptide could then be cyclization to 
the bisthiazoline. Oxidation using DBU and bromotrichloromethane rather then manganese 
dioxide would give the corresponding bisthiazole. After amine deprotection the compound could 
be activated by protonation, this in turn would result in elimination and hydrolysis to give the 
methyl ketone. The desired compound 47 could then be isolated after soaponification of the ester 
functionality (Scheme 69).
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Scheme 69. Tripeptide inspired retrosynthesis of saramycetic acid 47
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Orthogonal protection of the amine terminus of the fragment would be necessary. Therefore the 
parallel synthesis of two tripeptides was undertaken, one with a Boc protected amine 142 and the 
other with a Cbz protected amine 143. The AT-protected L-serine carboxylic acids, side chain 
protected as the te/T-butyl ethers were stirred with AT-methyl morpholine, isobutyl chloroformate 
in tetrahydrofuran at 0 °C for 20 minutes before adding H-L-Ser('Bu)-OMe, to give dipeptides 
144 and 145 in good yield (79 and 86% respectively). Hydrolysis of the esters with lithium 
hydroxide monohydrate in methanol-water gave the corresponding carboxylic acids (146, 99%; 
147, 88%) in good yield. Tripeptides 148 and 149 were prepared by using the same coupling 
method with H-L-serine-OMe (Scheme 70).
Scheme 70. Synthesis of tripeptides 148 and 149
Reagents and condtions: (a) NMM, isobutylchlorofbrmate, THF, 0 °C, 20 min; then H-L-Ser('Bu)-OMe, 0 
°C, 5 h; (b) LiOH, MeOH-H2 0, RT, 18 h; (c) NMM, isobutylchlorofbrmate, THF, 0 °C, 20 min, then H-l- 
Ser-OMe, 0 °C, 5 h.
'BuO.
CbzHN'XOzH
143
feuO.
BocHN C02H
142
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Tripeptide 148 was isolated in good overall yield (61%) from amino acid 142, whereas tripeptide 
149 was isolated in moderate overall yield (26%) from amino acid 143. In order for cyclization to 
be performed the tripeptide side chains were deprotected according to literature procedures,48 in 
dichloromethane-trifluoroacetic acid (10:1) at 0 °C for 4 hours. The ‘H NMR spectrum of the 
crude material from both reactions indicated that multiple side reactions had occurred and it was 
difficult to identify a solvent system by thin layer chromatography that would separate pure 
material. Due to the difficulties experienced in preparing the deprotected tripeptides in 
combination with the problematic thiazolidine chemistry, we decided to concentrate our efforts on 
an Hantzsch inspired synthesis of saramycetic acid 147.
3.63 Hantzsch-inspired synthesis of saramycetic acid I
Encouraged by our reported method for the synthesis of acetal protected thiazole 94 (3.2.2) in the 
synthesis of degradation products of the sulfomycins,23 and in combination with our work on the 
simple thionation of nitriles to give thioamides,15 we investigated a similar method for the 
preparation of saramycetic acid 147 (Scheme 71).
Scheme 71. Hantzsch-inspired retrosynthesis of saramycetic acid I 47
Commercially available 2,2-dimethoxypropionitrile 150 was stirred in methanol and ammonium 
sulphide (50 wt% in water) under a range of reaction conditions (Scheme 72, Table 29).
Scheme 72. Hantzsch thiazole synthesis from 2,2-diethoxypropionitrile 150
EtOv?Et microwave or thermal S Q yp
--------------------------------- ► EtO-y \  +
/  NH2  '  NH2
150 151 152
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Table 29. Thionation of 2,2-diethoxypropionitrile 150
Entry Condtions Temperature /°C Time/h Product (Yield%)
1 microwave 80 0.25 151 (7) 152 (4)
2 microwave 130 0.5 151 (5) 152 (7)
3 thermal RT 18 151 (7) 152 (1)
4 thermal 50 4 151 (21)
5 thermal RT 2.5 151 (47)*
aNo aqueous workup was employed
When compound 150 was reacted according to reported procedures, 15 a low yield of isolated 
thioamide 151 was observed and deprotected ketal 152 (determined by *H NMR spectroscopy) 
was also isolated as a separate fraction by column chromatography under microwave or thermal 
conditions (entries 1-3). When the reaction was repeated under thermal conditions at 50 °C an 
increased yield was observed (entry 4), indicating that the acetal protected compounds may not be 
stable to high temperatures or microwave irradiation. Furthermore when compound 150 was 
reacted in methanol at room temperature for two and a half hours without an aqueous work up (as 
previously used), the desired ketal protected thioamide 151 was isolated in moderate yield (47%) 
(entry 5), indicating that compound 151 may be soluble in aqueous medium. To our 
disappointment when thioamide 151 was reacted under our reported Hantzsch conditions,23 
deprotection of the acetal occurred to give a mixture of protected and unprotected ketones 153 and 
154 (determined by *H NMR spectroscopy). This trend was observed when attempts to hydrolyze 
the ketal-protected thiazole ester 153 to the corresponding carboxylic acid gave the mixed 
ketal/ketone thiazole carboxylic acids 154 and 156 (determined by !H NMR spectroscopy) 
(Scheme 73).
Scheme 73. Hantzsch thiazole synthesis from 2,2-diethoxypropionitrile 150
EtOv?Et a EtO SE tO -W  ----------*
/  NH2
EtO c
• EKyHX —C02Et
EtO o
BOt1A
co2h
150 151 153 155
+
Ov 7SM'  nh2
+
Hi.C02Et
+
Q s
N co2h
152 154 156
Reagents and condtions: (a) (NH4 feS, MeOH, RT, 2.5 h (47%); (b) ethyl bromopyruvate, EtOH, reflux, 1 h 
(41%); (c) LiOH, MeOH-H20 , 18 h (40%).
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Even though synthesis of thiazole 153 was unsuccessful our strategy was still viable by utilizing 
our reported synthesis of thiazole 94. Notably thiazole 94 has an acetal functionality whereas 
thiazole 153 differs only in that it has a ketal functionality. Furthermore we have already reported 
good yields for the reaction of thioamide 92 under Hantzsch with subsequent hydrolysis (3.2.2).23 
Therefore if the bisthiazole fragment was constructed by a second Hantzsch thiazole synthesis via 
elaboration of the 4—substituent of thiazole 94, deprotection of the acetal would follow and 
Grignard addition-oxidation-hydrolysis steps would give the desired acetyl moiety.
In order to access the necessary thioamide, saponification of thiazole ester 94 with lithium 
hydroxide in methanol-water gave carboxylic acid 157 in good yield (64%) followed by 
ammonolysis in tetrahydrofuran with ethyl chloroformate, triethylamine and saturated ammonia 
solution to give amide 158 in 85% yield. Amide 158 was then treated with Lawesson’s reagent in 
dichloromethane at either reflux or room temperature for 18 hours. The desired thioamide 160 
was not formed and even after column chromatography and isolation of numerous fractions no 
starting material was identified either, indicating that Lawesson’s reagent caused amide 158 to 
undergo mixed reactions. In order to circumvent thionation of amide 158 and to explore the 
versatility of our reported procedure for thionation of nitriles, amide 158 was reacted with 
phosphorous oxychloride whilst stirring in pyridine at room temperature for two hours to give 
nitrile 159 in good yield (83%). Gratifyingly when nitrile 159 was stirred in methanol with 
ammonium sulphide at room temperature for 18 hours thioamide 160 was isolated in quantitative 
yield, with no need for purification by column chromatography. Furthermore when thioamide 
160 was reacted according to our Hantzsch thiazole procedure bisthiazole 161 was isolated after 
simple extraction in quantitative yield (Scheme 74).
Scheme 74. Synthesis of bisthiazole 161
EtO a, b EtO N ^ C° 2 Et c EtO N ^ c ° 2 h d EtO N^ C 0 N H 2J - ^ n ----------------------------      ) _ ^ T    )-h? T
EtO EtO S EtO S EtO
92 94 157 158
EtO N ^ CN f Et°x N- V ' C S N H 2  g n A-K* -1- .M* — »vrr^
EtO
159 160 161
C02Et
Reagents and conditions: (a) (NH^S, MeOH, RT, 18 h (100%); (b) ethyl bromopyruvate, EtOH, reflux, 1 h (100%); (c) 
LiOH, MeOH-H2 0, RT, 18 h (64%); (d) ethyl chloroformate, Et3 N, THF, 0 °C, 1 h; then NH4 OH, 0 °C, 1 h (85%); (e) 
POCI3, pyridine, 0 °C-RT, 2 h (83%); (f) (NH4 )2 S, MeOH, RT, 18 h (100%); (g) ethyl bromopyruvate, EtOH, reflux, 1 h 
(100%).
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With the synthesis of the bisthiazole fragment completed, deprotection of acetal 161 was achieved 
in 87% yield to give aldehyde 162. Grignard addition with methylmagnesium bromide in 
dichloromethane at 0 °C for 18 hours gave the methyl alcohol 163 in 41% yield and returned 
starting material in 38% yield. Compound 163 was oxidized to ketone 164 using either 
manganese dioxide (52%) in dichloromethane or o-iodoxybenzoic acid (IBX) (50%) in 
dimethylsulphoxide. Hydrolysis of 164 by stirring in a slight excess of lithium hydroxide in 
methanol-water for 18 hours, gave saramycetic acid I 47 in 11 steps and 8% overall yield 
(Scheme 75).
Scheme 75. Synthesis of saramycetic acid I 47
C02Et C02Et COaEt C02Et
rS _ —5— f> x SEtO N ^ S  O HO O.
H J  H J  H JEtO ST r $ r
161 162 163 164
e
Saramycetic acid 147
Reagents and conditions: (a) 2M HCI (aq), acetone, reflux, 1 h (87%); (b) MeMgBr, CH2 CI2, 0 °C-RT, 18 h (41%); (c)
Mn02, CH2 CI2, RT, 40 min (52%); (d) IBX, DMSO, RT, 1 h (50%); (e) LiOH, MeOH-H20 , 18 h (100%).
The spectroscopic data of the synthetic material [!H NMR SO(CD3)2) 8 8.85 (0.18H, s, 5’-H), 
8.82 (0.82H, s, 5’-H), 8.71 (0.18H, s, 5-H), 8.63 (0.82H, s, 5-H), 2.77 (3H, s, Me); ,3C NMR 
(125 MHz; SO(CD3)2) 5 191.4 (C), 167.9 (C), 162.4 (C), 161.7 (C), 149.8 (C), 148.8 (C), 130.1 
(CH), 125.8 (CH), 26.3 (Me); m/z (APcI) 255 (MH+, 40%); UV (MeOH)/nm A,max 220 (log s 
4.29), 291 (log e 4.14)] were in good agreement with the literature data on the degradation 
product [*H NMR (SO(CD3)2) 5 8.97 (1H, s, 5-H), 7.92 (1H, s, 5-H), 2.70 (3H, s, Me); 13C NMR 
(SO(CD3)2) 8 189.6, 165.4, 162.4, 158.4, 157.5, 122.7, 120.7, 24.4; UV (MeOH)/nm ^ 2 1 8  (log 
s 4.32), 291 (log 8 4.16)]27 confirming the outcome of the degradation studies27,28 and providing a 
new viable route to bisthiazoles that could be applied to the synthesis of a range of thiopeptide 
antibiotics.
Efforts to improve the synthesis of saramycetic acid I was undertaken at various stages of the 
procedure. Initially an investigation of direct ammonolysis under thermal49 and under microwave
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conditions,50 of either thiazole 96 or 94 in methanolic ammonia under various conditions was 
attempted (Table 30).
Table 30. Ammonolysis of thiazole esters 94 and 96
EtO N ^ /C° 2 Et 
EtO
94
MeO N ^ c ° 2 Me
> - o rMeO S 
96
EtO N- ^ c o n h 2X j
EtO S 
158
MeO N^ c o n h 2  EtO N^ c ° 2 MeH jf  X J
MeO $ EtO S 
165 166
Entry Startingmaterial Conditions8
Temperature
rc Time
Compound (Yield%) 
Ester Amide
Overall
yield%
1 96 microwave 60 40 min 96(81) 165(19) 100
2 96 microwave 60 4 h 96(19) 165(77) 95
3 96 microwave 60 40 min 96(79) 165(21) 85
4 96 microwave 100 80 min 96(45) 165 (40) 85
5 94 microwave 80 4 h 166(15) 158 (29) 44
6 94 microwave 120 2  h 166 (9) 158 (9) 18
7 94 microwave 100 2  h 166 (34) 158(66) 100
8 94 microwave 100 4 h 166(9) 158(33) 42
9 94 microwave6 100 1  h 166 (28) 158(21) 49
10 94 microwave0 80 1  h 94c — —
11 94 microwave*1 80 1 h 94e — —
12 94 thermal 50 1 h 166(18) 158(51) 69
13 94 thermal 25 3d 166 (2) 158 (41) 43
14 94 thermal 50 4 d — 158 (50) 50
15 94 thermal 25 36 h — 158 (53) 53
16 94 thermal 45 7 d 166 (7) 158 (65) 72
8 Reactions carried out in methanol. b Reaction run without cooling air on. 0 Reaction run in THF as solvent. 
d Reaction run with acetonitrile as solvente Compound identified by *H NMR spectrum of crude residue.
When thiazoles 94 and 96 were reacted under microwave conditions (entries 1-11) the overall 
yields were found to range between 42-100%, the greatest recorded yield of amide 158 and 165 
was 77% and 67%, respectively (entry 2 and 7). Temperatures between 60-100 °C did not 
adversely effect the reaction however at 120 °C an overall yield of only 18% was observed (entry 
6) compared to an overall yield of 100% when the same reaction was run at 100 °C (entry 7). 
When thiazole 96 was reacted for 40 minutes a ratio of 4:1 in favour of the ester was recorded 
(entry 1), however when the same reaction was run for 4 hours a ratio of 4:1 in favour of amide 
formation was observed (entry 2), and when the reaction was run for 80 minutes (although at 
higher temperature) a ratio of 1:1 was observed (entry 4).
It was noteworthy to identify that methanol was also acting as a competing nucleophile in the 
reaction, demonstrated by the isolation of methyl ester 166 (identified by *H NMR spectroscopy)
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when using ethyl ester thiazole 94. In order to prevent competition of ammonium with methanol,
methanol and tetrahydrofuran for its capacity to dissolve ammonia. When thiazole 94 was reacted 
in the microwave using either acetonitrile or tetrahydrofuran under conditions known to promote 
amide formation, no reaction occurred (entries 10 and 11). Although changing the solvent system 
prevented competing reactions from taking place, the chosen solvents also prevented ammonia 
attacking the ester, returning thiazole 94. In the case of acetonitrile this could be explained by the 
poor solubility of ammonia. In the case of tetrahydrofuran we envisage poor energy transfer is 
probably to blame due to the low dielectric, concluding methanol is the best solvent to use out of 
those investigated.
When reactions were attempted under thermal conditions, there was a notable reduction in the 
amount of ester isolated at the end of the reaction period (entries 12-16). At 25 °C, when the 
reaction was run for 36 hours, amide 158 was isolated in 53% yield with no return of starting 
material (entry 15), whereas when the same reaction was run for 3 days amide 158 was isolated in 
41% yield and starting material 166 in 2% yield (entry 13). When the reaction was run at 50 °C 
for 1 hour or 4 days no adverse effect on the yield of amide 158 (51% and 50% respectively) was 
observed (entries 12 and 14). Curiously the best yield of amide 158 was recorded under thermal 
conditions (65%) when stirred for 7 days at 45 °C (entry 16).
Even though microwave conditions gave a good yield of amide in a short period of time, (entries 
2 and 7), the thermal conditions are more favourable. At 45 °C in methanolic ammonia over a 
period of 7 days amide 158 was produced in 65% yield (entry 16). More importantly, in 
comparison to our original procedure which gave amide 158 in 54% yield over two steps, we have 
successfully improved the overall yield and reduced the number of steps (Scheme 76).
two other solvents were investigated, acetonitrile due to its comparable dielectric constant with
Scheme 76. Optimising the ammonolysis of thiazole 94 and 96
MeO N^ c ° 2Me MeO N- ^ c o n h 2
+
MeO N ~^c ° 2 Me
96 165 96
b, c
EtO N- V ' C 0 N H 2
+
EtO N^ C 0 2Me
94 158 166
Reagents and conditions: (a) MeOH-NH3, microwave, 60 °C, 4 h (6 6 %); (b) LiOH, MeOH- 
H2 0, RT, 18 h (64%); (c) ethyl chloroformate, Et3 N, THF, 0 °C, 1 h; then NH4 OH, 0 °C, 1 h 
(85%); (d) MeOH-NH3, 45 °C, 7 d (65%).
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Given the ease with which thioamide 160 undergoes a Hantzsch thiazole synthesis and the 
simplicity of the deprotection method to give aldehyde 162, we tested the hypothesis that these 
two transformations could be achieved in one step without any loss of yield and without the need 
for purification by column chromatography. Therefore thioamide 160 was reacted according to 
our Hantzsch thiazole procedure. After evaporation in vacuo the residue was dissolved in a 
solution of acetone-aqueous hydrochloric acid (2M) and stirred at reflux for a further 1.5 hours. 
Gratifyingly after a simple aqueous work up with dichloromethane, aldehyde 162 was isolated in 
excellent yield (100%), providing a more direct route to saramycetic acid I 47 without 
compromising yield. In fact the overall yield over the two steps was increased by 17% (Scheme 
77).
Scheme 77. Direct route to aldehyde 162
EtO N -w/ ' s n h 2 a and b\—^
EtO S o r c
160 162
R eagents and conditions: (a) ethyl bromopyruvate, EtOH, reflux, 1 h 
(100%); (b) 2M HCI (aq), acetone, reflux, 1 h (87%); (c) ethyl 
bromopyruvate, EtOH, reflux, 1 h, then 2M HCI (aq), acetone, reflux,
1.5 h (100%).
It is noteworthy at this time to consider the reactivity of aldehyde 162. The reaction of 162 with 
methylmagnesium bromide to form ethyl alcohol 163 (Table 31), identified that the electrophilic 
potential of the aldehyde carbonyl appeared to be significantly reduced making nucleophilic 
attack at this position difficult. When the reaction was carried out over 1.5 hours with 1.2 
equivalents of methylmagnesium bromide a mixture of starting material and product was formed, 
the combined yields of which made up only 21% of the original quantity of starting material
Table 31. Reaction of aldehyde 162 under a range of conditions
Entry Grignardreagent
Equivalents 
of reagent Solvent
Temperature
rc Time/h Compound (Yield%)
Overall
yield%
1 MeMgBr 1.2 THF 0-RT 1.5 162 (8) 163 (13) 21
2 MeMgBr 1.1 + 12 THF 0-RT 0.33+0.66 162(10) 163(15) 25
3 MeMgBr 1+0.5 THF 0-RT 1+0.5 162 (3) 163 (39) 42
4 MeMgBr 1.03 CH2C12 0-RT 18 162(38) 163(41) 79
5 MeLi 1.03 THF 0 1 162 -
6 MeLi 1.03 THF 0 1.5 162(10) - 10
7 MeLi” 1.03 THF 0 1 162 (6) - 6
a 12-Crown-4-ether used
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(entry 1). By reducing the reaction time and adding an additional aliquot of methylmagnesium 
bromide there was no significant difference in the quantity of isolated material and overall yield 
(entry 2). However when 1.5 equivalents of methylmagnesium bromide were added to a reaction 
and stirred for 1.5 hours a significant decrease in isolated starting material 162 and an increase in 
the isolated yield of the desired product 163 was observed (entry 3). When the reaction was run 
for 18 hours in dichloromethane with only 1.03 equivalents of Grignard reagent the best isolated 
yield of desired product (41%) was obtained with a substantial amount of unreacted starting 
material (38%) (entry 4).
In an attempt to the improve yield, reactions were run using 1.03 equivalents of methyl lithium, 
an alternative nucleophile. When the reaction was run for 1 hour only starting material was 
observed by *H NMR spectroscopy (entry 5). Increasing the reaction time to 1.5 hours resulted in 
isolation of starting material (10%) and a mixture of unidentifiable products. 12-crown—4-ether 
was added in order to manipulate the reactivity of the nucleophile, however only 6% of unreacted 
starting material was isolated and again a mixture of unidentifiable products, (entry 6).
In summary efforts to improve the nucleophilic addition to bisthiazole-aldehyde 162 gave little 
success, identifying the unreactivity of this moiety is probably a consequence of the resonance of 
the thiazole ring (Figure 11).
Figure 11. Deactivation of the carbonyl group of aldehyde 162
C 0 2Et
N-C
( S ^ N^ Sb 
162
Lewis acid activation was not attempted and it is likely that it too, would deactivate compound 
162 as shown in figure 11, however, it would be worth investigating in the future. Nonetheless as 
a result of improvements in the formation of amide 158 and bisthiazole 162, saramycetic acid I 47 
was synthesized in 9 steps and 11% overall yield.
3.7 Conclusion
Degradation studies of thiopeptide antibiotics have led to the isolation of fragments that can help 
in the structural elucidation of the parent molecules. Many of the fragments have been assigned 
based on spectroscopic data, although very few of these hypotheses have been verified by 
chemical synthesis. Our efforts to synthesize degradation fragments from thiopeptide antibiotics
C 0 2Et
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have helped to address this short fall, validating known data and consolidating methods that could 
lead to the total synthesis of the parent antibiotics.
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4  Towards the total synthesis of the core of micrococcin
4.1 Micrococcin
Micrococcin was the first example of a thiopeptide antibiotic to be recorded, appearing in “The 
British Journal of Experimental Pathology” in 1948 and was discovered from a strain of 
Micrococcus found in the sewage from the city of oxford,1 although no structural data on this 
thiopeptide was ever reported. Structural investigation of material obtained from soil collected in 
East Africa containing a spore-bearing bacillus called Bacillus pumilus2 demonstrated a 
considerable degree of homology with the antibiotic isolated from Micrococcus, suggesting two 
members of a closely related family and as such this new material was named micrococcin P. 
Interestingly this antibiotic consisted of two distinct components, present in a ratio of 7:1 and 
designated micrococcin Pi and P2, respectively.3 More recently micrococcin Pi has been isolated 
from Staphylococcus equorum WS2733 found in French Raclette cheese,4 a gratifying discovery 
due to the difficulties experienced in obtaining the compounds from their original sources. The 
isolate has been shown to inhibit growth of the malaria parasite Plasmodium falciparum and 
ribosomal protein biosynthesis in Gram-positive bacteria, the latter through binding to the 
complex of protein LI 1 and 23S rRNA in the bacterial 50S subunit.5 Work spanning the 50 year 
period following initial isolation to elucidate the correct structure and stereochemistry of 
micrococcin Pi, tells an extraordinary stoiy. Despite considerable spectroscopic and synthetic 
advances in combination with a number of total syntheses the correct structure remains 
unresolved.3
Initially due to the lack of structural data, micrococcin Pi (also described as micrococcin PI and 
MP1), was characterized by examination of its acid hydrolysates.6 Analysis of the acid soluble 
component gave a laevorotatoiy hydrochloride that was assigned as L-threonine.HCl by IR 
spectroscopy. Further analysis identified the central heterocyclic domain as micrococcinic acid 
167 and methyl micrococcinate 168 and an aminoalcohol that was later identified as (R)~ 
isoalaninol from 13C NMR studies of the natural product. The net result of these studies was the 
proposal of the Walker-Lukacs structure 169 which assumes structural homology with other 
thiopeptide antibiotics, such as thiostrepton and nosiheptide (Figure 12).7
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Figure 12. Hydrolysates of micrococcin Pj and the Walker-Lukacs structure
ro2c
R = H, micrococcinic add 167 
R = Me, methyl micrococdnate 168
HN
HN
NH
'"OHWalker-Lukacs structure of MP1 169
Bycroft and Gowland separated micrococcin Pi and micrococcin P2 in order to carry out their own 
studies and analyses of the acid hydrolysates of micrococcin Pi. Only one mole of threonine was 
produced in these experiments, which was in contrast to the findings of Walker and Lukacs. As a 
result the Bycroft-Gowland structures of micrococcin Pi 170 and P2 171 were proposed (Figure 
13).8
Figure 13. Proposed structures of the micrococcins
HN
HN
Bycroft-Gowland structure of:
MP1 170 R1 = OH, R2  = H, R3  = CHMe2 , R4  = H; 
MP2 171 R1 ,R2  = O (Jt-bond), R3  = CHMe2, R4  = H; 
Shin's synthetic epimer of:
MP1 172 R1 = H, R2  =OH, R3  = CHMe2, R4  = H; 
Probable structure of:
MP1 173 R1 = OH, R2  = H, R3  = H, R4  = CHMe2; 
MP2 174 R1 ,R2  = O fo-bond), R3  = H, R4  = CHMe2.
The proposed structure was assumed to be correct for twenty years until in 1999 Ciufolini 
completed an elegant total synthesis of the Bycroft-Gowland micrococcin Pi structure and found 
that the data of the synthetic material did not correspond to that of the natural product.9 The 
situation was further confounded by Shin’s synthesis of two epimeric substances of Walker- 
Lukacs and Bycroft-Gowland structures, described as micrococcin P and micrococcin Pi 17210 
(Figure 13). Later Ciufolini drew together all of these findings and validated the order of the 
residues in micrococcin Pi according to the Bycroft-Gowland hypothesis, discovering that the 
correct order had been postulated. This result indicated that the real structure of micrococcin Pi 
was different from Bycroft-Gowland’s structure only in its stereochemistry. Therefore the origin
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of this discrepancy must be in either the configuration of the L—threonine-derived thiazole at the 
3-position of the pyridine core domain and/or in the (7?)-valine-derived thiazole in the peptide 
macrocycle, both of which were proposed in the absence of reliable experimental evidence.6,11 
Synthetic studies performed recently within our own group have provided evidence in support of 
Walker’s isolation of laevorotatory valine, indicating that the correct stereochemistry of the 
valine-derived residue is S 173 (Figure 13).5
4.2 Retrosynthesis of micrococcin Pj
In view of our recent studies into the stereochemistry of micrococcin Pi, the challenge has been 
presented to synthesize this ageing molecule with the correct stereochemistry in order to solve the 
long standing mystery surrounding this relatively simple thiopeptide antibiotic. Retrosynthetic 
analysis has provided a number of target molecules, the backbone of micrococcin Pi 175 and the 
core of micrococcin Pi 176, (Figure 14).
Figure 14. Retrosynthesis of the proposed structure of micrococcin Pj
nh 2
HN
H2 N'
,NH
HN
"OH
176
HN
HN
.NH
"OH
173
It follows that the forward synthesis of molecule 175 is proposed to be achieved by methodology 
originating from the Bagley laboratory.5 The core of micrococcin Pi 176 consists of an ester in 
the 3-position and a side chain attached to the 6-position of the pyridine ring via a 2-bisthiazole 
which is further substituted at the 4’-position by a demethyldehydrovaline and (R)-isoalaninol 
moiety. Furthermore an L-threonine-derived thiazole moiety is attached at the 2-position of the 
pyridine core via the 4-position of the thiazole. Retrosynthetic analyses of the protected core 177 
reveals fragments A, B and C which identify the potential for the forward synthesis to incorporate 
a Bohlmann-Rahtz pyridine synthesis (Scheme 78).
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Scheme 78. Bohlmann-Rahtz inspired retrosynthesis of the protect core of micrococcin Pj 177 
• > < = W h  Et02C~ ^  ■■■• ^  s
2  Bohlmaniv-Rahtz
N ~ ^  pyridine synthesis
.NHx'OP p = protection group
177 ^  'OP A
co2h
The remainder of this chapter explores the synthesis of fragments A, B and C in order to identify 
a viable and convergent route to the synthesis of 177, that could be utilized in the total synthesis 
of micrococcin Pi 173.
4.3 Synthesis of dipeptide A
The synthesis of peptide A was undertaken with the view to incorporate a protected alcohol on the 
threonine that was orthogonal to the protection group of the alcohol found in the (R)-isoalaninol 
moiety. Furthermore we decided to attempt the synthesis of a selenide protection group for a 
threonine amino acid according to literature procedures,12 this would provide chemical 
differentiation between other threonine protection groups and therefore orthogonality..
Boc—L-Thr-OH 178 was treated with benzyl bromide and triethylamine in NJV- 
dimethylformamide at 0 °C for 3 hours. After warming to room temperature the solution was 
stirred for 2 days and purified to give the benzyl protected threonine 179 in good yield (65%). 
Tosylation of the free alcohol was achieved by treatment with tosyl chloride (TsCl) in pyridine at 
0 °C over 2 days. After purification by column chromatography, tosyl-protected threonine 180 
was isolated in moderate yield (45%). Tosylate displacement of 180 was carried out according to 
the literature procedure but gave the elimination product 181 in 60% yield, instead of the desired 
residue, phenyl selenide 182 (Scheme 79).
Scheme 79. Phenyl selenide: a masked enamine
HO/,
BocH N * X 0 2H
178
r TsO,,r
BocHN*XX>2Bn
179
BocH N^C 02Bn
180
XBocHN C02Bn 
181
BocHN C02Bn
Reagents and conditions: (a) BnBr, Et3 N, DMF, 0 °C, 3 h then RT, 2 d (65%); (b) TsCl, pyridine, 0 °C, 2 d (45%); (c) PhSeK, 
DMF, 48 h (60%).
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In an effort to avoid elimination, the less basic selenophenol (PhSeH) was stirred with 180 for 
either 4 days at room temperature or for 2 days at reflux, but in both cases only starting material 
was returned with no trace of elimination product 181 or the desired selenide product 182. Due to 
the limited information available in the literature on how to perform the procedure this method 
was abandoned in preference for alternative protecting group strategies.
Boc-L-Thr-OH 178 was treated with /Moluenesulphonic acid and 2,2-dimethoxypropane in 
tetrahydrofuran at reflux for 18 hours to give oxazolidine 183 in excellent yield (99%). 
Commercially available (/?)-isoalaninol was coupled with oxazolidine 183, by treatment with 
pyBOP and triethylamine in dichloromethane for 18 hours to give dipeptide 184 in excellent yield 
(100%). In order to provide orthogonal protection of the free alcohol of (i?)-isoalaninol, reaction 
with either acetic anhydride in pyridine for 36 hours or ferf-butyldimethylsilylchloride, imidazole 
and A^A^-dimethylaminopyridine in A^V-dimethylformamide for 36 hours gave fully protected 
dipeptide 185 or 186 in 73 and 98% yield, respectively (Scheme 80).
Scheme 80. Synthesis of 185 and 186, the side chain of micrococcin Pj
>ecBocHN C02H boc C° 2H
1 7 8  183 '  \ / ° ' Y  H 9 TBS
186
Reagents and conditions: (a) p-TsOH, 2,2-dimethoxypropane, THF, reflux, 18 h (99%); (b) (R)—isoalaninol, Et3 N, 
pyBOP, CH2 Cl2 , 0 °C-RT, 18 h (100%); (c) acetic anhydride, pyridine, RT, 36 h (73%); (d) imidazole, DMAP, 
TBDMSCI, DMF, 36 h (98%).
Before proceeding it is worth considering the first reaction in Scheme 80, where Boc-L-Thr-OH 
178, 2,2-dimethoxypropane and /Moluenesulphonic acid in THF generates oxazolidine 183. 2,2- 
dimethoxypropane is the acetal protected acetone and interestingly this reaction does not proceed 
if the acetal was substituted for the unprotected ketone. The reason for this is quite obvious, the 
free ketone under the conditions above will undergo mixed reactions, the acetone is easily 
converted into an enol 188 as well as the activated oxonium ion 189. The two species would 
freely react in an aldol reaction (a) (Scheme 81) and continue to do so forming mixed aldol 
products. 2,2-dimethoxypropane is therefore used to mitigate against competing side reactions.
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Scheme 81. Mechanism for oxazolidine formation 183
BocHN^ COzHOMe b +OMe BocHNV -C
^  =  ^  * H .A
190 178 191 192 183
The mechanism of the reaction to form oxazolidine 183 begins with the protonation of 2,2- 
dimethoxypropane by p-TsOH present in catalytic amounts followed by intramolecular 
displacement of methanol (b), forming the activated oxonium ion 190. Boc-L-Thr-OH 178 will 
attack oxonium ion 190 through the hydroxyl group (c) forming acetal 191. Through protonation 
of the remaining methoxy group and intramolecular displacement (d) oxonium ion 192 is 
generated. The lone pair of electrons on the nitrogen is more available then if it was an amide due 
to the carbarmate functionality present as a consequence of the Boc group. Therefore nitrogen 
attacks oxonium ion 192 (e) forming oxazolidine 183.
4.4 Synthesis of alkynone B
Synthesis of bisthiazole aldehyde 162 was achieved in 54% yield over 6 steps using methodology 
developed in the synthesis of saramycetic acid I 47 (Chapter 3-3.6.3). Grignard addition of the 
corresponding ethynylmagnesium bromide with aldehyde 162 gave the propargylic alcohol 193 in 
moderate yield (54%). Attempts to hydrolyze the terminal ester of 193 to a carboxylic acid for 
incorporation of the threonine-(/?)-isoalaninol side chain were unsuccessful, resulting in the 
isolation of unidentified material. Gratifyingly oxidation of the propargylic alcohol 193 to give 
the desired alkynone 194 was achieved by treatment with o-iodoxybenzoic acid in 
dimethylsulphoxide for 2 hours in excellent yield (95%). Typically alkynone 194 was unstable in 
air and characterization of the compound could only be achieved from *H and 13C NMR 
spectroscopic data. Nonetheless synthesis of compound 194 demonstrates that a Bohlmann- 
Rahtz precursor based on the side chain of micrococcin Pi could be synthesized in preparation for 
pyridine synthesis (Scheme 82).
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Scheme 82. Synthesis of alkynone 194
co 2Et
Eto 6 steps t5? y°)
C02Et C02EtrS b rS\     m ^  a II / II/  =N ____  ^ Q l y     HO  ^ o.0 Vr8 /V /V
162 193 194
Reagents and conditions: (a) HCCMgBr, THF, 0 °C-RT, 1 h (47%); (b) IBX, DMSO, RT, 2 h (95%).
In order to incorporate the whole of the side chain of micrococcin Pi in an alkynone suitable for a 
Bohlmann-Rahtz synthesis we explored the hydrolysis of the 4’-ester of bisthiazole 162. Initially 
aldehyde 162 was treated with six equivalents of lithium hydroxide in methanol-water and stirred 
for 18 hours. After acidic work up, *H NMR spectroscopic analysis indicated multiple reaction 
products which could be indicative of the Cannizzaro reaction13 (side reaction of aldehydes in 
concentrated base), giving dicarboxylic acid 195 and alcohol 196. This was further supported by 
low resolution mass spectrometiy, identifying both parent ions. The mechanism by which 
compounds 195 and 196 were generated follows a relatively simple pathway (Scheme 83). Ester 
hydrolysis would occur (a), in concentrated base the resulting aldehyde may undergo nucleophilic 
attack from excess hydroxide ions (b) forming an anion which in turn is deprotonated by another 
hydroxide ion (c) forming a dianion. The dianion is so electron rich that it can donate a hydride to 
a corresponding aldehyde, generating, after acidic work up the diacid 195 and alcohol 196 (d).
Scheme 83. Hydrolysis of aldehyde 162
C02Et C02H C02H
b j l  MeOH-H20  l 5  .  i S
V i  S hoV T  s HV i  s
162 195 196
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When one equivalent of lithium hydroxide was used, there was no evidence of the Canizarro 
products by *H NMR spectroscopy, but in addition to starting material other unidentifiable 
products were present that could not be removed using available methods. Due to the difficulties 
experienced in hydrolysing aldehyde 162, it was decided to attempt the hydrolysis of the ester 
from the diethoxyacetal-protected bisthiazole 161 which was synthesized in 6 steps and 54% 
overall yield in the synthesis of saramycetic acid I 47. Gratifyingly when compound 161 was 
treated with 6 equivalents of lithium hydroxide in methanol-water for 18 hours the desired acetal 
protected carboxylic acid 197 was isolated cleanly and in good yield (85%) after simple acidic 
extraction (Scheme 84).
Scheme 84. Hydrolysis of bisthiazole 161
EtO
EtO
161
c o2h
MeOH-H20
^ EtO N / —“S 
6  eq. LiOH, 18 h (85%) \ __*  J
EtO S "
197
Compound 185 was iV-deprotected according to literature procedures9 to give the amine as its 
TFA-acetate salt which, after evaporation in vacuo, was submitted for peptide coupling with 
triethylamine, pyBOP and acid 197 in dichloromethane for 4 hours. Purification by column 
chromatography gave the desired acetal protected side chain of micrococcin Pi 198 in limited 
yield (7%), perhaps due to steric hinderance from the threonine hydroxyl group. This 
demonstrated the potential for the preparation of a Bohlmann-Rahtz precursor containing the 
micrococcin Pi side chain, but limited material prevented further progress in this study (Scheme 
85).
Scheme 85. Synthesis of the acetal protected side chain of micrococcin Pj
>co OAc
O
185
OAc
EtO
M J
EtO
197
OAc
198
Reagents and conditions: (a) TFA-CH2 CI2, RT, 4 h; (b) Et3 N, pyBOP, CH2 CI2, 0 °C-RT, 4 h (7%).
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4.5 Synthesis of fragment C
Starting with oxazolidine 183, peptide coupling was achieved by activation with ethyl 
chloroformate in the presence of triethylamine and H-i-serine-OMe in tetrahydrofuran at 0 °C 
for 3.5 hours to give the desired oxazolidine dipeptide 199 after column chromatography in 
excellent yield (93%). Subsequent treatment with DAST in dichloromethane at -78 °C for 3 
hours according to literature procedures14 gave cyclized oxazoline 200 in excellent yield (89%) 
(Scheme 86).
Scheme 86. Synthesis of oxazoline 200
X°X — A ' O - ' C O . M e  C^Cn
Boc C02H Boc §  = Boc T  V - c o ^ e
OH u ^'/
183 199 200
Reagents and conditions: (a) ethyl chloroformate, Et3 N, THF, 0 °C, 1 h; then HCI.H-Ser- 
OMe, 0 °C, 2.5 h (94%); (c) DAST, CH2 CI2, -78 °C, 3 h (89%).
According to the literature, there are two possible mechanisms that facilitate cyclization using 
DAST,15 these mechanisms can be consider to be identical for Deoxofluor (an analogous reagent 
to DAST) that exhibits superior thermal stability then DAST and therefore can be used at a higher 
temperature (Chapter Three-3.2.3). Neither mechanism has been shown by mechanistic studies 
however they are still worthy of consideration, in the example mechanisms (Scheme 87) to follow 
the cyclization agent used will be DAST.
Mechanism 1 is thought to initiate through the carbonyl of the amide in compound 199 by 
nucleophilic attack on the sulphur atom of DAST. This process is enhanced by proton abstraction 
by the amine functionality of the cyclizing agent and furthermore results in loss of fluoride (a). 
Curiously the imidate 201 is thought to undergo nucleophilic attack from fluoride (b) causing loss 
of cyclizing agent possibly as the zwitterion intermediate and generation of fluoroimine 202. 
Clearly fluoroimine 202 is activated for intramolecular nucleophilic attack from the hydroxyl 
group (c), giving the desired product 200 and hydrogen fluoride as a leaving group. It is likely 
that hydrogen fluoride and the zwitterion intermediate forming a tight ion complex, compound 
203, as any free hydrogen fluoride generated in the reaction would have deleterious effects on 
silyl protection groups, a feature not observed when using either DAST or Deoxofluor.16 
The explanation for mechanism 2 begins with nucleophilic attack from the oxygen of the 
hydroxyl group in compound 199 to the sulphur of the cyclizing agent (d) generating an ionic 
complex. Activation of the hydroxyl group now undergoes nucleophilic substitution from the
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amide functionality in compound 204 (e), resulting in generation of the desired product 200 and 
the tight ion complex 203.
Scheme 87. Mechanism for oxazoline formation from Deoxofluor or DAST
v F 
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It is unlikely that mechanism 1 is a viable route to cyclization for two reasons, firstly fluoride is 
not a good nucleophile and therefore intermolecular attack process (b) would not be expected to 
occur over intramolecular attack from the hydroxyl group. Secondly and equally importantly, is 
the example used in the synthesis of the oxazole fragment for methyl sulfomycinate (Chapter 3- 
3.2.3). The dipeptide 103 underwent cyclization and inversion at the 5’ position on the oxazoline 
ring 104 (Scheme 87). It is accepted that inversion at the (3-position will occur when using these 
cyclizing agents,17 this could not be achieved through mechanism 1. Although the actually 
mechanism is not clear, mechanism 2 is more favourable since it is simpler and does not over 
complicate the process. It is remarkable to observe that silyl protection groups tolerate the 
reaction conditions and is evidence in support of tight ion complex formation which would be a 
side product of both mechanisms.
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Thionation of oxazoline 200 was achieved by treatment with hydrogen sulphide gas and 
triethylamine in methanol at room temperature for 4 hours to give thioamide 205 in moderate 
yield (45%). Cyclization using DAST in dichloromethane at -78 °C for 3 hours gave thiazoline 
206, followed by treatment with DBU and bromotrichloromethane at -20 °C for 18 hours gave 
thiazole 207 in 62% isolated yield. Moreover thiazole 207 was isolated in 60% yield from a one- 
pot two-step reaction of thioamide 205, a transformation not previously reported, by treatment 
with DAST in dichloromethane at -78 °C for 3 hours, immediately followed by a temperature 
raise to -20 °C, the addition of DBU and bromotrichloromethane and stirring the reaction for 18 
hours. Saponification of thiazole 207 with lithium hydroxide in methanol-water gave carboxylic 
acid 208 in quantitative yield (Scheme 88).
Scheme 88. Synthesis of carboxylic acid 208
1
> C C n — ><N^YKv.C02Me — ^N-Cn —C—  K -C n
800 S V. 800 |^ J> ',,C02Me Boc r j ^ - c 0 2Me
9 0 0  __  I—  R = Me, 207
200 205 206 e L_^R=H,208
Reagents and conditions: (a) H2 S, MeOH-Et3 N, RT, 4 h (45%); (b) DAST, CH2 CI2) -78 °C, 3 h (100%); (c) CBrCI3, DBU, CH2 CI2,
-20 °C, 18 h (62%); (d) DAST, CH2 CI2, -78 °C, 3 h; then CBrCI3, DBU, -20 °C, 18 h (60%); (e) LiOH, MeOH-H2 Q, RT, 18 h (100%).
Activation o f208 by treatment with ethyl chloroformate and triethylamine in tetrahydroftiran at 0 
°C gave the mixed anhydride intermediate 209. Reaction o f209 with either the lithium enolate of 
ethyl acetate or the magnesium enolate of ethyl potassium malonate gave |3-keto ester 210 as a 
mixture of tautomers in 16 and 58% isolated yield, respectively (Scheme 89).
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Scheme 89. Synthesis of p-keto ester 210
208 209 2 1 0
Reagents and conditions: (a) Ethyl chloroformate, Et3 N, THF, 0 °C, 1.5 h; (b) "BuLi, 'Pr2 NH, THF, 0 °C; then 
-78 °C, EtOAc, 30 min; 187, 1.5 h (16%); (c) ethyl chforoformate, E^N, THF, 0 °C, 20 min; (d) MeMgBr, 
potassium ethyl malonate, THF, 0 °C, 30 min; RT, 1.5 h; 187,3.5 h (58%).
Thus far |3-keto ester 210 has been generated in 7 steps and 13% overall yield by preparing a 
thiazole directly from the secondaiy thioamide in a hitherto unreported procedure. Generation of 
enamine 211 from P-keto ester 210 was attempted under various conditions (Scheme 90, Table 
32), but was not easily achieved. All of the conditions used to synthesize 211 failed to generate 
the enamine (entries 1-10). Reacting the material for longer periods of time did not promote 
enamine formation (entries 2,3,9 & 10). When microwave irradiation was used at high 
temperature and elevated pressure, the reaction was irreproducible (entries 5 & 6). Even the use 
of toluene-acetic acid (5:1), a tried and tested method for enamine formation, gave only starting 
material by NMR spectroscopy or after column chromatography. A 14 fold excess of 
ammonium acetate under Dean-Stark conditions also proved unsuccessful (entry 9), and the use 
of aqueous ammonium hydroxide in methanol in large excess (1:3) only returned starting material 
(entiy 10). It is not clear why enamine formation proved so difficult to achieve, the presence of 
the oxazolidine ring may be contributing to steric effects. There appears to be only one example 
in the literature for the transformation of a p-keto-ester thiazole to an enamine thiazole.18 This 
method was attempted (entiy 5 and 6) but returned only starting material.
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Scheme 90. Generation of enamine 211
OEt OEt
210 211
Table 32. Efforts to synthesis enamine 211 from 210
Entry
n h 3
source
Equivalents
ofNH3 Solvent
Temperature
/°c Conditions Time Compound8
1 NH4OAc 5 EtOH 50 thermal 4 h 210
2 NH4OAc 5 PhMe 120 thermal 18 h 210
3 NH4OAc 10 PhMe-AcOH (5:1) 120 thermal 18 h 210
4 NH4OAc 10 PhMe-AcOH (5:1) 120 thermal 4 h 210
5 NH4OAc 10 PhMe-AcOH (5:1) 120 microwave6 30 min -
6 NH4OAc 10 PhMe-AcOH (5:1) 120 microwave6 30 min 210c
7 NH4OAc 12 PhMe 120 microwave6 30 min 210
8 NH4OAc 12 PhMe-AcOH (5:1) 120 microwave6 30 min 210
9 NH4OAc 14 PhMe-AcOH (5:1) 120 thermal, Dean-Stark 18 h 210d
10 n h 4oh -
MeOH-NH4OH (aq) 
(3:1)
25 thermal 18 h 210
8 Outcome determined by 'h NMR spectroscopic analysis only.b simultaneous cooling.0 50% isolated recovery of 
starting material by column chromatography.d 4% isolated recovery of starting material by column chromatography.
In an effort to circumvent the need to synthesize (3-keto ester 210 in the synthesis of enamine 211, 
the ready conversion of nitriles to enamines was investigated.19 Thiazole ester 207 was stirred in 
methanolic ammonia for 18 hours at room temperature and after purification gave the 
corresponding amide 212 in quantitative yield. Treatment of the amide with phosphorous 
oxychloride in pyridine at 0 °C for 2 hours gave the corresponding nitrile 213 in good yield (77%) 
(Scheme 91).
Scheme 91. Synthesis of nitirile 213
-  >fc - >0Boc r j ^ c ° 2Me Boc I J ^ C O N H j Boc V o z
207 2 1 2 213
Reagents and conditions: (a) NH3> MeOH, RT, 18 h (100%); (b) POCI3, pyridine, 0 °C-RT, 2 h (77%).
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Nitrile 213 was reacted according to a modified literature procedure19 with the magnesium enolate 
of ethyl acetate generated from lithium diisopropylamine and methylmagnesium bromide. After 
stirring at 0 °C for 1 hour the reaction was quenched with saturated ammonium chloride and 
extracted with dichloromethane, starting material was recovered in quantitative yield. When the 
reaction was attempted using potassium ethyl malonate as the nucleophile, only starting material 
was isolated. In an effort to ensure protonation of the reaction intermediate the reaction was 
carried out in a 25% w/v sodium methoxide-methanol solution and stirred in the microwave 
under cooling conditions at 110 °C for 1 hour. A congealed brown gel was isolated directly from 
the microwave which was partitioned between water and dichloromethane, with the addition of 
ethyl acetate to aid solvation of the suspension. In contrast no starting material was observed in 
the NMR spectrum of the extracted material, but multiple products were formed which did not 
support enamine formation but suggested some degradation of the oxazolidine ring.
4.7 Conclusion
Steps towards the total synthesis of micrococcin Pi have proven to be challenging, requiring 
efforts that have been both disappointing and rewarding. Although greater diversity of protection 
group chemistry utilizing selenium chemistry was unsuccessful, the synthesis of two orthogonally 
protected side chain dipeptides was achieved. Our study demonstrates that the synthesis of a 
precursor to the Bohlmann-Rahtz pyridine is viable en route to the core of micrococcin Pi. 
Synthesis of a bisthiazole-alkynone was achieved in 8 steps and 24% overall yield. In addition, 
we have investigated the hydrolysis of various bisthiazole fragments, identifying that the acetal 
protected bisthiazole can be successfully hydrolyzed and coupled to a side chain precursor for 
elaboration to an alkynone in the total synthesis of micrococcin Pi.
The corresponding Bohlmann-Rahtz precursor, namely |3-keto ester 210 has been synthesized in 
7 steps and 13% overall yield. It is noteworthy to recognize that this strategy appears to be the 
only example in the literature that cyclizes and oxidises a secondaiy thioamide to the 
corresponding thiazole in one pot. Enamine formation was unsuccessful from the (3-keto ester 
under the conditions described and is likely due in part to steric hindrance by the 
butoxycarbonyloxazolidine and secondly to the increased propensity of the thiazole adjacent to 
the |3-keto ester to promote formation of the enol tautomer. Recently however the enamine was 
isolated within the group using copious quantities of ammonium acetate under harsh microwave- 
assisted conditions giving consistently 37% yield from the [3-keto ester. Indeed a one-pot two- 
or three-component reaction as described in the introduction may be the way forward. In addition 
further investigation of nucleophilic addition to the corresponding nitrile may yield the desired 
enamine when more encouraging conditions have been found.
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5 Summary
The re-emergence of the Bohlmann-Rahtz pyridine synthesis over the last decade has provided a 
viable route to 2,3,6-trisubstituted, 2,3,4,6-tetrasubstituted and 2,3,5,6-tetrasubstituted pyridines, 
the latter providing a substitution pattern hitherto unreported from Bohlmann-Rahtz 
intermediates. These methods have been broadened further by the introduction of mild reaction 
conditions using either NIS or iodine to facilitate facile cyclodehydration of the Bohlmann-Rahtz 
intermediate with total regiocontrol. In particular NIS methods have been shown to provide a 
valuable route to the core domain of the series d  thiopeptide antibiotic, cyclothiazomycin. 
Furthermore these new methods have the potential to provide complementary and independent 
pathways to access many of the thiopeptide antibiotics.
Degradation studies of thiopeptide antibiotics have led to the isolation of fragments that can help 
in the structural elucidation of the parent molecules. Although many of the fragments have been 
assigned based on spectroscopic data, very few of these hypotheses have been verified by 
chemical synthesis. Our efforts to synthesize degradation fragments from thiopeptide antibiotics 
have helped to address this short fall, validating known data and consolidating methods that could 
lead to the total synthesis of the parent antibiotics.
Successes include the synthesis of methyl sulfomycinate 39 in 9 steps from H-Thr-OMe and 15% 
overall yield, and elaboration of this target molecule to give sulfomycinic amide 38 and 
sulfomycinine 37. This has enabled us to confirm the outcome of Abe’s methanolysis studies and 
has provided a viable route to this region of the sulfomycin cyclic peptides. The total synthesis of 
saramycetic acid I 47 in 9 steps and 11% overall yield using methodology developed within the 
research group provided bisthiazoles for application in the total synthesis of the thiopeptide 
antibiotics.
Steps towards the total synthesis of micrococcin Pi have demonstrated that the synthesis of 
enamine and alkynone precursors of Bohlmann-Rahtz pyridines is viable en route to the core of 
micrococcin Pi. The bisthiazole-alkynone 194 was synthesized in 8 steps and 24% overall yield, 
whilst the corresponding (3—keto ester 210 was synthesized in 7 steps and 13% overall yield. 
These methods could be used in the future to construct micrococcin Pi in order to specify once 
and for all the correct stereochemistry of this biologically important thiopeptide antibiotic.
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6  Experimental
6.1 Experimental techniques
Commercially available reagents were used without further purification; solvents were dried by 
standard procedures. Light petroleum refers to the fraction with bp 40-60 °C, ether (Et2 0 ) refers 
to diethyl ether and EtOAc refers to ethyl acetate. Column chromatography was carried out using 
Merck Kieselgel 60 H silica or Matrex silica 60. Analytical thin layer chromatography was 
carried out using aluminium-backed plates coated with Merck Kieselgel 60 GF254 that were 
visualised under UV light (at 254 and/or 360 nm). Melting points (mp) were determined on a 
Kofler hot stage apparatus and are uncorrected. Infra-red (IR) spectra were recorded in the range 
4000-600 cm-1 on a Perkin-Elmer 1600 series FTIR spectrometer using KBr disks for solid 
samples and thin films between NaCl plates for liquid samples or as a nujol mull and are reported 
in cm-1. Nuclear magnetic resonance (NMR) spectra were recorded in CDCI3 at 25 °C unless 
stated otherwise using a Bruker DPX 400 instrument operating at 400 MHz for 'H spectra and 
100 MHz for ,3C spectra and were reported in ppm; J  values were recorded in Hz and 
multiplicities were expressed by the usual conventions (s=singlet, d=doublet, t=triplet, 
app=apparent, m=multiplet). Low-resolution mass spectra (MS) were determined using a Fisons 
VG Platform II Quadrupole instrument using atmospheric pressure chemical ionization (APcI) 
unless otherwise stated. ES refers to electrospray ionization, Cl refers to chemical ionization 
(ammonia) and El refers to electron impact. High-resolution mass spectra were obtained courtesy 
of the EPSRC Mass Spectrometry Service at Swansea, UK using the ionisation methods specified. 
Microanalyses were recorded using a Perkin-Elmer 240C Elemental Analyzer. Specific rotations 
were measured at the indicated temperature using an AA-1000 (Optical Activity Ltd) polarimeter 
at the sodium D line and are given in deg cm3g-1dm-1 with concentration c in 10~2 gem-3. In 
vacuo refers to evaporation at reduced pressure using a rotary evaporator and diaphragm pump, 
followed by the removal of trace volatiles using a vacuum (oil) pump. Microwave experiments 
were carried out in a CEM Discovery microwave synthesiser at the temperature and initial power 
stated.
6.2 General experimental procedures
6.2.1 General procedure for Michael addition of enamines and alkynones
A solution of enamine 1 (0.36 mmol, 1 equiv.) and alkynone 2 (0.56 mmol, 1.5 equiv.) in EtOH 
(5 ml) was stirred at 50 °C for 1-7 h, cooled and evaporated in vacuo to give the crude 
aminodienone 3.
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6.2.2 General procedure for the cyclodehydration of aminodienones using NIS
A solution of aminodienone 3 (0.2 mmol, 1 equiv.) and iV-iodosuccinimide (0.25 mmol, 1.2 
equiv.) in EtOH (4 ml) was stirred at 0 °C for 1 h and then evaporated in vacuo, to give the crude 
pyridine 4.
6.2.3 General procedure for the catalytic cyclodehydration of aminodienones using iodine
A solution of aminodienone 3 (0.22 mmol, 1 equiv.) and iodine (0.04 mmol, 20 mol%) in EtOH 
(4 ml) was stirred at RT for 30 min and an aqueous solution of sodium thiosulphate (10% w/v, 10 
ml) was added. The mixture was extracted with CH2CI2 (3 x 20 ml) and the organic extracts were 
combined, dried (Na2S0 4 ) and evaporated in vacuo to give pyridine 4.
6.2.4 General procedure for the bromocyclization of aminodienones using NBS
A solution of aminodienone 3 (0.28 mmol, 1 equiv.) and iV-bromosuccinimide (0.34 mmol, 1.2 
equiv.) in EtOH (5 ml) was stirred at 0 °C for 1 h and evaporated in vacuo, to give the crude 
bromopyridine 70.
6.2.5 General procedure for the synthesis of propargylic alcohols from aldehydes
A solution of aldehyde 67 (5.0 mmol) in dry THF (10 ml) was added to a stirred solution of 
ethynylmagnesium bromide in THF (0.5 M; 15 ml, 7.5 mmol) at 0 °C. The mixture was stirred at 
0 °C for 2 h, warmed to room temperature and stirred overnight. Saturated aqueous NH4CI 
solution (2 ml) was added, the mixture was evaporated in vacuo and partitioned between Et2 0  (30 
ml) and saturated aqueous ammonium chloride solution (30 ml). The ethereal layer was washed 
with brine (30 ml), dried (Na2SC>4) and evaporated in vacuo.
6.3 Experimental procedures 
terf-Butyl (3-aminocrotonate (le)
n YH2^ 'k ^ C O z 'B u  ------------- -  / ^ C 0 2'Bu
Ammonium hydroxide solution (35%, 40 ml) was added to a mixture of tert-butyl acetoacetate 
7b (4 ml, 24.2 mmol) in MeOH (40 ml) and stirred at 50 °C for 18 h. After cooling, the solution 
was evaporated in vacuo and partitioned between H2O (40 ml) and Et2 0  (40 ml). The aqueous 
layer was further extracted with EtO Ac (2 x 35 ml) and the combined organic extracts were 
washed with brine (25 ml), dried (Na2S0 4 ) and evaporated in vacuo to give the title compound1 as 
a clear oil (3.72 g, 98%) (Found: MH+, 158.1178. CgHieNCh, requires M /f\ 158.1176); IR 
(film)/cm_1 vmax 3554, 3341, 2980, 2919, 1666, 1622, 1567, 1454, 1390, 1366, 1296, 1150, 983,
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790; JH NMR (400 MHz; CDC13) 5 8.20 (1H, bs, NH), 4.20 (1H, bs, NH), 4.35 (1H, s, CH), 1.80 
(3H, s, Me), 1.38 (9H, s, CMe3); 13C NMR (100 MHz, CDC13) 5 170.3 (C), 158.8 (C), 85.9 (CH),
78.2 (C), 28.6 (Me), 22.4 (Me); m/z (APcI) 158 (MH+, 77%).
Ethyl 3-amino-3-phenylpropenoate (If)
PhX / C 0 2Et -  phA ^ C 0 2Et
Ammonium acetate (13.4 g, 0.17 mol) was added to a solution of ethyl benzoylacetate 7d (5 ml,
29.0 mmol) and the mixture was heated at reflux in toluene-glacial acetic acid (5:1; 40 ml) for 20 
h. After partitioning between H2O (100 ml) and Et2 0  (60 ml), the aqueous layer was further 
extracted with Et2 0  (2 x 25 ml) and the combined organic extracts were washed sequentially with 
saturated aqueous NaHC03 solution (50 ml) and brine (25 ml), dried (MgS0 4 ) and evaporated in 
vacuo. Purification by column chromatography on SiC>2, eluting with light petroleum-EtOAc 
(3:1) (R/0.11), gave the title compound1 as a pale yellow oil (3.32 g, 60%) (Found: MNH4+, 
209.1289. C11H17N2O2, requires MNH4\  209.1285); IR (film)/cm_1 vmax 3441, 3326, 2979, 2936, 
1663, 1617, 1555, 1492, 1364, 1176, 1095, 1025, 796, 772, 699; lH NMR (400 MHz; CDC13) 8  
8.35 (1H, bs, NH), 7.33-7.12 (5H, PhH), 7.00 (1H, bs, NH), 4.75 (1H, s, CH), 3.95 (2H, q, J 7.1, 
OCi72Me), 1.05 (3H, t, J  7.1, CH2Me); 13C NMR (100 MHz, CDC13) 8  170.5 (C), 160.5 (C),
137.7 (C), 130.3 (CH), 128.9 (CH), 126.2 (CH), 84.7 (CH), 59.0 (CH2), 14.6 (Me); m/z (APcI) 
192 (MH+, 100%) and 146 (13).
l-Phenylprop-2-yn-l-one (2a)
A solution of o- iodoxybenzoic acid (IBX) (3.65 g, 13.0 mmol) in DMSO (110 ml) was stirred for 
15 min at room temperature until homogeneous. A solution of l-phenyl-2-propyn-l-ol 6 8 a 
(1.32 g, 10.0 mmol) in DMSO (10 ml) was added and the mixture was stirred for 5 h. H2O (30 
ml) was added and the mixture was stirred at room temperature for 1 0  min, cooled in ice and 
partitioned between H2O (120 ml) and Et2 0  (90 ml). The mixture was filtered through Celite® and 
the aqueous layer was further extracted with Et2 0  (50 ml). The organic extracts were combined, 
washed sequentially with H2O (3 x 50 ml), saturated aqueous (NaHC03) solution (70 ml) and
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brine (70 ml), dried (Na2SC>4) and evaporated in vacuo to give the title compound as a pale yellow 
solid (1.0 g, 77%), mp 49-50 °C (MeOH) (lit.3 mp 47-48 °C) (Found: tvT, 130.0414. CoH60, 
requires lv t , 130.0413); IR (KBr)/cm ' vm»  3231, 2094, 1645, 1593, 1578, 1452, 1317, 1261, 
1173, 1005, 695; 'H NMR (400 MHz; CDCb) 8  8.12 (2H, m, o-PhH), 7.55 (1H, m, /> Ph/7), 7.45 
(2H, m, m—PhH), 3.36 (1H, s, CH); ,3C NMR (100 MHz; CDCI3) 8  177.5 (C), 136.1 (C), 134.6 
(CH), 129.7 (CH), 128.7 (CH), 80.9 (C), 80.3 (CH); m/z (El) 130 (M +, 16%), 77 (32), 53 (100).
l-(4-Chlorophenyl)prop-2-yii-l-one (2h)
OH 0
A solution of o-iodoxybenzoic acid (IBX) (5.84 g, 20.8 mmol) in DMSO (120 ml) was stirred for 
15 min at room temperature until homogeneous. A solution of l-(4—chlorophenyl)prop-2-yn-l- 
ol 68b (2.72 g, 16.3 mmol) in DMSO (20 ml) was added and the mixture was stirred for 5 h. H2O 
(40 ml) was added and the mixture was stirred at room temperature for 10 min, cooled in ice and 
partitioned between H2O (120 ml) and Et2 0  (90 ml). The mixture was filtered through Celite® and 
the aqueous layer was further extracted with Et2 0  (50 ml). The organic extracts were combined, 
washed sequentially with H2O (3 x 50 ml), saturated aqueous NaHCOa solution (70 ml) and brine 
(70 ml), dried (Na2S0 4 ) and evaporated in vacuo. Purification by column chromatography on 
SiC>2, eluting with CHCI3 (R/0.45), gave the title compounct as a pale yellow solid (2.50 g, 93%), 
mp 68-69 °C (MeOH) (lit.4 mp 68-69 °C) (Found: M+, 165.9991. CjHsCFo, requires A t, 
165.9994); IR (KBr)/cm_1 vmax 2921, 2853, 2360, 1662, 1462, 1377, 1248, 1094, 1003, 722; ‘H 
NMR (400 MHz; CDC13) 8  7.98 (2H, appd, J  8 .6 , 3’,4’-PhH), 7.41 (2H, appd, J  8 .6 , 2’,5’-PhH),
3.38 (1H, s, CH); 13C NMR (100 MHz; CDC13) 8  176.1 (C), 141.3 (C), 134.5 (C), 131.0 (CH),
129.1 (CH), 81.4 (C), 79.9 (CH); m/z (El) 166 (M +, 7%), 164 (M+, 21), 138 (11), 136 (33), 113 
(3), 111 (12), 53 (100).
l-(4-M ethoxyphenyl)prop-2-yn-l-one (2i)
OH O
107
Chapter 6 <PhSD. ‘Thesis 2006 ‘ExperimentaC
A solution of o-iodoxybenzoic acid (IBX) (5.14 g, 18.3 mmol) in DMSO (120 ml) was stirred for 
15 min at room temperature until homogeneous. A solution of l-(4-methoxyphenyl)prop-2-yn- 
l-ol 6 8 c (2.27 g, 14.0 mmol) in DMSO (20 ml) was added and the mixture was stirred for 5 h. 
Water (40 ml) was added and the mixture was stirred at room temperature for 10 min, cooled in 
ice and partitioned between H2O (120 ml) and Et2 0  (90 ml). The mixture was filtered through 
Celite® and the aqueous layer was further extracted with Et2 0  (80 ml). The organic extracts were 
combined, washed sequentially with H2O (3 x 50 ml), saturated aqueous NaHCOa solution (70 
ml) and brine (70 ml), dried (Na2S0 4 ) and evaporated in vacuo. Purification by column 
chromatography on SiC>2, eluting with CHCI3 (R/0.29), gave the title compound as a pale yellow 
solid (2.24 g, 89%), mp 86-87 °C (MeOH) (lit.4 mp 85-87 °C) (Found: MH+, 161.0597. Ci0H9O2, 
requires M ft, 161.0597); IR (KBr)/cm_1 v ,^  3297, 2092, 1641, 1597, 1572, 1511, 1423, 1252, 
1170, 1116, 1023, 841, 758, 710, 685; JH NMR (400 MHz; CDC13) 8  8.05 (2H, appd, J  8.7, 2 \6 - 
PhH), 6 . 8 8  (2H, appd, J  8.7, 3 \5 ’-PhH), 3.88 (3H, s, OMe), 3.29 (1H, s, CH); 13C NMR (100 
MHz; CDCI3) 5 176.0 (C), 164.8 (C), 132.2 (CH), 129.2 (CH), 113.9 (CH), 80.4 (C), 80.1 (C),
55.6 (Me); m/z (APcI) 161 (MFC, 100%).
(4£)-2-Amino-3—ethoxycarbonylhexa-2,4-diene-6—one (3a)
n h 2
^ ^ C 0 2Et
Aminodienone 3a was prepared according to the general procedure 6.2.1 using ethyl (3- 
aminocrotonate la  and 4-(trimethylsilyl)but-3-yn-2-one 2d. Purification by column 
chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 0.23), gave the title 
compound as a yellow solid (58 mg, 82 %), mp 125-126 °C (light petroleum-EtOAc) (lit.3 mp 
125.5-126.4 °C) (Found: C, 60.6; H, 7.7; N, 7.0. Calc, for CioH^NCb: C, 60.1; H, 7.7; N, 7.1%) 
(Found: MH+, 198.1125. Ci0Hi6NO3 requires M/T", 198.1125); IR (KBr)/cm_1 vmax 3334, 3193, 
2977,1647, 1546, 1488, 1459, 1362, 1319, 1286, 1205, 1180, 1112, 1024, 970, 950, 844; ’HNMR 
(400 MHz; CDC13) 8  9.65 (1H, bs, NH), 7.55 (1H, d, J  15.6, 4-H), 6.50 (1H, d, J  15.6, 5-H), 5.5 
(1H, bs, NH), 4.22 (2H, q, J7.1, OCH2Mq), 2.22 (3H, s, Me), 2.15 (3H, s, Me), 1.28 (3H, t, J7.1, 
CH2M?); 13C NMR (100 MHz; CDC13) 8199.0 (C), 169.7 (C), 165.7 (C), 139.5 (CH), 121.1 (CH),
94.4 (C), 60.0 (CH2), 28.4 (Me), 22.6 (Me), 14.4 (Me); m/z (APcI) 198 (MH+, 100%) and 181 
(48).
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(4£)-2-Amino-3—ethoxycarbonyl-6-phenylhexa-2,4—diene—6—one (3b)
n h 2
^U^C02Et
Aminodienone 3b was prepared according to the general procedure 6.2.1 using ethyl [3- 
aminocrotonate la  and l-phenylprop-2-yn-l-one 2a. Purification by column chromatography 
on SiC>2 , eluting with light petroleum-EtOAc (1:1) (R/0.24), gave the title compound" as a yellow 
solid (79 mg, 85 %), mp 156-157 °C (light petroleum-EtOAc) (Found: C, 69.4; H, 6 .6 ; N, 5.2. 
Calc, for Ci5H18N 03: C, 69.5; H, 6 .6 ; N, 5.4%) (Found: MH+, 260.1282. Ci5H17N 03 requires 
M id, 260.1281); IR (KBr)/cm-1 vmax 3342, 3203, 2976, 1623, 1580, 1539, 1497, 1378, 1354, 
1320, 1286, 1223, 1205, 1178, 1110, 1055, 1036, 1023, 976, 847, 705, 626; *H NMR (400 MHz; 
CDC13) 6  9.67 (1H, bs, NH), 7.94 (2H, m, o-Phtf), 7.86 (1H, d, J  15.0, 4-H), 7.43 (3H, m,p- 
PhH), 7.39 (1H, d, J  15.0, 5-H), 5.70 (1H, bs, NH), 4.24 (2H, q, J  7.1, OCtf2Me), 2.33 (3H, s, 
Me), 1.35 (3H, t, J7.1, CH2M?); 13C NMR (100 MHz; CDC13) 8  190.9 (C), 169.8 (C), 166.7 (C),
141.1 (CH), 139.7 (C), 131.8 (CH), 128.4 (CH), 128.1 (CH), 115.8 (CH), 95.6 (C), 60.0 (CH2),
22.6 (Me), 14.5 (Me); m/z (APcI) 260 (MFT, 100%).
(4£)—2-Amino-3-ethoxycarbonyl-6-(4—chlorophenyl)hexa-2,4—diene—6 -one (3c)
n h 2
/ A^,C0 2Et
C 0 2Et
Aminodienone 3c was prepared according to the general procedure 6.2.1 using ethyl (3- 
aminocrotonate la  and l-(4-chlorophenyl)prop-2-yn-l-one 2h. Purification by column 
chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 0.18), gave the title 
compound as a yellow solid (91 mg, 8 6  %), mp 163-164 °C (light petroleum-EtOAc) (Found: 
MPT, 294.0893. Ci5Hi7ClN0 3 requires M id, 294.0891); IR (KBr)/cm_1 Vmax 3315, 3168, 2964, 
1653, 1630, 1591, 1571, 1539, 1485, 1350, 1323, 1288, 1224, 1177, 1120, 1089, 1057, 1037, 
1012, 975, 856, 824, 743, 713, 642, 589, 538, 502; lU NMR (400 MHz; CDC13) 8  9.71 (1H, bs, 
NH), 7.88 (1H, d, J  15.0, 4-H), 7.84 (2H, appd, J8.5, 2 \6 ’-PhH), 7.36 (2H, appd, J8.5, 3 \5 ’-
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PhH), 7.33 (1H, d, J  15.0, 5-H), 5.78 (1H, bs, NH), 4.20 (2H, q, J  7.1, OCH2Me), 2.27 (3H, s 
Me), 1.35 (3H, t, J7A , CH2Me); 13C NMR (100 MHz; CDC13) 8 189.5 (C), 169.7 (C), 167.0 (C),
141.6 (CH), 138.0 (C), 138.0 (C), 129.5 (CH), 128.6 (CH), 115.1 (CH), 95.7 (C), 60.1 (CH2), 22.6 
(Me), 14.5 (Me); m /z(APcI) 296 (Mil*. 32%), 294 (MU', 100).
(4£)—2-Amino-3—ethoxycarbonyl—6—(4-methoxyphenyl)hexa-2,4-diene-6-one (3d)
n h 2
J ^ co2ei
NH;
MeO'
Aminodienone 3d was prepared according to the general procedure 6.2.1 using ethyl |3- 
aminocrotonate la  and l-(4-methoxyphenyl)prop-2-yn-l-one 2i. Purification by column 
chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) (R/ 0.50), gave the title 
compound6 as a yellow solid (99 mg, 95 %), mp 155-156 °C (light petroleum-EtOAc) (lit.8 159 
°C) (Found: MH+, 290.1386. C16H20NO4 requires M Rt, 290.1387); IR (KBr)/cm_1 vmax 3297, 
3145, 2974, 1717, 1627, 1598, 1576, 1539, 1511, 1475, 1362, 1321, 1300, 1263, 1231, 1168, 
1126 1021, 834, 586; lU NMR (400 MHz; CDC13) 6  9.63 (1H, bs, NH), 7.91 (2H, appd, J  8 .8 , 
2’,6’-PhH), 7.82 (1H, d, J  15.0, 4-H), 7.38 (1H, d, J  15.0, 5-H), 6.85 (1H, appd, J  8 .8 , 3 \5 ’-  
PhH), 5.63 (1H, bs, NH), 4.23 (2H, q, J7.2, OC//2Me), 3.83 (3H, s, OMe), 2.25 (3H, s Me), 1.35 
(3H, t, J7.2, CH2M 0 ; 13C NMR (100 MHz; CDC13) 8  189.3 (C), 169.9 (C), 166.3 (C), 162.7 (C),
140.2 (CH), 132.4 (C), 130.2 (CH), 115.7 (CH), 113.6 (CH), 95.5 (C), 60.0 (CH2), 55.4 (Me), 
22.6 (Me), 14.5 (Me); m/z (APcI) 290 (MH+, 100%).
(4£)-2-Aiiiino-3-ethoxycarbonyl-l-phenylhexa-2,4-diene-6-one (3e)
Ph
n h 2
/U^.C0 2Et
Aminodienone 3e was prepared according to the general procedure 6.2.1 using ethyl 3-amino-3- 
phenylpropenoate I f and 4-(trimethylsilyl)but-3-yn-2-one 2d. Purification by column 
chromatography on Si02, eluting with light petroleum-EtOAc (1:1) {Rf 0.24), gave the title 
compound as a yellow solid (22 mg, 23%), mp 104-105 °C (light petroleum-EtOAc) (Found: C,
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69.2; H, 6 .6 ; N, 5.2. Calc, for C15H17NO3 : C, 69.5; H, 6 .6 ; N, 5.4%); IR (KBr)/cm_1 3317, 
3120, 2980, 1654, 1586, 1507, 1461, 1345, 1285, 1257, 1210, 1119, 1023, 1002, 979, 927, 852, 
768, 702, 632, 358; ]H NMR (400 MHz; CDC13) 5 9.40 (1H, bs, NH), 7.50-7.30 (5H, PhH), 7.08 
(1H, d, J  15.9, 4-H), 6.45 (1H, d, J  15.9, 5-H), 5.45 (1H, bs, NH), 4.25 (2H, q, J7.1, OC/fcMe), 
1.88 (3H, s, Me), 1.35 (3H, t, J  7A, CH2M>); 13C NMR (100 MHz; CDC13) 8  190.2 (C), 169.8 
(C), 167.4 (C), 142.1 (CH), 136.8 (CH), 130.5 (CH), 128.9 (CH), 128.4 (CH), 122.6 (CH), 95.5 
(C), 60.3 (CH2), 26.8 (Me), 14.5 (CH2); m/z (APcI) 260 (MH+, 100%) and 243 (12).
Alternative procedure: A solution of ethyl 3-amino-3-phenylpropenoate I f  (1.25 g, 6.54 mmol) 
and 4-(trimethylsilyl)but-3-yn-2-one 2d (1.29 g, 9.2 mmol) in EtOH (20 ml) was stirred at 50 
°C for 18 h, cooled and then evaporated in vacuo. Purification by column chromatography on 
Si02, eluting with light petroleum-EtOAc (1:1) fft/0.24), gave the title compound as a yellow 
solid (0.79 g, 47%) with identical physical and spectroscopic properties.
(4£)-2-Amino—3-/erf-butoxycarbonylhexa-2,4—diene—6 —one (3f)
n h 2
Aminodienone 3f was prepared according to the general procedure 6.2.1 using tert-Butyl 13- 
ami nocrotonate le  and 4—(trimethylsilyl)but-3-yn-2-one 2d. Purification by column 
chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 0.26), gave the title 
compound as a yellow solid (55 mg, 6 8  %), mp 142-143 °C (light petroleum-EtOAc) (Found: C, 
63.8; H, 8.5; N, 6.1. Calc, for Ci2Hi9N 03: C, 64.0; H, 8.5; N, 6.2%) (Found: MH*, 226.1437. 
Ci2H20NO3, requires M H \ 226.1438); IR (KBr)/cm_1 vmax 3341, 3198, 2975, 1654, 1539, 1485, 
1454, 1362, 1323, 1295, 1218, 1160, 1111, 1034, 970, 840, 692, 572; *H NMR (400 MHz; 
CDC13) 8  9.60 (1H, bs, NH), 7.48 (1H, d, J  15.4, 4-H), 6.45 (1H, d, J  15.4, 5-H), 5.39 (1H, bs, 
NH), 2.20 (3H, s, Me), 2.18 (3H, s, Me), 1.48 (9H, s, CMe3); 13C NMR (100 MHz; CDC13) 
8  198.8 (C), 169.1 (C), 165.2 (C), 139.9 (CH), 120.8 (CH), 95.7 (C), 80.8 (C), 28.5 (Me), 28.4 
(Me), 22.7 (Me); m/z (APcI) 226 (MH*, 98%), 208 (54), and 152 (100).
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(4£)-2-Amino-3-terf-butoxycarbonyI-6-phenylhexa-2,4-dienes-6-one (3g)
nh2
/•k^C 0 2fBu
PhT^ O
.C02'Bu
Aminodienone 3g was prepared according to the general procedure 6.2.1 using ter/-butyl (3- 
aminocrotonate le  and 1—phenylprop-2-yn-l-one 2a. Purification by column chromatography 
on SiC>2, eluting with light petroleum-EtOAc (1:1) (K/0 .2 1 ), gave the title compound7 as a yellow 
solid (87 mg, 84 %), mp 150-151 °C (light petroleum-EtOAc) (Found: MH*, 288.1599. 
C17H22NO3 requires M ¥ t, 288.1594); IR (KBr)/cm_1 vmax 3307, 3126, 2970, 1654, 1614, 1521, 
1393, 1359, 1298, 1214, 1158, 1122, 1053, 1022, 974, 840, 818, 786, 698; *H NMR (400 MHz; 
CDCI3) 5 9.72 (1H, bs, NH), 7.90 (2H, m, o-Phfl), 7.87 (1H, d, J  15.0, 4-H), 7.40 (3H, w, p -  
PbH), 7.36 (1H, d, J  15.0, 5-H), 5.55 (1H, bs, NH), 2.25 (3H, s, Me), 1.55 (9H, s, CMe3); 13C 
NMR (100 MHz; CDC13) 8  190.9 (C), 169.4 (C), 166.9 (C), 141.8 (CH), 139.8 (C), 131.7 (CH),
128.4 (CH), 128.0 (CH), 115.8 (CH), 96.8 (C), 80.7 (C), 29.7 (Me), 22.6 (Me); m/z (APcI) 288 
(MH+, 100%).
(4is)-2-Amino-3-^terf-butoxycarbonyI-6-(4-chlorophenyl)hexa-2,4-diene-6-one (3h)
Aminodienone 3h was prepared according to the general procedure 6.2.1 using terf-butyl (3- 
aminocrotonate le  and l-(4-chlorophenyl)prop-2-yn-l-one 2h. Purification by column 
chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) (Rf 0 .2 1 ), gave the title 
compound1 as a yellow solid (85 mg, 73 %), mp 158-159 °C (light petroleum-EtOAc) (Found: 
MH+, 322.1203. C 1 7 H 2 1 C I N O 3  requires M ft, 322.1204); IR (KBr)/cm ‘ Vmax 3324, 3178, 2976, 
2915, 2361, 1660, 1629, 1588, 1587, 1570, 1482, 1345, 1319, 1299, 1233, 1209, 1157, 1109, 
1089, 1052, 1024, 1010, 978; JH NMR (500 MHz; C D C 13 )  8  9.75 (1H, bs, N H ) ,  7.88 (1H, d, J
14.8, 4-H), 7.85 (2H, appd, J  8 .6 , 2 \6 ’-PhH), 7.37 (2H, appd, J  8 .6 , 3 \5 ’-PhH), 7.34 (1H, d, J
14.8, 5-H), 5.56 (1H, bs, NH), 2.27 (3H, s, Me), 1.58 (9H, s, CMe3); 13C NMR (100 MHz;
NHz
Cl
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CDCI3) 8  189.4 (C), 169.3 (C), 166.9 (C), 142.0 (CH), 138.2 (C), 137.9 (C), 129.4 (CH), 128.6 
(CH), 114.7 (CH), 96.9 (C), 80.9 (C), 28.6 (Me), 22.8 (Me); m/z (APcI) 322 (MH+, 100%).
(4£}-2-Ainino-3-terf-butoxycarboiiyl-6-(4-iiiethoxyplieiiyI)hexa-2,4—diene-6-one (3i)
nh2
MeO
Aminodienone 3i was prepared according to the general procedure 6.2.1 using tert-butyl (3- 
aminocrotonate le  and l-(4-methoxyphenyl)prop-2-yn-l-one 2i. Purification by column 
chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) (Rf 0 .2 1 ), gave the title 
compound1 as a yellow solid (98 mg, 8 6  %), mp 149-150 °C (light petroleum-EtOAc) (Found: 
MH+, 318.1702. Ci8H24N0 4  requires M ft, 318.1700); IR (KBr)/cm“‘ vmax 3311, 3176, 1708, 
1634, 1602, 1577, 1547, 1417, 1323, 1291, 1258, 1233, 1171, 1122, 1024, 953, 829, 745; ]H 
NMR (400 MHz; CDC13) 5 9.71 (1H, bs, NH), 7.90 (2H, appd, J  8.5, 2’,6’-PhH), 7.84 (1H, d, J
14.6, 4-H), 7.36 (1H, appd, J  14.6, 5-H), 6 . 8 6  (2H, d, J8.5, 3 \5 ’-PhH), 6.24 (1H, bs, NH), 3.78 
(3H, s, OMe), 2.26 (3H, s, Me), 1.55 (9H, s, CMe3); I3C NMR (100 MHz; CDC13) 8  189.6 (C),
169.4 (C), 167.0 (C), 162.6 (C), 141.2 (CH), 132.6 (C), 130.2 (CH), 114.6 (CH), 113.6 (CH), 96.6 
(C), 80.6 (C), 55.4 (C), 28.7 (Me), 22.4 (Me); m/z (APcI) 318 (MH\ 100%).
Ethyl 2,6-dimethylpyridine-3-carboxylate (4a)
Pyridine 4a was prepared using aminodienone 3a according to the general procedure 6.2.2, 
purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 
0.44), gave the title compound as a pale yellow solid (24 mg, 6 6 %). Pyridine 4a was also 
prepared using aminodienone 3a according to the general procedure 6.2.3 to give the title 
compound as a pale yellow solid (39 mg, 98%), mp 59-60 °C (ethanol) (lit.8 60 °C) (Found: 
MH+, 180.1017. Ci0Hi4NO2 requires M ft, 180.1019); IR (film)/cm_1 vmax 2924, 2825, 1730,
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1593, 1462, 1377, 1272, 1236, 1148, 1079, 770, 722; *H NMR (400 MHz; CDC13) 8  8.03 (1H, d, 
J  8.0, 4-H), 7.00 (1H, d, J  8.0, 5-H), 4.27 (2H, q, J7.2, OC//2Me), 2.75 (3H, s, Me), 2.50 (3H, s, 
Me), 1.33 (3H, t, J7.2, CH2M>); 13C NMR (100 MHz; CDC13) 8  166.7 (C), 161.1 (C), 159.4 (C),
138.9 (CH), 122.8 (C), 120.5 (CH), 61.1 (CH2), 24.8 (Me), 24.6 (Me), 13.7 (Me); m/z (APcI) 180 
(MH+, 100%).
Ethyl 6 -methyl—2-phenylpyridine-3-carboxylate (4f)
Pyridine 4f was prepared using aminodienone 3e according to the general procedure 6.2.2. 
Purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 
0.56), gave the title compound* as a pale yellow solid (47 mg, 98%), mp 45-46 °C (ethanol) (lit.8 
46 °C) (Found: MH+, 242.1175. Ci5Hi6N 02 requires M Ft, 242.1176); IR (film)/cm_1 vmax 3056, 
2963, 2915, 2855, 2363, 1715, 1589, 1440, 1356, 1278 1211, 1137, 1106, 1053, 797, 767, 740, 
699, 650; *H NMR (400 MHz; CDC13) 8  7.95 (1H, d, J  8.0, 4-H), 7.33-7.25 (5H, PhH), 7.12 (1H, 
d, J  8.0, 5-H), 4.05 (2H, q, J  7.1, OC/72Me), 2.55 (3H, s, Me), 0.94 (3H, t, J  7.1, CH2M?); 13C 
NMR (100 MHz; CDC13) 8  168.2 (C), 160.8 (C), 158.7 (C), 140.5 (C), 138.4 (CH), 128.5 (CH),
128.4 (CH), 128.1 (CH), 124.4 (C), 121.3 (CH), 61.3 (CH2), 24.8 (Me), 13.6 (Me); m/z (APcI) 
242 (MH+, 100%).
Ethyl 2-methyI-6-phenyIpyridine-3-carboxyIate (4q)
Pyridine 4q was prepared using aminodienone 3b according to the general procedure 6.2.2, 
purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 
0.62), gave the title compound as a pale yellow solid (47 mg, 98%), mp 44—45 °C (ethanol) (lit. 
44-45 °C) Pyridine 4q was also prepared using aminodienone 3b according to the general 
procedure 6.2.3 to give the title compound as a pale yellow solid (52 mg, 98%) mp 44—45 °C
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(methanol) (lit. 8 mp 44 °C) (Found: MH+, 242.1176. C15H16NO2 requires MH^, 242.1179); IR 
(KBr)/cm_1 vmax 2981, 1715, 1582, 1496, 1455, 1382, 1264, 1185, 1154, 1091, 1026, 922, 848, 
798, 757, 692; *H NMR (400 MHz; CDC13) 8  8.21 (1H, d, J8.2, 4-H), 8.02 (2H, m, o-PhH), 7.60 
(1H, d, J  8.2, 5-H), 7.42 (3H, mj>-?hH) 4.32 (2H, q, J  7.2, OC/72Me), 2.85 (3H, s, Me), 2.45 
(3H, t, J  7.2, CH2Me); 13C NMR (100 MHz; CDC13) 5 166.9 (C), 160.0 (C), 159.1 (C), 139.3 
(CH), 138.5 (C), 129.7 (CH), 128.8 (CH), 127.3 (CH), 123.7 (C), 117.4 (CH), 61.2 (CH2), 25.3 
(Me), 14.3 (Me); m/z (APcI) 242 (MFC, 100%).
Ethyl 2-methyl-6-(4-chIorophenyl)pyridine-3-carboxyIate (4r)
C02Et Et02C
Pyridine 4r was prepared using aminodienone 3c according to the general procedure 6.2.2, 
purification by column chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) {Rf 
0.68), gave the title compouiut as a pale yellow solid (54 mg, 98%). Pyridine 4r was also 
prepared using aminodienone 3c according to the general procedure 6.2.3 to give the title 
compound as a pale yellow solid (59 mg, 97%) mp 48-49 °C (aqueous EtOH) (lit.4 mp 47-48 °C) 
(Found: MH*, 276.0784. C15H15CINO2 requires 276.0786); IR (KBr)/cm_1 v,** 2985, 1720, 
1585, 1492, 1455, 1372, 1265, 1180, 1155, 1096, 1013, 896, 833, 786, 742, 705; ‘H NMR (400 
MHz; CDCI3) 5 8.23 (1H, d, J8.2, 4-H), 7.95 (2H, appd, J  8.5, 2 \6 ’-PhH), 7.54 (1H, d, J  8.2, 5- 
H), 7.40 (2H, appd, J  8.5, 3’,5’-PhH), 4.38 (2H, q, y  7.1, OC//2Me), 1.60 (3H, s, Me), 1.35 (3H, t 
J7.1, CH2Me); 13C NMR (100 MHz; CDCI3) 8  166.5 (C), 160.1 (C), 157.7 (C), 139.4 (CH), 136.9 
(C), 135.9 (C), 129.0 (CH), 128.6 (CH), 123.9 (C), 117.4 (CH), 61.2 (CH2), 25.3 (Me), 14.3 (Me); 
m/z (APcI) 276 (MH+, 100%), 278 (MH+, 33).
Ethyl 2-methyl-6-(4-methoxyphenyl)-3-carboxylate (4s)
n h 2
MeO
EtO^
OMe
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Pyridine 4s was prepared using aminodienone 3d according to the general procedure 6.2.2, 
purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 
0.63), gave the title compound? as a pale yellow solid (53 mg, 98%). Pyridine 4s was also 
prepared using aminodienone 3d according to general procedure 6.23 to give the title compound* 
as a pale yellow oil (55 mg, 92%) mp 68-69 °C (aq. EtOH) (lit.4 mp 68-69 °C) (Found: MH+, 
272.1284. Ci6H18N 0 3 requires M tf , 272.1281); IR (KBr)/cm_1 vmax 2989, 2895, 1717, 1605, 
1579, 1509, 1452, 1439, 1389, 1362, 1311, 1264, 1172, 1112, 1088, 1071, 1031, 832, 785; *H 
NMR (500 MHz; CDC13) 6  8.20 (1H, d, J8.2, 4-H), 7.95 (2H, appd, J  8.7, 2 \6 ’-PhH), 7.53 (1H, 
d, J  8.2, 5-H), 7.37 (2H, appd, J  8.7, 3 \5 ’-PhH), 4.34 (2H, q, J  7.1, OC//2Me), 3.82 (3H, s, 
OMe), 2.85 (3H, s, Me), 1.36 (3H, t J  7.1, CH2M?); 13C NMR (125 MHz; CDC13) 6  166.8 (C),
161.0 (C), 160.0 (C), 158.7 (C), 139.3 (CH), 131.7 (C), 128.7 (CH), 122.8 (C), 116.5 (CH), 114.2 
(CH), 61.1 (CH2), 55.4 (Me), 25.4 (Me), 14.4 (Me); m/z (APcI) 272 (MH+, 100%).
tert-Butyl 2,6-dimethylpyridine-3-carboxylate (4t)
fBu0 2CVs^ <^ :-XX
Pyridine 4t was prepared using aminodienone 3f according to the general procedure 6.2.2, 
purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 
0.59), gave the title compound as a pale yellow oil (41 mg, 98%) Pyridine 4t was also prepared 
using aminodienone 3f according to general procedure 6.23 to give the title compound as a pale 
yellow oil (45 mg, 98%) (Found: MH+, 208.1329. Ci2Hi8N 0 2 requires M H \ 208.1332); IR 
(film)/cm_1 2921, 2852, 1724, 1592, 1462, 1377, 1284, 1175, 1144, 1080, 771, 722; *HNMR 
(400 MHz; CDC13) 8  7.95 (1H, d, J  8.0, 4-H), 6.95 (1H, d, J  8.0, 5-H), 2.68 (3H, s, Me), 2.45 
(3H, s, Me), 1.50 (9H, s, CMe3); 13C NMR (100 MHz; CDC13) 8  166.1 (C), 160.6 (C), 158.7 (C),
138.8 (CH), 124.5 (C), 120.5 (CH), 81.7 (C), 28.2 (Me), 24.8 (Me), 24.6 (Me); m/z (APcI) 208 
(MH+, 100%).
116
Chapter 6 <Ph.<D. Thesis 2006
tert-Butyl 2-methyl-6-phenylpyridine-3-carboxylate (4u)
‘Experimental
fBuQ2C
Pyridine 4u was prepared using aminodienone 3g according to the general procedure 6.2.3 to give 
the title compound7 as a pale yellow oil (58 mg, 98%) (Found: MH*, 270.1490. C17H20NO2 
requires M U ', 270.1489); IR (film)/cm 1 v nBX 2976, 2925, 1714, 1581, 14554, 1367, 1282, 1172, 
1147, 1091, 1075, 838, 758, 690; 'H NMR (500 MHz; CDC13) 8  8.11 (1H, d, J  8.3, 4-H), 7.96 
(2H, m, o-PhH), 7.52 (1H, d, J  8.3, 5-H), 7.38 (3H, mjy-PhH), 2.81 (3H, s, Me), 1.54 (9H, s, 
CMe3); l3C NMR (125 MHz, CDCI3) 8  166.1 (C), 159.4 (C), 158.7 (C), 139.2 (CH), 138.7 (C),
129.5 (CH), 128.8 (CH), 127.3 (CH), 125.4 (C), 117.4 (CH), 81.8 (C), 28.3 (Me), 25.4 (Me); m/z 
(APcI) 270 (MH+, 100%).
tert-Butyl 2-methyl—6 —(4—chlorophenyl)pyridine-3-carboxylate (4v)
fB u 02C.
Pyridine 4v was prepared using aminodienone 3h according to the general procedure 6.23 to give 
the title compound1 as a pale yellow oil (61 mg, 92%) (Found: MH+, 304.1100. C17H19CINO2 
requires M H \ 304.1099); IR (film)/cm_1 vmax 2974, 2925, 1703, 1577, 1556, 1491, 1453, 1410, 
1365, 1293, 1254, 1172, 1146, 1096, 1010, 902, 828, 782; *H NMR (500 MHz; CDC13) 6  8.09 
(1H, d, J  8.2, 4-H), 7.91 (2H, appd, J  8 .6 , 2 \6 ’-PhH), 7.48 (1H, d, J  8.2, 5-H), 7.36 (2H, appd, J
8 .6 , 3’,5’-PhH), 2.79 (3H, s, Me), 1.54 (9H, s, CMe3); 13C NMR (125 MHz; CDCI3) 6  165.0 (C),
158.4 (C), 156.2 (C), 138.3 (CH), 136.0 (C), 134.7 (C), 127.9 (CH), 127.5 (CH), 124.6 (C), 116.5 
(CH), 80.9 (C), 27.2 (Me), 24.3 (Me); m/z (APcI) 304 (MH+, 100%).
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tert-Butyl 2-methyl-6-(4-methoxyphenyl)-3-carboxylate (4w)
n h 2
MeO
'BuOaC
OMe
Pyridine 4w was prepared using aminodienone 3i according to the general procedure 6.2 J  to give 
the title compound1 as a pale yellow oil (65 mg, 98%) (Found: MH+, 300.1591. C18H22NO3 
requires M tT , 300.1594); IR (film)/cm“' 2978, 2936, 1712, 1603, 1580, 1511, 1454, 1369, 
1283, 1252, 1170, 1152, 1111, 1092, 1072, 1029, 832, 787; 'H NMR (500 MHz; CDC13) 8  8.06 
(1H, d, J  8.3, 4-H), 7.93 (2H, appd, J  8.7, 2’,6’-PhH), 7.45 (1H, d ,J  8.3, 5-H), 6.91 (2H, appd, J  
8.7, 3’,5’-PhH), 3.77 (3H, s, OMe), 2.79 (3H, s, Me), 1.53 (9H, s, CMe3); l3C NMR (125 MHz; 
CDCI3) 8  166.2 (C), 160.0 (C), 159.3 (C), 158.3 (C), 139.2 (CH), 131.2 (C), 128.7 (CH), 124.6 
(C), 116.5 (CH), 114.2 (CH), 81.6 (C), 55.4 (Me), 28.3 (Me), 25.4 (Me); m/z (APcI) 300 (M lf, 
100%).
(±)-Siilfomyciiime.HCl (37). [6-Carboxy-5-methyl-8-oxo-5,6,7,8-tetrahydrothiazolo(3,4- 
a)pyrazinium chloride]
C02Me
Methyl sulfomycinate 39 (67 mg, 0.76 mmol) was stirred in hydrochloric acid ( 6  M; 9 ml) in a 
Carius tube at 110 °C for 2 h. After cooling, the mixture was evaporated in vacuo, by forming an 
azeotrope with MeOH. The residue was triturated with MeOH to give die title compound as a 
colourless solid (12 mg, 27%), mp 203-204 °C (dec.) (EtOAc) (lit.9 mp 205-207 °C) (Found: 
[M-C1]+ 213.0325. CgHg^OaS requires [M-Cl] +, 213.0328); IR (KBr)/cm_1 Vmax 3455, 3197, 
3096, 3055, 2370, 2288, 1740, 1686, 1575, 1436, 1192, 887, 761; UV (MeOH)/nm W  230 (log 
8  3.76) [lit.9 230 (log 8  3.85)]; *H NMR (500 MHz; D2O) 6  10.15 (1H, d, J2.4, exch. D2O, 3-H), 
8.77 (1H, d, J2 .4 , 1-H), 5.51 (1H, dq, J  1.5, 6.9, 5-H), 4.46 (1H, d, J  1.5, 6 -H), 1.61 (3H, d, J  
6.9, Me); 13C NMR (125 MHz; D2O) 8  172.3 (C), 159.7 (CH), 156.7 (C), 136.1 (C), 131.5 (CH),
59.8 (CH), 57.5 (CH), 19.6 (Me); m/z (ES) 215 ([M-C1]+, 100%).
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Sulfomycinic amide (38). 2-[l-{[2-(Dimethoxymethyl)thiazol-4—yl]carbonylamino}-l- 
propenyI]-5-methyloxazole-4-carboamide
A saturated solution of methanolic NH3 (20 ml) was added to methyl sulfomycinate 39 (70 mg, 
0.18 mmol) at room temperature. The mixture was stirred at this temperature for 2 d and then 
evaporated in vacuo. Purification by column chromatography on SiC>2, eluting with EtOAc, gave 
the title compound as a. colourless solid (16 mg, 24%), mp 188-189 °C (EtOAc) (lit. 10 mp 194.5- 
195 °C); (Found: MH+ 367.1070. Ci5H19N4 0 5S requires M/C, 367.1071); IR (KBr)/cm-1 Vmax
(C), 99.8 (CH), 53.6 (Me), 14.5 (Me), 11.9 (Me); m/z (APcI) 367 (MFC, 18%).
Methyl sulfomycinate (39). Methyl 2-(l-{[2-(Dimethosymethyl)thiazol-4- 
yl]carbonylamino}-l-propenyl)-5-methyloxazole-4-carboxyIate
A solution of alcohol 108 (344 mg, 0.86 mmol), Et3N (1.2 ml, 8 . 6  mmol) and MsCl (0.53 ml, 6.9 
mmol) in dry CH2CI2 (20 ml) was stirred for 1 h at room temperature. The solution was 
partitioned between H2O (45 ml) and CH2CI2 (30 ml) and the aqueous layer was further extracted 
with CHCI3 (2 x 40 ml). The combined organic extracts were dried (Na2SC>4) and evaporated in 
vacuo. The residue was dissolved in dry CH2CI2 (20 ml), Et3N (2.0 ml, 14.4 mmol) was added and 
the mixture was stirred for 18 h. After evaporating in vacuo, purification by column 
chromatography on SiC>2, eluting with EtOAc (Rf 0.44), gave the title compound as a colourless 
solid (198 mg, 60%), mp 122-123 °C (EtOAc) (lit. 10 mp 124-124.5 °C) (Found: MH+ 382.1066.
CONH;'C02M©
3474, 3360, 3284, 3153, 3090, 2940, 2842, 1687, 1636, 1604, 1555, 1531, 1497, 1482, 1449, 
1419, 1369, 1333, 1305, 1229, 1211, 1195, 1168, 1104, 1082, 1042, 1016, 990, 968, 956, 836, 
789, 762, 721, 707, 684; JH NMR (400 MHz; CDC13) 8  8.71 (1H, bs, NH), 8.13 (1H, s, 5” -H) 
6.84 (1H, bs, N//H), 6.61 (1H, q, J7.2, 2’-H), 5.58 (1H, bs, NH//), 5.53 (1H, s, CH), 3.37 (6 H, s, 
OMe), 2.55 (3H, s, 5-Me), 1.84 (3H, d, J7.2, 2’-Me); 13C NMR (100 MHz; CDC13) 8  168.2 (C),
164.0 (C), 159.0 (C), 156.7 (C), 153.9 (C), 149.7 (C), 129.4 (C), 128.7 (CH), 125.7 (CH), 122.2
C02MeC 02Me
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C16H20N3O6S requires MH*, 382.1067); IR (KBr)/cm_1 Vmax 3372, 3116, 2924, 2845, 2363, 2344, 
1719, 1684, 1618, 1527, 1469, 1439, 1351, 1233, 1189, 1101, 1062; UV (MeOH)/nm 246 
( lo g  e  4.40) [ l i t . 10 247 ( lo g  e  4.38)]; ‘H NMR (400 MHz; CDC13) 8  8.65 (1H, bs, NH), 8.14 (1H, s, 
5”—H), 6 . 6 8  (1H, q, J  7.2, 2’-H), 5.55 (1H, s, CH), 3.82 (3H, s, OMe), 3.41 (6 H, s, OMe), 2.57 
(3H, s, 5-Me), 1.84 (3H, d, J  7.2, 2’-Me); 13C NMR (100 MHz; CDCI3) 8  168.1 (C), 162.7 (C),
159.0 (C), 157.5 (C), 156.5 (C), 149.7 (C), 128.9 (CH), 128.1 (C), 125.7 (CH), 122.1 (C), 99.9 
(CH), 53.6 (Me), 52.0 (Me), 14.5 (Me), 12.2 (Me); m/z (Cl4) 382 (MH4, 100%).
Saramycetic acid I (47). 2-[2-(l-Acetyl)thiazol—4-yl]thiazoIe—4-carboxylic acid
LiOH monohydrate (17 mg, 0.41 mmol) was added to a stirred solution of ethyl ester 164 (110 
mg, 0.40 mmol) in MeOH-H20  (5:1) (12 ml) and the solution was stirred for 20 h. After 
evaporating in vacuo, the mixture was partitioned between aqueous KHSO4 solution (10% w/v; 
30 ml) and CH2CI2 (50 ml). The aqueous layer was further extracted with CH2CI2 ( 2  x 45 ml) and 
the organic extracts were combined, dried (Na2S0 4 ) and evaporated in vacuo to give the title 
compound1 as a colourless solid (102 mg, 100%), mp 244-245 °C (dec.) (MeOH) (Found: MH*, 
254.9893. C9H7N2O3S2 requires M lt , 254.9893); IR (KBr)/cm_1 v*** 3406, 3103, 2936, 2584, 
2514, 2362, 1734, 1689, 1492, 1412, 1356, 1296, 1220, 1192, 1097, 1061, 1008, 942, 8 6 8 , 809, 
753, 716; UV (MeOH)/nm A*** 220 (log 8  4.29), 291 (log 8  4.14) [lit. 12 218 (log 8  4.32), 291 (log 
8  4.16)]; lH NMR (500 MHz; SO(CD3)2) 5 8.85 (0.18H, s, 5’-H), 8.82 (0.82H, s, 5’-H), 8.71 
(0.18H, s, 5-H), 8.63 (0.82H, s, 5-H), 2.77 (3H, s, Me); 13C NMR (125 MHz; SO(CD3)2) 6  191.4 
(C), 167.9 (C), 162.4 (C), 161.7 (C), 149.8 (C), 148.8 (C), 130.1 (CH), 125.8 (CH), 26.3 (Me); 
m/z (APcI) 255 (MH*, 40%).
V-Benzyl—4—aminopent-3—en—2-one (66a)
0  O NHBn
" J^COM e
2,4 Pentadione 7e (1.20 ml, 12 mmol) was added to a solution of benzylamine (1.10 ml, 10 mmol) 
in MeOH (50 ml). The mixture was stirred at reflux for 21 h and evaporated in vacuo. 
Purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (R/
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0.42), gave the title compound13 as a yellow oil (1.88 g, 99%) (Found: MH+, 190.1227. C12H16NO 
requires Afff*, 190.1226); IR (film)/cm_1 3428, 3002, 1610, 1573, 1514, 1437, 1355, 1294, 
1237, 1102, 1072, 1027, 986, 966, 933, 747, 697; JH NMR (400 MHz; CDCI3) 6  11.1 (1H, bs, 
NH), 7.27 (2H, m, o-Ph//), 7.19 (3H, mp-PhH), 4.97 (1H, s, 3-H), 4.39 (2H, d, J  6.5, CH2), 1.96 
(3H, s, Me), 1.84 (3H, s, Me); 13C NMR (100 MHz; CDCI3) 8  195.4 (C), 163.2 (C), 138.0 (C),
128.8 (CH), 127.4 (CH), 126.7 (CH), 95.9 (CH), 46.7 (CH2), 29.0, (Me), 18.9 (Me); m/z (APcI) 
190 (MH*, 100%).
Methyl 3-(beiizylamino)but-2-enoate (6 6 b)
O NHBn
^ A ^ C 0 2Me ^ ^ , C 0 2Me
Methyl acetoacetate 7f (1.30 ml, 12 mmol) was added to a solution of benzylamine (1.10 ml, 10 
mmol) in MeOH (50 ml). The mixture was stirred at reflux for 21 h and evaporated in vacuo. 
Purification by column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 
0.63), gave the title compound14 as an orange oil (1.44 g, 70%) (Found: MH*, 206.1176. 
Cj2Hi6N 02 requires MH", 206.1175); IR (film)/cm_1 vmax 3292, 2947, 1652, 1606, 1496, 1440, 
1276, 1236, 1171, 1117, 1013, 931, 785, 731, 697; *H NMR (400 MHz; CDC13) 8  8.87 (1H, bs, 
NH), 7.27 (2H, m, o-PhH), 7.19 (3H, m,p-PhH), 4.47 (1H, s, 2-H), 4.36 (2H, d, J  6.5, CH2), 3.56 
(3H, s, OMe), 1.85 (3H, s, 4-H); 13C NMR (100 MHz; CDC13) 8  170.9 (C), 162.0 (C), 138.7 (C),
128.9 (CH), 127.8 (CH), 126.7 (CH), 82.7 (CH), 50.1 (Me), 46.8 (CH2), 19.4 (Me); m/z (APcI) 
206 (MH*, 100%).
l-(4-Chlorophenyl)prop-2-yn-l-ol (6 8 b)
O OHs? —
Propargylic alcohol 6 8 b was prepared using aldehyde 67b according to the general procedure
6.2.5. Purification by column chromatography on Si02, eluting with CH2 C12  (Rf 0.27), gave the 
title compound* as a pale yellow oil (635 mg, 76%) (Found: M*, 166.0181. C9 H7CIO, requires 
M*, 166.0180); IR (filmycnT1 vmax3418, 3296, 2884, 2119, 1904, 1645, 1597, 1490, 1406, 1257,
1192, 1092, 1015, 950, 909, 835, 791, 734, 650; *H NMR (400 MHz; CDCI3) 8  7.48 (2H, appd, J
8.4, 2 \6 ’-PhH), 7.33 (2H, appd, J  8.4, 3 \5 ’-PhH), 5.45 (1H, s, 1-H), 2.68 (1H, s, 3-H), 2.28
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(1H, s, OH); l3C NMR (100 MHz; CDCU) 8  138.4 (C), 134.4 (C), 128.8 (CH), 128.0 (CH), 83.1 
(CH), 75.3 (C), 63.7 (CH); m/z (El) 166 (M'+, 9%), 164 (27), 113 (5), 111 (14), 53 (100).
l-{4—Methoxyphenyl)prop-2-yn-l-ol (6 8 c)
Propargylic alcohol 6 8 c was prepared using aldehyde 67c according to the general procedure
6.2.5. Purification by column chromatography on Si02, eluting with CH2CI2 (fl/0.10), gave the 
title compound5 as a pale yellow oil (513 mg, 63%) (Found: [MH]+, 161.0596. C10H10O2, 
requires [M7/]*, 161.0597); IR (filmycm-1 vmax3438, 3284, 3003, 2935, 2837 1892 1611, 1512, 
1464, 1442, 1304, 1249, 1174, 1112, 1032, 948, 833, 768; *H NMR (400 MHz; CDC13) 5 7.50 
(2H, appd, J  8 .6 , 2’,6’-PhH), 6.90 (2H, appd, J  8 .6 , 3 \5 ’-PhH), 5.42 (1H, s, 1-H), 3.85 (3H, s, 
OMe), 2.65 (1H, s, 3-H); 13C NMR (100 MHz; CDC13) 5 159.8 (C), 132.4 (C), 128.1 (CH), 114.0 
(CH), 83.7 (CH), 74.7 (C), 64.0 (CH), 55.4 (Me); m/z (El) 162 (M*+, 100%), 161 (54), 145 (35), 
131 (38), 89 (57), 53 (43).
Ethyl 5-bromo-2,6-dimethyIpyridine-3-carboxylate (70a)
Bromopyridine 70a was prepared using aminodienone 3a according to the general procedure
6.2.4. Purification by column chromatography on Si0 2 , eluting with light petroleum-EtOAc (1:1) 
(i?/0.68), gave the title compound as an off-white solid (69 mg, 96 %), mp 31-32 °C (light 
petroleum-EtOAc) (lit.6 mp 32.1-32.2 °C) (Found: C, 46.5; H, 5.0; N, 5.4. Calc, for 
CioHi2BrN0 2 : C, 46.5; H, 4.7; N, 5.4%) (Found: MH*, 258.0128. CioHi3BrN0 2 , requires M £t, 
258.0124); I R ^ r y c m -1  vmax2924, 2852, 1732, 1572, 1462, 1377, 1247, 1093, 1016, 781, 722; 
*H NMR (400 MHz; CDC13) 8  8.22 (1H, s, 4-H), 4.30 (2H, q, J 7.2, OC//2Me), 2.70 (3H, s, Me), 
2.58 (3H, s, Me), 1.35 (3H, t, J  7.2, CH2M?); 13C NMR (100 MHz; CDC13) 8  165.2 (C), 160.0 
(C), 158.0 (C), 141.9 (CH), 124.4 (C), 118.0 (C), 61.5 (CH2), 24.0 (Me), 24.2 (Me), 14.3 (Me); 
m/z (APcI) 260 (MH*, 8 8 %), 258 (MH*, 100%).
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Ethyl 5-bromo-2-phenyl-6-methylpyridine-3-carboxylate (70b)
Bromopyridine 70b was prepared using aminodienone 3e according to the general procedure
6.2.4. Purification by column chromatography on SiC>2, eluting with light petroleum-Et20 (1:1) 
(Rf 0.50), gave the title compouruf as a brown oil (88 mg, 98 %), (Found: MH*, 320.0281. 
Ci5H,5BrN02, requires M H \  320.0281); IR (filmVcm1 2918, 2853, 1725, 1572, 1462, 
1377, 1295, 1242, 1112, 1061, 1027, 771, 722, 696; *H NMR (400 MHz; CDC13) 8 8.18 (1H, s, 
4-H), 7.50-7.34 (5H, PhH), 4.05 (2H, q, J  7.1, OCi/2Me), 2.68 (3H, s, Me), 1.00 (3H, t, J7.1, 
CH2Afe); 13C NMR (100 MHz; CDC13) 8 166.6 (C), 159.6 (C), 157.2 (C), 141.3 (CH), 139.5 (C),
128.7 (CH), 128.5 (CH), 128.2 (CH), 125.8 (C), 119.3 (C), 61.7 (CH2), 25.3 (Me), 13.7 (Me); m/z 
(APcI) 322 (MH*, 100%), 320 (98).
tert-Butyl 5—bromo-2,6—dimethyIpyridine-3-carboxylate (70f)
'Bu02c.
Bromopyridine 70f was prepared using aminodienone 3f according to the general procedure 6.2.4. 
Purification by column chromatography on SiC>2, eluting with light petroleum-Et20 (1:1) (Rf 
0.53), gave the title compouruf as a brown oil (78 mg, 97 %), (Found: M*, 285.0359. 
Ci2Hi6BrNC>2, requires MF/*, 285.0359); IR (film)/cm-1 Vmax 2922, 2852, 1726, 1579, 1462, 
1377, 1277, 1167, 1095, 970, 848, 782, 722; *H NMR (400 MHz; CDC13) 8 8.11 (1H, s, 4-H), 
2.81 (3H, s, Me), 2.62 (3H, s, Me), 1.55 (9H, s, CMe3); 13C NMR (100 MHz; CDC13) 8 177.3 (C),
165.1 (C), 159.9 (C), 157.9 (C), 142.0 (CH), 124.5 (C), 118.1 (C), 24.9 (Me), 24.1 (Me), 14.3 
(Me); m/z (APcI) 288 (MH*, 100%), 286 (94).
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(2J£,4Z)-Methyl 5-amino-4-ethoxycarbonyl-hexa-2,4-dienoate (76)
n h 2
/U ^C 0 2Et
MeO O
Methyl propiolate 78 (0.65 g, 7.75 mmol) was added to a solution of ethyl p-aminocrotonate la  
(0.5 g, 3.85 mmol) in MeOH (13 ml). The mixture was stirred at reflux for 18 h and then 
evaporated in vacuo. Purification by column chromatography on Si0 2 , eluting with light 
petroleum-EtOAc (4:1) (Rf 0.48), gave the title compound as a yellow solid (0.5 lg 67%), mp 
107-108 °C (light petroleum-EtOAc) (lit. 16 mp 108 °C) (Found: MH*, 214.1073. Ci0H|6NO4 
requires MH*, 214.1074); IR (KBr)/cm_1 vmax 3331, 3187, 1669, 1590, 1433, 1331, 1273, 1217, 
1163, 11 2 2 , 1030, 978,950, 845; NMR (400 MHz; CDCb) 8  9.53 (1H, bs, NH), 7.59 (1H, d, J
15.6, 3-H), 6.11 (1H, d, J  15.6, 2-H), 5.34 (1H, bs, NH), 4.19 (2H, q, .113, OCTftMe), 3.67 (3H, 
s, OMe), 2.21 (3H, s, 6 -H), 1.29 (3H, t, J7.3, CH2Me); l3C NMR (100 MHz; CDC13) 8  169.9 (C),
169.8 (C), 165.0 (C), 140.4 (CH), 110.7 (CH), 94.4 (C), 59.9 (CH2), 51.2 (Me), 22.5 (Me), 14.5 
(Me); m/z (APcI) 214 (MH*, 100%), 168 (50).
6-Methyl-5-ethoxycarbonylpyrid-2-one (77)
Methyl propiolate 78 (0.65 g, 7.75 mmol) was added to a solution of ethyl |3-aminocrotonate la  
(0.5 g, 3.85 mmol) in MeOH (13 ml). The mixture was stirred at reflux for 18 h and then 
evaporated in vacuo. Purification by column chromatography on Si0 2 , eluting with light 
petroleum-EtOAc (4:1) (Rf 0 .1 2 ), gave the title compound as a yellow solid (0.18 g 26%), mp 
206-207 °C (light petroleum-EtOAc) (lit. 17 mp 207 °C) (Found: MH+, 182.0810. C9H12NO3 
requires M H \  182.0812); IR (KBr)/cm_1 2940, 2094, 2952, 2358, 1712, 1608, 1465, 1378, 
1259, 1198, 1147, 1097, 1028, 917, 850, 780, 727; lH NMR (400 MHz; CDC13) 8  12.94 (1H, bs, 
NH), 7.98 (1H, d, J 9.5, 4-H), 6.35 (1H, d, J9 .5 , 3-H), 4.25 (2H, q, J 7.0, OC/72Me), 2.68 (3H, s, 
6 -Me), 1.30 (3H, t, J  7.0, CH2M>); 13C NMR (100 MHz; CDC13) 8  165.5 (C), 164.9 (C), 153.0
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(C), 142.9 (CH), 116.2 (CH), 109.0 (C), 60.2 (CH2), 19.8 (Me), 14.3 (Me); m/z (APcI) 182 (MH*, 
100%), 154 (57).
Diethoxythioacetamide (93)
Eto Eto s
) - cn  ------------ -
Eto Eto NH2
A mixture of 2,2-diethoxyacetonitrile 92 (1.12 ml, 8.06 mmol) and ammonium sulphide (50 wt. 
% in H2O; 1.5 ml, 11.0 mmol) in MeOH (100 ml) was stirred overnight. The mixture was
evaporated in vacuo to give the title compound as a pale yellow solid (1.5 g, 100%), mp 92-93 °C
(lit. 18 mp 81-82 °C) (Found: MH*, 164.0743. C6H14NO2S requires Affl*, 164.0740) (Found; C, 
44.1; H, 8.0; N, 8.4; S, 19.5. Calc, for CsH^NCbS: C, 44.2; H, 8.0; N, 8 .6 ; S, 19.6%); IR 
(KBr)/cm_l 3371, 3256, 2971, 2916, 1604, 1424, 1368, 1246, 1121, 1057, 960, 918, 824, 
724; ‘H NMR (400 MHz; CDCb) 8  7.87 (1H, bs, NH), 7.62 (1H, bs, NH), 5.05 (1H, s, CH), 3.76 
(2H, dq, J  9.5, 7, 20C//HMe). 3.67 (2H, dq, J  9.5, 7, 2(X'II//Me). 1.18 (6 H, t , ./ 7. CHj.We); 13C 
NMR (125 MHz; CDC13) 5 202.2 (C), 103.0 (CH), 62.9 (CH2), 15.1 (Me); m/z (El) 163 (M * 
2%), 118(15), 103(87).
Diethoxythioacetamide (93)
EK5m °  --------- - e,0m s
EtO NH2  EtO NH,
Phosphorous pentasulphide (30.0 g, 6 8  mmol) was added to a solution of 2,2-diethoxyacetamide 
91 (20.0 g, 0.136 M) in CH2CI2 (250 ml). The mixture was stirred for 2 h at 0°C, filtered through 
Celite®, washing with CH2CI2 (2 x 20 ml), and evaporated in vacuo. Purification by column 
chromatography on SiC>2, eluting with light petroleum-EtOAc (3:2), followed by recrystalization 
from light petroleum-Et2 0  (7:3) gave the title compound18 as a pale orange solid (5 g, 23%) with 
identical physical and spectroscopic properties.
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Ethyl 2-{diethoxymethyl)thiazole—4-carboxylate (94)
EtO S EtO S-^
y-K  ---------   ) 4 jl
EtO NH2  EtO N' x ? 0 2Et
Ethyl bromopyruvate (1.71 ml, 13.6 mmol) was added to a stirred solution of 2,2- 
diethoxythioacetamide 93 (1.22 g, 7.47 mmol) in EtOH (16 ml) over 4A molecular sieves (14 g) 
and the mixture was heated at reflux for 1 h. The solution was allowed to cool, filtered through 
Celite® and evaporated in vacuo. Purification twice by column chromatography on SiC ,^ eluting 
with light petroleum-Et2 0  (4:1) and light petroleum-Et2 0  (1:1) (Rf 0.28), gave the title 
compound19 as a pale yellow oil (1.94 g, 100%) (Found: MH*, 260.0956. C11H18NO4S requires 
Aff/*, 260.0951); IR (film)/cm_1 v™* 3441, 3113, 2983, 2359, 1694, 1556, 1454, 1391, 1368, 
1332, 1216, 1101, 1020, 953, 882, 860, 767, 704; *H NMR (400 MHz; CDC13) 8  8.10 (1H, s, 5- 
H), 5.63 (1H, s, CH), 4.32 (2H, q, J7.1, OC/f2Me), 3.69 (2H, dq, J 9.5, 7, 20C//H), 3.60 (2H, dq, 
J  9.5, 7, 20CHH), 1.35 (3H, t, J7 .1 , CH2Me), 1.18 (6 H, app t, J7.1, 2CH2M?); 13C NMR (100 
MHz; CDCI3) 5 170.2 (C), 161.4 (C), 147.1 (C), 128.5 (CH), 98.7 (CH), 62.8 (CH2), 61.5 (CH2),
15.1 (Me), 14.4 (Me); m/z (APcI) 260 (MH*, 37%).
Ethyl 2-(dimethoxymethyl)thiazole-4-carboxylate (95)
EtO MeO
)—^ X  --------- - )—4 X
EtO N^ C 0 2Et MeO N C02Et
p -T sOH monohydrate (30 mg, 20 mol%) was added to a stirred solution of ethyl 2- 
(diethoxymethyl)thiazole-4-carboxylate 94 (200 mg, 0.77 mmol) in dry MeOH (5 ml) and the 
mixture heated at reflux for 6  h. After evaporating in vacuo, die mixture was partition between 
saturated aqueous NaHC0 3  solution (15 ml) and CH2CI2 (30 ml). The aqueous layer was further 
extracted with CH2CI2 ( 2  x 30 ml) and the organic extracts were combined, dried (Na2S0 4) and 
evaporated in vacuo. Purification by column chromatography on Si0 2 , eluting with EtOAc-light 
petroleum (1:1) (Rf 0.41), gave the title compound9 as a brown oil (118 mg, 6 6 %) (Found: MH*, 
232.0638. C9H14NO4 S requires M ft, 232.0637); IR (film)/cm_I 3439, 3106, 2981, 1730, 
1454, 1369, 1332, 1248, 1216, 1095, 1021, 950.1, 860, 766; !H NMR (400 MHz; CDC13) 8  8.14 
(1H, s, 5-H), 5.52 (1H, s, CH), 4.35 (2H, q, J7.1, OCH2Me), 3.39 (6 H, s, 20Me), 1.34 (3H, t, J
7.1, CH2A/e); 13C NMR (100 MHz; CDC13) 8  168.9 (C), 161.4 (C), 147.3 (C), 128.6 (CH), 100.3 
(CH), 61.6 (CH2), 54.0 (Me), 14.4 (Me); m/z (APcI) 232 (MFC, 73 %).
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Methyl 2-(dimethoxymethyl)thiazole-^4-carboxylate (96)
‘Experimented
EtO N ^ c ° 2 e*
H J
-  C02Me
/*-TsOH monohydrate (293 mg, 40 mol%) was added to a stirred solution of thiazole 94 (1.0 g, 
3.86 mmol) in MeOH (25 ml) and the mixture heated at reflux overnight. After evaporating in 
vacuo, the mixture was partition between saturated aqueous NaHC0 3  solution (40 ml) and EtOAc 
(50 ml). The aqueous layer was further extracted with EtOAc (2 x 40 ml) and the organic extracts 
were combined, dried (Na2S0 4 ) and evaporated in vacuo. Purification by column chromatography 
on Si0 2 , eluting with EtOAc-light petroleum (1:1) (Rf 0.29), gave the title compound as a clear oil 
(506 mg, 60%) (Found: MH*, 218.0482. C8H|2N04S requires MH*, 218.0482); IR (film)/cm_l
3.39 (6 H, s, 20Me); ,3C NMR (100 MHz; CDC13) 8  169.0 (C), 161.8 (C), 146.9 (C), 128.8 (CH),
100.3 (CH), 54.0 (Me), 52.5 (Me); m/z (APcI) 218 (MH*, 100 %).
2-(Dimethoxymethyl)thiazole-4-carboxylic acid (98)
LiOH monohydrate (108 mg, 2.6 mmol) was added to a stirred solution of thaizole 95 (100 mg, 
0.43 mmol) in MeOH-H2 0  (5:1) (4 ml) and the solution was stirred overnight. After evaporating 
in vacuo, the mixture was partitioned between aqueous citric acid (1 M; 8  ml) and CH2CI2 (35 
ml). The aqueous layer was further extracted with CH2CI2 (2 x 20 ml) and the organic extracts 
were combined, washed with brine (30 ml), dried (Na2S0 4 ) and evaporated in vacuo to give the 
title compound9 as a brown solid (56 mg, 64%), mp 112-113 °C (EtOAc) (Found: MH+ 
204.0325. C7H,oN04S requires MH* 204.0325); IR (KBr)/cm_l Vm«  3391, 2885, 2698, 2586, 
2511, 1726, 1503, 1484, 1459, 1399, 1320, 1205, 1092, 1062, 984, 953, 905, 872, 820, 770, 732, 
670; 'H NMR (400 MHz; CDCb) 8  9.40 (1H, bs, OH), 8.25 (1H, s, 5-H), 5.52 (1H, s, CH), 3.36 
(6 H, s, 20Me); 13C NMR ( 1 0 0  MHz; CDCb) 8  168.5 (C), 161.3 (C), 147.4 (C), 129.1 (CH),
100.2 (CH), 53.1 (Me); m/z (APcI) 204 (MH*, 100 %).
3111, 2953, 2835, 2360, 1737, 1489, 1435, 1328, 1248, 1217, 1092, 1068, 1000, 973, 919, 
864, 763; ‘H NMR (400 MHz; CDCb) 8  8.14 (1H, s, 5-H), 5.55 (1H, s, CH), 3.92 (3H, s, OMe),
127
Chapter 6 <Ph.<D. Thesis 2006 ‘Experimental
2-(Dimethoxymethyl)thiazole-4-carboxylic acid (98) from 94
/>-TsOH monohydrate (300 mg, 156 mmol) was added to a stirred solution of ethyl 2- 
(diethoxymethyl)thiazole-4-carboxylate 94 (2 g, 7.7 mmol) in MeOH (60 ml) and the mixture 
heated at reflux for 6.5 h. After cooling to room temperature, LiOH monohydrate (1.9 g, 46 
mmol) and water (12 ml) were added and the solution was stirred for 48 h at room temperature. 
After evaporating in vacuo, the mixture was partitioned between aqueous citric acid (1 M; 40 ml) 
and CH2CI2 (80 ml). The aqueous layer was further extracted with CH2CI2 (2 x 60 ml) and the 
organic extracts were combined, dried (Na2S0 4 ) and evaporated in vacuo to give the title 
compound9 as an off-white solid (0.85 g, 54%), mp 115-116 °C, with identical spectroscopic 
properties.
(2.S,3J?)-Metliyl 2-benzyloxycarbonylamino-3-hydroxybutanoate (100). (Z-L-Thr-OMe)
Benzyl chloroformate (4.90 ml, 32.5 mmol) was added to a solution of HCl.H-Thr-OMe 99 (5.0 
g, 29.5 mmol) and sodium hydrogen carbonate (5.45 g, 64.9 mmol) in H2O (250 ml). The 
solution was stirred at RT for 72 h and extracted with CHCI3 (200 ml). The aqueous layer was 
further extracted with CHCI3 ( 2  x 150 ml) and the combined organic extracts were dried 
(Na2SC>4), and evaporated in vacuo to give the title compound as a colourless solid (7.36 g, 93%), 
mp 92-93 °C (EtOAc) (lit.20 mp 93-96 °C) (Found: MH*, 268.1178. Ci3Hi8N 0 5 requires M H \ 
268.1179); [<x] D28 -12.33 (cl.20, CHC13) {lit20 [a]D2°-13.7 (cl.20, CHC13)>; IR (KBr)/cm_1 vmax 
3471, 3314, 3058, 3032, 2979, 2955, 2930, 2899, 1720, 1689, 1546, 1498, 1468, 1455, 1441, 
1477, 1335, 1247, 1176, 1130, 1092, 1072, 1020, 982, 967, 939, 914, 867, 841, 790, 756, 729, 
698; *H NMR (400 MHz; CDC13) 5 7.28 (5H, m, PhH), 5.58 (1H, d, J  9.0, NH), 5.07 (1H, d, J
12.8, OCHH), 5.04 ( 1H, d, J  12.8, OCHtf), 4.27 (1H, s, 2 -H), 4.25 (1 H, s, 3-H), 3.69 (3H, s, 
OMe), 1.17 (3H, d, J6.5 , 4-H); 13C NMR (100 MHz; CDC13) 8  171.7 (C), 156.7 (C), 136.1 (C),
128.6 (CH), 128.3 (CH), 128.1 (CH), 68.0 (CH), 67.2 (CH2), 59.0 (Me), 52.7 (CH), 19.9 (Me); 
m/z (APcI) 268 (MH*, 100%).
H2fT C02Me CbzHN C02Me
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(2S,3R)-Methyl 2-benzyloxycarbonylamino-3—(terr-butyldimethylsilyl)oxybutanoate (101). 
(Z-Lr-Thr(TBS)-OMe)
Imidazole (1.5 g, 22 mmol), DMAP (0.92 g, 7.5 mmol) and TBDMSC1 (2.3 g, 15 mmol) were 
added successively to a solution of Z-L-Thr-OMe 100 (3.0 g, 11 mmol) in DMF (11 ml). The 
mixture was stirred at room temperature for 36 h, acidified with hydrochloric acid (1 M; 15 ml) 
and extracted with Et2 0  (3 x 40 ml). The combined organic extracts were washed with H2O (3 x 
60 ml), dried (Na2SC>4) and evaporated in vacuo to give the title compound as a pale yellow oil 
(4.3 g, 100%) (Found: MH*, 382.2048. C i^ N O sS i requires MH", 382.2044); [<x] D30 - 6 . 6  
(c2.05, CHCI3) (lit.21 [a ] D24 -7.31 (c3.55, CHC13)}; IR (filmycm" 1 Vmax 3449, 2954, 2856, 1730, 
1507, 1472, 1436, 1378, 1344, 1315, 1255, 1209, 1174, 1129, 1101, 1071, 1030, 1004, 963, 838, 
810, 777; *H NMR (400 MHz; CDC13) 6  7.35 (5H, PhH), 5.42 (1H, bd, J9.8, NH), 5.13 (2H, s, 
OCH2), 4.42 (1H, dq, J  6.3, 1.7, 3-H), 4.25 (1H, dd, J  9.8, 1.7, 2-H), 3.67 (3H, s, OMe), 1.17 
(3H, d, J6.3, 4-H) 0.8 (9H, s, CMe3), -0.01 (3H, s, MeSiMe), -0.05 (3H, s, MeSiMe); 13C NMR 
(100 MHz; CDCI3) 8  171.4 (C), 156.8 (C), 136 .3 (C), 128.6 (CH), 128.5 (CH), 122.3 (CH), 69.8 
(CH), 67.2 (CH2), 59.9 (CH), 52.3 (Me), 25.6 (Me), 20.8 (Me), 17.8 (C), -4.39 (Me), -5.34 (Me); 
m/z (APcI) 382 (MH*, 100%).
(2<S)-Benzyloxycarbonylamino-(3if)-(/^/t-butyldimethylsilyl)oxybutanoic acid (102). (Z -L -  
Thr(TBS)-OH)
LiOH monohydrate (1.05 g, 25.0 mmol) was added to a stirred solution of Z-L-Thr(TBS)-OMe 
101 (1.5 g, 3.93 mmol) in MeOH-H2 0  (5:1) (40 ml). After stirring for 18 h, the mixture was 
partitioned between hydrochloric acid (1 M; 40 ml) and CH2CI2 (60 ml). The aqueous layer was 
further extracted with CH2CI2 (2 x 60 ml) and the organic extracts were combined, dried (Na2SC>4) 
and evaporated in vacuo to give the title compound as a colourless solid (1.38 g, 96%), mp 149- 
150 °C (triturated with light petroleum-EtOAc) (lit.22 mp 154—157 °C) (Found: MH*, 368.1883. 
CigHaoNOsSi requires Mi/*, 368.1888); [a ]o 31 +10.3 (c2.82, CHCI3) {lit.22 [a]o22 +10.5 (cl.69, 
CHCI3)}; IR (KBr)/cm_1 3440, 3035, 2956, 2856, 1702, 1600, 1514, 1455, 1413, 1344, 1308,
HO TBSO
CbzHN C O ^ e CbzHN C02Me
TBSO TBSO
CbzHN C02Me CbzHN C02H
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1257, 1102, 1042, 1005, 975, 836, 813, 778, 733, 696; *H NMR (500 MHz; CDC13) 8  9.6 (1H, bs, 
C02H), 7.3 (5H, PhH), 5.43 (1H, bd, J 8 .6 , NH), 5.04 (2H, s, OCH2), 4.40 (1H, dq, J2A,  6.3, 3- 
H), 4.24 (1H, dd, J  8 .6 , 2.4, 2-H), 1.11 (3H, d, J  6.3, 4-H), 0.75 (9H, s, CMe3), -0.02 (3H, s, 
MeSiMe), -0.03 (3H, s, MeSiMe); 13C NMR (125 MHz; CDC13) 8  175.7 (C), 156.7 (C), 136.1 
(C), 128.6 (CH), 128.3 (CH), 128.2 (CH), 68.5 (CH), 67.3 (CH2), 59.4 (CH), 25.7 (Me), 20.3 
(Me), 17.9 (C), -4.6 (Me), -5.1 (Me); m/z (Cl) 368 (MH+, 28%), 277 (100).
{2Sj5R/2 ’SV3 ’/?)—Methyl 2-({(2—benzyIoxycarbonylamino)-3—[ferf-butyldimethylsilyloxy]-
butanoyl}amino)—3-hydroxybutanoate (103). Z-L-Thr(TBS)-Lr-Thr-OMe
TBSO,, /
CbzHN-VNY C°2Me
°  A > H
Et3N (0.95 ml, 6 . 8  mmol) was added dropwise over 30 min to a stirred solution of acid 102 (1.0 g,
2.7 mmol), HCl.H-L-Thr-OMe (0.509 g, 3.0 mmol) and pyBOP (1.56 g, 3.0 mmol) in dry 
CH2C12 (13 ml) at 0 °C. The solution was allowed to warm to room temperature and stirred for a 
further 18 h. After evaporating in vacuo, purification by column chromatography on Si02, eluting 
with light petroleum-EtOAc (1:1) (R/0.49), gave the title compound19 as a colourless solid (1.1 g, 
83%), mp 133-134 °C (light petroleum-EtOAc) (Found: MH+, 483.2521. C23H39N2C>7Si requires 
M/C, 483.2521); [a ] D32 +13.1 (cl.05, CHC13); IR (KBr)/cm_1 3446, 3357, 2955, 1752, 1723, 
1670, 1507, 1253, 1207, 1132, 1102, 1078, 967, 839, 780; !H NMR (400 MHz; CDC13) 8  7.43 
(1H, bd, J  8 .8 , NH), 7.20 (5H, PhH), 5.74 (1H, bd, J  5.7, NH), 5.01 (1H, d, J  12, OC//H), 4.92 
(1H, d, J 12, OCH#), 4.42 (1H, dd, J 8 .8 , 1.7, 2-H), 4.21 (2H, 2 and 2’-H), 4.14 (1H, m, 2'-H), 
3.60 (3H, s, OMe), 2.05 (1H, bs, OH), 1.05 (3H, d, J  6.4, Me), 1.01 (3H, d, J  6.2, Me), 0.78 (9H, 
s, CMe3), 0.04 (3H, s, MeSiMe), 0.00 (3H, s, MeSiMe); 13C NMR (100 MHz; CDC13) 8  171.1 (C),
170.1 (C), 156.2 (C), 136.1 (C), 128.6 (CH), 128.2 (CH), 128.1 (CH), 68.4 (CH), 67.6 (CH), 67.0 
(CH2), 59.1 (CH), 57.3 (CH), 52.5 (Me), 25.7 (C), 19.9 (Me), 17.9 (Me), 17.4 (Me), ^1.8 (Me), -
5.0 (Me); m/z (APcI) 483 (MFC, 100%).
TBSO,,,^
C bzH N *X 02H
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(45,55,1’S',2’J?)-Methyl 2 -[l-(benzyloxycarbonylamino)-2 -{fcrf-butyldiniethylsilyloxy)-
prop-l-yI]-4,5-dihydro-5-methyloxazoIe-4-carboxylate (104)
[Bis(2-methoxyethyl)amino]sulfur trifluoride (Deoxo-Fluor) (0.37 ml, 2.0 mmol) was added 
dropwise to a stirred solution of Z-L-Thr(TBS)-L-Thr-OMe 103 (0.95 g, 1.97 mmol) in dry 
CH2CI2 (30 ml) at -20 °C. The solution was stirred for 18 h and then quenched by the addition of 
saturated aqueous NaHCC>3 solution (30 ml). After warming to room temperature, the mixture 
was extracted with CH2CI2 (3 x 40 ml). The organic extracts were combined, dried (Na2S0 4 ) and 
evaporated in vacuo. Purification by column chromatography on SiC>2, eluting with light 
petroleum-EtOAc (R/0.39), gave the title compound9 as a colourless oil (595 mg, 65%); (Found: 
MH" 465.2418. C23H37N20 6 Si requires M rf, 465.2415); [<x] D32 +7.4 (cl.05, CHCI3); IR 
(film)/cm-1 vmax 3330, 3034, 2954, 2856, 2358, 1731, 1674, 1504, 1383, 1258, 1212, 1101, 836, 
778, 698; *H NMR (400 MHz; CDC13) 8  7.33 (5H, PhH), 5.45 (1H, bd, J  9.5, NH), 5.11 (1H, d, J
13.7, OCtfH), 5.08 (1H, d, J  13.7, OCHtf), 4.90 (1H, dq, J  10.4, 6.3, 5-H), 4.78 (1H, d, J  10.4,4- 
H), 4.42 (1H, d, J 9.5, l ’-H), 4.35 (1H, q, J 6.3, 2’-H), 3.75 (3H, s, OMe), 1.25 (3H, d, J6.3, 5- 
Me), 1.17 (3H, d, J  6.3, 2’-Me), 0.80 (9H, s, CMe3), 0.00 (3H, s, MeSiMe), -0.06 (3H, s, 
MeSiM?); 13C NMR (100 MHz; CDCI3) 8  170.0 (C), 168.8 (C), 156.4 (C), 136.4 (C), 128.6 (CH),
128.5 (CH), 128.1 (CH), 78.1 (CH), 71.3 (CH), 69.3 (CH), 67.0 (CH2), 55.5 (CH), 52.1 (Me),
25.7 (Me), 20.6 (Me), 17.9 (C), 16.3 (Me), -4.4 (Me), -5.0 (Me); m/z (APcI) 465 (MH*, 50%).
( l ’5,2’J?)-Methyl 2-[l-(benzyIoxycarbonylamino)-2-(/c/t-butyldimethylsilyloxy)prop-l- 
yl]-5-methyloxazole-4-carboxylate (105)
BrCCh (0.88 ml, 8.9 mmol) and DBU (0.88 ml, 5.9 mmol) were added successively to a stirred 
solution of the oxazoline 104 (0.60 g, 1.28 mmol) in diy CH2CI2 (24 ml) at -20 °C. After stirring 
for 18 h, the mixture was poured into saturated aqueous NaHCC>3 solution (40 ml) and extracted 
with ethyl acetate (3 x 60 ml). The organic extracts were combined, dried (Na2SC>4) and
TBSO.
N. oC02Me CbzHN'CbzHN " > "C02Me
1
CbzHN CbzHN" Y "C02Me
1—J -C02Me
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evaporated in vacuo. Purification by column chromatography on Si02, eluting with light 
petroleum-EtOAc (Rf 0.63), gave the title compound19 as a colourless oil (0.31 g, 52%) (Found: 
MH* 463.2258. C23H35N2O6 S1 requires MH*, 463.2259); [a ] D33 -5.7 (c2.75, CHCI3); IR
Deoxo-Fluor (0.72 ml, 3.9 mmol) was added dropwise to a stirred solution of Z-L-Thr(TBS)-L- 
Thr-OMe 103 (1.87 g, 3.87 mmol) in diy CH2CI2 (60 ml) at -20 °C. The solution was stirred for 
18 h and then quenched by the addition of saturated aqueous NaHC(> 3  solution (30 ml). After 
warming to room temperature, the mixture was extracted with CH2CI2 (3 x 100 ml). The organic 
extracts were combined, dried (Na2S0 4 ) and evaporated in vacuo to give the crude oxazoline 104 
as a brown oil (2.1 g). The residue was dissolved in dry CH2CI2 (70 ml) and cooled to -20 °C. 
B1CCI3 (1.7 ml, 17.4 mmol) and DBU (2.6 ml, 17.4 mmol) were added and the solution was 
stirred at -20 °C for 18 h. The mixture was poured into saturated aqueous NaHCC>3 solution (70 
ml) and extracted with ethyl acetate (3 x 60 ml). The organic extracts were combined, dried 
(Na2SC>4) and evaporated in vacuo. Purification by column chromatography on Si0 2 , eluting with 
light petroleum-Et2 0  (R/0.15), gave the title compound19 as a colourless oil (0.94 g, 52%) with 
identical physical and spectroscopic properties.
(film)/cm_1 3436, 3352, 2954, 2925, 2857, 2361, 1732, 1622, 1587, 1504, 1442, 1352, 1253, 
1211, 1100, 965, 915, 838, 810, 778, 739, 698; NMR (400 MHz; CDC13) 8  7.35 (5H, PhH), 
5.72 (1H, bd, J9.4, NH), 5.15 (2H, s, OCH2), 4.93 (1H, dd, J9.4, 2.1, l ’-H), 4.42 (1H, qd, J 6.2,
2.1, 2’—H), 3.90 (3H, s, OMe), 2.60 (3H, s, 5-Me), 1.26 (3H, d, J6.2, 2’-Me) 0.78 (9H, s, CMe3), 
0.03 (3H, s, MeSiMe), -0.17 (3H, s, MeSiMe); 13C NMR (100 MHz; CDC13) 8  162.6 (C), 160.9 
(C), 156.4 (C), 156.4 (C), 136.2 (C), 128.6 (CH), 128.2, (CH), 127.8 (CH), 127.5 (C), 70.0 (CH),
67.3 (CH2), 55.5 (CH), 52.0 (Me), 25.5 (Me), 20.4 (Me), 17.8 (C), 11.9 (Me), -4.7 (Me), -5.5 
(Me); m/z (APcI) 463 (MH*, 100%).
Oxazole 105 from Z^L-Thr(TBS)-L-Thr-OMe (103)
NL o.C02MeCbzHN' CbzHN'
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(1’5,2’5)-M ethyl 2-[l-amino-2-(teit-butyldimethylsilyloxy)prop-l-yl]-5-methyloxazole-
4-carboxylate (106)
TBSO,,, ^  TBSO.,,
CbzHN' v ^ - c c y i e  -------------  H!N ' V V - C 0 2Me
A solution of oxazole 105 (0.94 g, 2.0 mmol) in MeOH (34 ml) was stirred over Pd-C (10 wt. %; 
817 mg) under an atmosphere of hydrogen for 3 h. The mixture was filtered through Celite and 
evaporated in vacuo to give the title compound as a colourless solid, mp 75-76 °C (623 mg, 
93%) (Found: MH* 329.1890, Ci5H29N204Si requires M rf 329.1891); [a ] D31 -29.3 (c2.78, 
CHCb); IR (film)/cm_l v™, 3387, 2955, 2857, 1721, 1621, 1441, 1351, 1256, 1205, 1098, 970, 
837, 776, 6 6 6 ; 'H  NMR (500 MHz; CDCb) 8  8.80-6.10 (2H, bs, NH), 4.45 (2H, l ’,2’-H), 3.85 
(3H, s, OMe), 2.53 (3H, s, 5-Me) 1.35 (3H, bs, 2’-Me) 0.75 (9H, s, CMe3), 0.05 (3H, s, 
MeSiMe), -0.1 (3H, s, MeSiMe); 13C NMR (100 MHz; CDCI3) 8  164.0 (C), 162.8 (C), 156.3 (C),
127.2 (C), 70.7 (CH), 56.5 (CH), 52.0 (Me), 25.7 (Me), 20.5 (Me), 17.8 (C), 11.9 (Me), -4.5 
(Me), -5.3 (Me); m/z (APcI) 329 (MH*, 100%).
( l ’S',2’J?)-Methyl 2-(l-{[2-(Dimethoxyinethyl)thiazol-4-ylcarbonylammo]-2-te/T-butyl- 
dimethy!silyloxypropyl})-5-methyIoxazoIe-4-carboxylate (107)
C02MeC02Me
EtsN (0.50 ml, 3.6 mmol) was added dropwise over 30 min to a stirred solution of acid 98 (325 
mg, 1.6 mmol), amine 106 (420 mg, 1.3 mmol) and pyBOP (830 mg, 1.6 mmol) in dry CH2C12 
(13 ml) at 0 °C. The solution was allowed to warm to room temperature and stirred for a further 
18 h. After concentrating in vacuo, purification by column chromatography on SiO^ eluting with 
light petroleum-EtOAc (1:1) (Rf 0.31), gave the title compound9 as a colourless oil (580 mg, 
8 8 %) (Found: MH* 514.2044, C22H36N3 0 ?SSi requires M f t ,  514.2038); [<x]d2 5  +16 (c2.3, 
CHCb); IR (film)/cm_1 vmax 3409, 3116, 2956, 2857, 2400, 1731, 1682, 1621, 1538, 1499, 1471, 
1352, 1258, 1186, 1098, 973, 910, 838, 756, 6 6 6 ; ’H NMR (400 MHz; CDCb) 5 8.30 (1H, s, 5”-  
H), 8.20 (1H, d, J8.9, NH), 5.72 (1H, s, CH), 5.41 (1H, dd, J8.9, 2.8, l ’-H), 4.65 (1H, qd, y 6.1,
2.8, 2’-H), 4.07 (3H, s, OMe), 3.68 (3H, s, OMe), 3.40 (3H, s, OMe), 2.75 (3H, s, Me), 1.41 (3H,
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d, J  6.1, 2’-Me), 1.05 (9H, s, CMe3), 0.22 (3H, s, MeSiMe), 0.03 (3H, s, MeSiMe); 13C NMR 
(100 MHz; CDCb) 8 167.9 (C), 162.7 (C), 161.1 (C), 160.7 (C), 156.4 (C), 149.5 (C), 127.5 (C),
125.0 (CH), 100.3 (CH), 70.0 (CH), 54.1 (Me), 53.8 (Me), 53.4 (CH), 52.0 (Me), 25.5 (Me), 20.7 
(Me), 17.8 (C), 12.0 (Me), -4.6 (Me), -5.4 (Me); m/z (Cl4) 514 (MH4, 95%).
(1 ’5,2’i?)-Methyl 2—(l-{l-[2-(Dimethoxymethyl)thiazol-4-ylcarbonylamino]-2-hydroxy}- 
propy !)-5-methyIoxazole-4-carboxyIate (108)
CC^Me
A solution of TBAF (1.0 M; 1.8 mmol) in THF (1.8 ml) was added to a stirred solution of silyl 
ether 107 (580 mg, 1.1 mmol) in dry THF (21 ml) at 0 °C. After warming to room temperature, 
the mixture was stirred for 4.5 h and then partitioned between H2O (15 ml) and EtOAc (20 ml). 
The aqueous layer was further extracted with EtOAc (2 x 20 ml) and the combined organic 
extracts were dried (Na2SC>4) and evaporated in vacuo. Purification by column chromatography on 
SiC>2, eluting with EtOAc (Rf 0.31), gave the title compound9 as a colourless solid (344 mg, 
77%), mp 159-160 °C (light petroleum-EtOAc) (1:3) (Found: MH+ 400.1171. C16H22N3O7S 
requires M ff, 400.1173); [cc] D27 -14.7 (c2.3, CHCI3); IR (KBrycm" 1 vmax 3458, 3277, 3123, 
2956, 2825, 2362, 1715, 1668, 1540, 1497, 1453, 1391, 1376, 1334, 1247, 1217, 1192, 1148, 
1098, 1063, 982, 828, 797; *H NMR (400 MHz; CDC13) 8  8.11 (1H, s, 5” -H), 8.03 (1H, d, 79.3, 
NH) 5.45 (1H, s, CH), 5.24 (1H, dd, 79.3, 2.9, l ’-H), 4.51 (1H, qd, 76.3, 2.9, 2’-H), 3.82 (3H, s, 
OMe), 3.61 (1H, s, OH), 3.37 (6 H, s, OMe), 2.53 (3H, s, 5-Me), 1.22 (3H, d, 76.3, 2’-Me); 13C 
NMR (100 MHz; CDCI3) 8  168.2 (C), 162.4 (C), 161.3 (C), 160.6 (C), 156.9 (C), 149.3 (C),
127.3 (C), 125.5 (CH), 99.9 (CH), 67.7 (CH), 53.7 (Me), 52.0 (Me), 51.9 (CH), 19.2 (Me), 12.1 
(Me); m/z (CI+) 400 (MH*, 100%).
(4/?)-2,2—Dimethyl-4-(ethoxycarbonyl)tliiazolidine (140)
HS1    XIH2 N ^ C 0 2Et fj C02Et
Et3N (4.0 ml, 28.7 mmol) was added to a solution of HCl.H-L-Cys-OEt 138 (5.40 g, 28.8 mmol) 
in acetone (analytical grade) (90 ml). The mixture was stirred for 1 h, filtered over Celite® and
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washed with acetone (30 ml). The solution was stirred at 60 °C for 2 h, cooled and evaporated in 
vacuo. Purification by column chromatography on SiC>2, eluting with light petroleum-EtOAc 
(1:1) (ft/0.57), gave the title compound13 as a brown oil (5.31 g, 97%) (Found: MH* 190.0898, 
C8H16N 02S requires 190.0896); [ajo23 -68.3 (cl .30, MeOH); IR (film)/cm_1 3306, 
2978, 2931, 1738, 1447, 1371, 1334, 1227, 1187, 1027, 856, 801, 650; *H NMR (400 MHz; 
CDC13) 8  4.17 (2H, q, J 7.0, OCftfcMe), 4.00 (1H, dd, J9.0, 7.0, 4-H), 3.37 (1H, dd, J  10.5, 7.0,
5-MI), 2.95 (1H, dd, J  10.5, 9.0, 5-H//), 2.49 (1H, bs, NH), 1.64 (3H, s, 2-Me), 1.49 (3H, s, 2- 
Me), 1.23 (3H, t, J7 .0 , CH2Me); ,3C (100 MHz; CDC13) 8  171.6 (C), 75.8 (C), 65.5 (CH), 61.6 
(CH2), 40.4 (CH2), 32.7 (Me), 30.5 (Me), 14.2 (Me); m/z (APcI) 190 (MH+, 98%), 150 (100), 118 
(75).
(4i?)-2,2-Dimethyl—3—(rc/f-butoxycarbonyl)-^4—(ethoxy carbonyl)thiazolidine (141)
H ^ C 0 2Et ^ B ^ C 0 2Et
DIEA (1.00 ml, 5.81 mmol) was added to a solution of thiazolidine 140 (1.0 g, 5.28 mmol) and 
di-/cr/-butylbicarbonate (1.73 g, 7.93 mmol) in dry MeCN (10 ml) under nitrogen. The solution 
was stirred at 50 °C for 2 d, then allowed to cool and evaporated in vacuo. Purification twice by 
column chromatography, eluting with light petroleum-Et20  (1:1) and light petroleum-Et20  (4:1) 
(.ft/0.14), gave the title compound as a clear oil (80 mg, 6 %) (Found: MH+ 290.1422, CoH^NC^S 
requires M ft  290.1421); [afc23 - 6 6 . 6  (c2.95, CHC13); IR (film)/cm_1 2976, 2933, 1754, 
1704, 1454, 1362, 1291, 1257, 1192, 1172, 1125, 1069, 1031, 959, 934, 858, 818, 772; 'HNMR 
(500 MHz; CDC13) 8  4.88 (0.45H, s, 4-H), 4.74 (0.55H, s, 4-H), 4.14 (2H, m, OC/f2Me), 3.20 
(1H, m, 5-M I), 3.03 (1H, m, 5-Htf), 1.79 (1.65H, s, 2-Me), 1.74 (1.35H, s, 2-Me), 1.72 (1.65H, 
s, 2-Me), 1.68 (1.35H, s, 2-Me), 1.43 (4H, s, CMe3), 1.34 (5H, s, CMe3), 1.21 (3H, m, CH2Afe); 
I3C NMR (125 MHz; C D C I 3 )  8  171.1 (C), 170.5 (C), 152.9 (C), 151.7 (C), 80.8 (C), 80.3 (C),
71.6 (C), 69.9 (C), 66.2 (CH), 65.5 (CH), 61.3 (CH2), 31.0 (Me), 30.5 (CH2), 30.1 (CH2), 29.7 
(Me), 28.3 (Me), 28.2 (Me), 27.7 (Me), 27.3 (Me), 14.2 (Me), 14.1 (Me); m/z (APcI) 290 (MET, 
48%), 251 (30), 190 (75).
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(2<S',2’5)-Methyl 2-{[(2-te/*-butoxycarbonylamino)-3—(terf-butoxy)propanoyl]amino}-3- 
(terf-butoxy)butanoate (144). Boc-Ser(/Bu)-Ser(/Bu)-OMe
r° H
Bo*mK o#  ------------ '  80CHNJ Y NY C° 2Me
0  "o'Bu
Boc-L-Ser(rBu)-OH.DCHA 142 (250 mg, 0.56 mmol) was dissolved in dry THF (1.1 ml) at 0 °C. 
NMM (0.12 ml, 1.12 mmol) and isobutyl chloroformate (0.10 ml, 0.76 mmol) were added 
dropwise and the mixture was stirred for 20 min. H-Ser('Bu)-OMe (142 mg, 0.67 mmol) was 
added and the solution was stirred at 0 °C for 5 h, evaporated in vacuo and partitioned between 
aqueous KHSO4 solution (10% w/v, 15 ml) and CH2CI2 (20 ml). The aqueous layer was further 
extracted with CH2CI2 (2x15  ml) and the combined organic layers were washed with brine (50 
ml), dried (Na2SC>4), filtered and evaporated in vacuo. Purification by column chromatography on 
Si02, eluting with light petroleum-EtOAc (1:1) (i?/0.53) gave the title compound as a clear oil 
(229 mg, 98%) (Found: MH* 419.2753. C20H39N2O7 requires M ¥t, 419.2752); [a ] D23 +9.12 
(c2.73, CHCI3); IR (film)/cm-1  v ^  3342, 2975, 2925, 2875, 2360, 1755, 1717, 1681, 1484, 1392, 
1365, 1293, 1236, 1192, 1170, 1097, 1048, 1023, 881; *H NMR (400 MHz; CDC13) 6  7.56 (1H, d, 
J 8.0, NH), 5.44 (1H, d, J5.5 , NH), 4.64 (1H, dt, J8.0, 3.0, 2-H), 4.16 (1H, m, 2’-H), 3.77 (1H, 
dd, J  9.0, 3.0, 3-M i), 3.70 (1H, dd, J8 .0 , 3.0, 3’-M i), 3.66 (3H, s, OMe), 3.47 (1H, dd, J  9.0,
3.0, 3-H//), 3.35 (1H, m, 3’-H H), 1.39 (9H, s, CMe3), 1.16 (9H, s, CMe3), 1.07 (9H, s, CMe3); 
13C NMR (100 MHz; CDCI3) 8  170.8 (C), 170.6 (C), 155.5 (C), 79.8 (C), 74.1 (C), 73.4 (C), 62.0 
(CH2), 61.9 (CH2), 53.8 (Me), 53.1 (CH), 52.3 (CH), 29.7 (Me), 27.4 (Me), 27.3 (Me); m/z (APcI) 
419 (MH+, 100%), 383 (80).
(25,2 ’S)-Methyl 2-{ [(2-benzyloxycarbonyIamrao)-3-(terf-biitoxy)propanoyI]aniino}-3- 
(terf-butoxy)butanoate (145). Z - Ser(/Bu)-Ser(/Bu)-OMe
.0*Bu
^COzMe
C bzH N '"C 02H o  L
OfBu
,Of
" C b z H N 'V '4'
NMM (0.19 ml, 1.7 mmol) and isobutyl chloroformate (0.13 ml, 0.94 mmol) were added 
dropwise to a solution of Z-Ser(rBu)-OH 143 (250 mg, 0.85 mmol) in dry THF (1.7 ml) at 0 °C 
and the mixture was stirred for 20 min. H—Ser(,Bu)-OMe (196 mg, 0.94 mmol) was added and
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the solution was stirred at 0 °C for 5 h, evaporated in vacuo and partition between aqueous
KHSO4 solution (10% w/v, 15 ml) and CH2CI2 (15 ml). The aqueous layer was further extracted 
with CH2CI2 (2x15  ml) and the combined organic layers were washed with brine (50 ml), dried 
(Na2S0 4 ), filtered and evaporated in vacuo. Purification by column chromatography on Si02, 
eluting with light petroleum—EtOAc (1:1) (R/ 0.54), gave the title compound as a colourless oil 
(340 mg, 8 8 %) (Found: MH+ 453.2590. C23H37N2O7 requires AffT, 453.2595); [ct] D21 +42.3
52.3 (CH), 27.4 (Me), 27.3 (Me); m/z (APcI) 453 (MH+, 100%).
(2*S',2’*S)-2-{!(2-ferf—butoxycarbonylamino)-3-(terf—butoxy)propanoyllamino}—3-(ferf- 
butoxy)propanoic acid (146). Boc—Ser(rBu)-Ser(rBu)-OH
LiOH monohydrate (107 mg, 2.5 mmol) was added to a solution of Boc-Ser(/Bu)-Ser(/Bu)-OMe 
144 (175 mg, 0.42 mmol) in MeOH-H2 0  (5:1) (4.0 ml). The mixture was stirred for 18 h at room 
temperature. The solution was evaporated in vacuo and partitioned between hydrochloric acid 
(1M , 30 ml) and CH2CI2 (50 ml). The aqueous layer was further extracted with CH2CI2 ( 2  x 30 
ml) and the organic extracts were combined, dried (Na2SC>4), filtered and evaporated in vacuo to 
give the title compound14 as a colourless oil (240 mg, 99%) (Found: MFC 405.2594. C19H37N2O7 
requires MM, 405.2595); [a ] D23 +19.4 (c3.20, CHC13); IR (filmycm 1 Vmax 3425, 3327, 2975, 
2251, 1713, 1669, 1486, 1392, 1365, 1194, 1100, 1023, 910, 881, 733; *H NMR (400 MHz; 
CDCI3) 5 7.50 (1H, d, J7 .5 , NH), 6.30 (1H, bs, OH), 5.68 (1H, bs, NH), 4.47 (1H, m, 2-H), 4.20 
(1H, m, 2’—H), 3.78 (1H, m, 3-MI), 3.67 (1H, m, 3’-M I), 3.52 (1H, m, 3-HH), 3.40 (1H, m, 3’-  
HH)y 1.37 (9H, s, CMe3), 1.13 (9H, s, CMe3), 1.09 (9H, s, CMe3); ,3C NMR (100 MHz; CDC13) 
5 173.8 (C), 170.8 (C), 156.2 (C), 136.2 (C), 128.6 (CH), 128.4 (CH), 128.2 (CH), 74.4 (C), 73.9
(c2.50, CHCI3); IR (filmycm 1 Vmax 3340, 2975, 2877, 1730, 1681, 1504, 1392, 1365,1194, 1142, 
1098, 1049, 985, 931, 875, 848, 755, 698; !H NMR (400 MHz; CDC13) 8  7.57 (1H, d, /8 .5 , NH), 
7.28 (5H, m, PhH) 5.71 (1H, d, J  6.0, NH), 5.02 (2H, s, OCH2), 4.63 (1H, dt, J  8.5, 3.0, 2-H), 
4.22 (1H, m, 2’—H), 3.78 (1H, dd, J9 .0 , 3.0, 3-MI), 3.76 (1H, m, 3’-M I), 3.66 (3H, s, OMe),
3.47 (1H, dd, J  9.0, 3.0, 3-HH)y 3.37 (1H, app t, J  9, 3’-H H), 1.17 (9H, s, CMe3), 1.10 (9H, s, 
CMe3); 13C NMR (100 MHz; CDC13) 8  170.5 (C), 170.4 (C), 156.0 (C), 136.3 (C), 128.7 (CH),
128.2 (CH), 128.1 (CH), 74.3 (C), 66.9 (CH2), 62.0 (CH2), 61.8 (CH2), 54.1 (Me), 53.1 (CH),
N^CQ2MeBocHN BocHN
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(C), 67.1 (CH2), 61.7 (CH2), 61.6 (CH2), 54.2 (CH), 52.9 (CH), 27.3 (Me), 27.1 (Me); m/z (ES)
403 ([M-H~], 100%), 329 (60).
(2<S ’^<S)-2-{[(2-be!izyloxycartMmylamino)-3-(ferf-butoxy)propai>oyl]a!iiiiio}-3-(ferf- 
butoxy)propanoic acid (147). Z-Ser('Bu)-Ser('Bu}-OH
LiOH monohydrate (170 mg, 4.0 mmol) was added to a solution of Z-Ser('Bu)-Ser(*Bu)-OMe 
145 (300 mg, 0.66 mmol) in MeOH-H20  (5:1) (7.0 ml). The mixture was stirred for 18 h at room 
temperature. The solution was evaporated in vacuo and partitioned between hydrochloric acid 
(1M, 25 ml) and CH2C12 (35 ml). The aqueous layer was further extracted with CH2C12 (2 x 35 
ml) and the organic extracts were combined, dried (Na2SC>4), filtered and evaporated in vacuo to 
give the title compound24 as a colourless oil (255 mg, 8 8 %) (Found: MH+ 439.2438. C22H3sN20 7  
requires M tf , 439.2436); [a]i>23 +19.7 (c2.67, CHC13); IR (film)/cm_1 vmax 3328, 2972, 2614, 
1731, 1679, 1654, 1504, 1392, 1365, 1195, 1100, 875, 755, 698, 650; *H NMR (400 MHz; 
CDC13) 6  7.48 and 7.40 (1H, J8.0, NH), 7.26 (5H, m, PhH), 6.33 (1H, bs, OH), 5.79 (1H, d, J6.0, 
NH), 5.05 (2H, s, OCH2), 4.63 (1H, m, 2-H), 4.25 (1H, m, 2’-H), 3.83 (1H, m, 3-MI), 3.71 (1H, 
m, 3’-M I), 3.47 (1H, m, 3-HH), 3.37 (1H, m, 3’-Hi/), 1.13 (9H, s, CMe3), 1.09 (9H, s, CMe3); 
13C NMR (100 MHz; CDC13) 5 173.8 (C), 170.8 (C), 156.2 (C), 136.2 (C), 128.6 (CH), 128.4 
(CH), 128.2 (CH), 74.4 (C), 73.9 (C), 67.1 (CH2), 61.7 (CH2), 61.6 (CH2), 54.2 (CH), 52.9 (CH),
27.3 (Me), 27.1 (Me); m/z (APcI) 439 (MH+, 100%), 363 (95).
(IS/I ’5,2 ’ ’S^M ethy 1 2—{({[(2-terf-butoxycarbonylamino)-3-(ferf-butoxy)propanoyll-
amino}-3-{terf-butoxy)propa«oyl)ainino]-3-hydroxypropanoate (148). Boc-Ser^Bu)- 
Ser(*Bu)-Ser—OMe
NMM (0.13 ml, 1.2 mmol) and isobutyl chloroformate (0.10 ml, 0.76 mmol) were added 
dropwise to a solution of Boc-Ser(rBu)-Ser(/Bu)-OH 146 (240 mg, 0.59 mmol) in dry THF (1.0
CbzHN CbzHN
BocHN BocHN C02Me
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ml) at 0 °C and the mixture was stirred for 20 min. H-Ser-OMe (140 mg, 0.90 mmol) was added 
and the solution was stirred at 0 °C for 5 h, evaporated in vacuo and partitioned between aqueous 
KHSO4 solution (10% w/v, 25 ml) and CH2CI2 (35 ml). The aqueous layer was further extracted 
with CH2CI2 ( 2  x 35 ml) and the combined organic layers were washed with brine (50 ml), dried 
(Na2SC>4), filtered and evaporated in vacuo. Purification by column chromatography on Si0 2 , 
eluting with EtOAc (R/0.44), gave the title compound as a colourless oil (234 mg, 78%) (Found: 
MPT 506.3080. C23H44N3O9 requires M ft, 506.3072); [<x] D23 +16.2 (c2.60, CHC13); IR (film)/cm“ 
1 vmax 3404, 2975, 1710, 1650, 1504, 1366, 1169, 1091, 1017, 878, 730, 650; *H NMR (400 MHz; 
SO(CD3)2) 5 8.23 (1H, m, 2-NH), 7.87 (0.5H, d, J8.0, 2’-NH) 7.77 (0.5H, d, J8.0, 2’-NH), 6 . 8 6  
(0.5H, d, J  8.0, 2” —NH), 6.75 (0.5H, d, J8.0, 2” -NH), 5.14 (1H, m, 3-/7H), 4.51 (1H, m, 2’-H),
4.48 (1H, m, 2-H), 4.23 (0.5H, m, 2” -H), 4.11 (0.5, m, 2” -H), 3.82-3.41 (5H, 2CH2 and CH//),
3.74 (3H, s, OMe), 3.41 (1H, s, OH), 1.45 (9H, s, CMe3), 1.17 (18H, s, CMe3); 13C NMR (100 
MHz; SO(CD3)2) 5 171.8 (C), 171.4 (C), 171.3 (C), 171.2 (C), 170.3 (C), 170.1 (C), 155.7 (C),
155.6 (C), 78.7 (C), 78.7 (C), 73.4 (C), 73.3 (C), 73.2 (C), 70.5 (C), 62.3 (CH2), 61.8 (CH2), 61.7 
(CH2), 55.4 (CH), 55.2 (CH), 55.0 (CH), 53.3 (CH), 53.2 (CH), 53.0 (CH), 52.3 (Me), 28.6 (Me),
27.6 (Me), 27.5 (Me); m/z (APcI) 506 (MH+, 100%).
(2S,2 'S,2 ’ ’5)-Methy I 2-[({[((2-benzyloxycarbonylamino)-3-(/e/t-butoxy)propanoyl]-
amino}-3-(te/t-butoxy)propanoyl)amino]-3-hydroxypropanoate (149). Z-Ser^Bu)- 
Ser(/Bu)-Ser-OMe
NMM (0.13 ml, 1.2 mmol) and isobutyl chloroformate (0.10 ml, 0.76 mmol) were added 
dropwise to a solution of Z-Ser('Bu)-Ser('Bu)-OH 147 (255 mg, 0.58 mmol) in dry THF (1.0 ml) 
at 0 °C and the mixture was stirred for 20 min. H-Ser-OMe (140 mg, 0.90 mmol) was added and 
the solution was stirred at 0 °C for 5 h, evaporated in vacuo and partitioned between aqueous 
KHSO4 solution (10% w/v, 25 ml) and CH2CI2 (35 ml). The aqueous layer was further extracted 
with CH2C12 ( 2  x 35 ml) and the combined organic layers were washed with brine (50 ml), dried 
(Na2SC>4), filtered and evaporated in vacuo. Purification by column chromatography on SiC>2, 
eluting with EtOAc (R/0.52), gave the title compound as a colourless oil (182 mg, 34%) (Found: 
MH+ 540.2910. C26H42N3O9 requiresMH^, 540.2916); [a ] D23 +16.4 (cl.27, CHCI3); IR (film)/cm~ 
1 vmax 3332, 2974, 1730, 1660, 1518, 1366, 1195, 1086; *H NMR (400 MHz; SO(CD3)2) 8  8.89
CbzHN CbzHN COjMe
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(1H, bs, NH), 8.25 (0.5H, d, J  8.0, NH), 8.21 (0.5H, d, J  8.0, NH), 7.42-7.35 (5H, PhH), 5.11 
(2H, s, OCH2), 4.81 (1H, bs, NH), 4.42 (2H, 2CH), 4.24-3.42 (8 H, 3CH2, CH and OH), 3.68 (3H, 
s, OMe), 1.13 (18H, s, 2CMe3); 13C NMR (100 MHz; SO(CD3)2) 8  171.9 (C), 171.3 (C), 170.1 
(C), 156.4 (C), 137.4 (C), 128.8 (CH), 128.1 (CH), 127.1 (CH), 73.4 (C), 73.3 (C), 65.9 (CH2),
63.3 (CH2), 62.3 (CH2), 61.7 (CH2), 55.8 (CH), 55.7 (CH), 55.4 (CH), 55.0 (CH), 53.2 (CH), 53.1 
(CH), 52.3 (Me), 27.6 (Me), 27.6 (Me); m/z (APcI) 540 (MH+, 12%), 464 (100).
2,2-Diethoxy-3—thioamide (151)
EtO OEt OEt 
EtO-L ,NH,
" h '
A mixture of 2,2 diethoxypropionitrile 150 (0.5 ml, 3.2 mmol) and ammonium sulphide (50 wt.% 
in H20 ; 1.0 ml, 7.4 mmol) in MeOH (25 ml) was stirred for 2.5 h. The mixture was evaporated in 
vacuo, purification by column chromatography on Si02, eluting with light petroleum-EtOAc 
(1:1) (Rf 0.64), to give the title compound as an off white solid (267 mg, 47%), mp 110-111 °C 
(light petroleum:EtOAc) (Found: MH+, 178.0892. C7Hi5N0 2S requires MfjT, 178.0896); IR 
(KBr)/cm_1 3427, 3305, 2975, 2933, 2891, 2362, 1597, 1428, 1265, 1192, 1144, 1129, 1051, 
962, 864, 823, 728, 677; *H NMR (400 MHz; CDC13) 8  8.16 (2H, bs, NH2), 3.49 (2H, dq, J9.0,
7.0, 20Ci/HMe), 3.44 (2H, dq, J  9.0, 7.0, 20CH//Me), 1.60 (3H, s, Me), 1.16 (6 H, appt, J7.0, 
2CH2M?); 13C NMR (100 MHz; CDC13) 8  206.6 (C), 103.0 (C), 58.0 (CH2), 24.7 (Me), 15.2 
(Me); m/z (APcI) 178 (MH+, 30%), 132 (100).
2—(Diethoxymethyl)thiazole-^I—carboxylic acid (157)
EtO N ^ C° 2 Et EtO N ^ C° 2 hX  J ---  H  XEtO S EtO S
LiOH monohydrate (2.73 g, 65.1 mmol) was added to a stirred solution of thiazole 94 (2.55 g,
11.0 mmol) in MeOH-H20  (5:1) (100 ml) and the solution was stirred overnight. After 
evaporating in vacuo, the mixture was partitioned between citric acid (1 M; 40 ml) and CH2C12 
(150 ml). The aqueous layer was further extracted with CH2C12 (2 x 100 ml) and the organic 
extracts were combined, washed with brine (60 ml), dried (Na2SC>4) and evaporated in vacuo to 
give the title compound as a white solid (1.63 g, 64%), mp 97-98 °C (EtOAc) (Found: MH+
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232.0639. C9H14N 04S requires M Ft 232.0638); IR (KBrycm-1 v™* 3105, 2978, 2865, 2725, 
2634, 2534, 1684, 1482, 1410, 1360, 1274, 1227, 1191, 1070, 1010, 941, 848, 779, 746; ’HNMR 
(400 MHz; CDC13) 6  10.88 (1H, bs, OH), 8.21 (1H, s, 5-H), 5.68 (1H, s, CH), 3.64 (2H, dq, J9.0,
7.0, 20C//HMe), 3.58 (2H, dq, J  9.0, 7.0, 20CH7/Me), 1.18 (6 H, app t, J  7.0, 2CH2Me); ,3C 
NMR (100 MHz; CDC13) 6  170.3 (C), 165.2 (C), 147.6 (C), 129.0 (CH), 98.4 (CH), 62.6 (CH2),
15.0 (Me); m/z (APcI) 232 (MH+, 100 %).
2-(Diethoxymethyl)thiazoIe-4—carboxamide (158)
EtO N ^ C°2h EtO N ^ /CONH2>-t J  ----- ► H JEtO EtO
Ethyl chloroformate (0.68 ml, 7.15 mmol) was added to a solution of thiazole 157 (1.63 g, 7.05 
mmol) and Et3N (1.0 ml, 7.15 mmol) in diy THF (30 ml) and stirred at 0 °C for 1 h. Aqueous 
NH4OH (35% w/v) (5.2 ml) was added and the solution stirred at 0 °C for lh, allowed to warm to 
RT and evaporated in vacuo. The residue was partitioned between H20  (70 ml) and EtOAc (150 
ml), aqueous layer was further extracted with EtOAc (2 x 100 ml), the combined layers were 
washed with brine (60 ml), dried (Na2S04), in evaporated in vacuo, purification by column 
chromatography on Si02, eluting with EtOAc (R/0.30), gave the title compound17 as a colourless 
solid (1.38 g, 85%) mp 115-116 °C (EtOAc) (Found: MH+, 231.0801. C9Hi5N20 3S requires 
MH*, 231.0798); IR (KBr)/cm_1 v™* 3385, 3207, 3096, 2975, 2925, 2885, 1679, 1648, 1609, 
1574, 1522, 1488, 1391, 1322, 1195, 1087, 1059, 937, 902, 841, 784, 708; lH NMR (500 MHz; 
CDC13) 6  8.12 (1H, s, 5-H), 7.20 (1H, bs, NH), 6.46 (1H, bs, NH), 5.61 (1H, s, CH), 3.63 (4H, m, 
20CH2), 1.25 (6 H, m, 2Me); 13C NMR (125 MHz; CDC13) 8  169.2 (C), 163.3 (C), 149.7 (C),
125.3 (CH), 98.1 (CH), 62.1 (CH2), 15.1 (Me); m/z (APcI) 231 (MH+, 100%).
2-{Diethoxymethyl)thiazole-4-carboxamide (158)
EtO N ^ C°2Et EtO N -^ C0NH2
y - c  J   ► >-GrEtO EtO
Thiazole 94 (12.45 g, 54 mmol) was dissolved in a saturated solution of ammonia in MeOH (220 
ml) and stirred at 45 °C for 7 d. The solution was evaporated in vacuo, purification by column
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chromatography on SiC>2 , eluting with EtOAc (R/0.30), gave the title compound17 as a colourless 
solid (8.12 g, 65%) with the same spectroscopic properties.
2-(Diethoxyniethyl)thiazole—4-carbonitriIe (159)
EtO N ^ / C 0NH 2 EtO
X  J  ---------   X J
EtO $  EtO
Phosphorous oxylchlroide (7.56 ml, 81.0 mmol) was added dropwise to a cold (0 °C) solution of 
thiazole 158 (8.12 g, 35.3 mmol) in pyridine (120 ml). The solution was warmed to RT and 
stirred for 2  h and evaporated in vacuo. Purification by column chromatography on SiC>2, eluting 
with light petroleum-EtOAc (1:1) (Rf 0.56), gave the title compound as a brown oil (6.20 g, 83%) 
(Found: MH*, 213.0690. C9H13N2O2S requires M tt , 213.0692); IR (film)/cm-1  Vmax 3106, 2979, 
2931, 2889, 2240, 1496, 1444, 1392, 1371, 1319, 1062, 951, 906, 8 6 8 , 787; *H NMR (400 MHz; 
C D C I 3 )  8  7.93 (1H, s, 5-H), 5.66 (1H, s, CH), 3.71 (2H, dq, J 9.5, 7.0, 20C//HMe), 3.62 (2H, dq, 
J  9.5, 7.0, 20CH//Me), 1.21 (6 H, app t, J7 .0 , 2CH2Me); 13C NMR (125 MHz; CDC13) 8  171.4 
(C), 131.5 (CH), 126.9 (C), 113.9 (C), 98.2 (CH), 62.7 (CH2), 15.0 (Me); m/z (APcI) 213 (MfT, 
97%), 139 (100).
2-(Diethoxy methyl)thiazole-4-thioamide (160)
EtO, N ^ C N  EtO N-^CSNH 2
X  T  --------- - p k T V 1
EtO Et°  S
A mixture of thiazole 159 (2.51 g, 11.83 mmol) and ammonium sulphide (50 wt. % in H2O; 3.2 
ml, 23.4 mmol) in MeOH (50 ml) was stirred overnight. The mixture was evaporated in vacuo to 
give the title compound as a pale yellow solid (2.9 g, 100%), mp 80-81 °C (EtOAc) (Found: 
MH+, 247.0568. Q H ^ C ^  requires M ft,  247.0569); IR (KBr)/cm_1 Vmax 3330, 3247, 3150, 
2973, 2929, 1635, 1611, 1505, 1444, 1400, 1370, 1338, 1316, 1212, 1159, 1130, 1057, 1007, 970, 
909, 878, 836; *H NMR (400 MHz; CDC13) 8  8.59 (1H, bs, NH), 8.40 (1H, s, 5-H), 7.50 (1H, bs, 
NH), 5.60 (1H, s, CH), 3.64 (2H, dq, J  9.0, 7.0, 20C//HMe), 3.60 (2H, dq, J  9.0, 7.0, 
20CH#Me), 1.21 (6 H, appt, J  7.0, 2CH2M?); 13C NMR (100 MHz; CDC13) 8  190.6 (C), 168.9 
(C), 153.3 (C), 128.9 (CH), 98.0 (CH), 62.1 (CH2), 15.1 (Me); m/z (APcI) 247 230 (100%), 247 
(MET, 95).
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Ethyl 2-[2-(diethoxymethyl)thiazol-4-yl]thiazole-4-carboxylate 161
CSNH-
Ethyl bromopyruvate (0.56 ml, 4.48 mmol) was added to a stirred solution of thiazole 160 (0.92 g, 
3.73 mmol) in EtOH (10 ml) over 4A molecular sieves (2.5 g) and the mixture was heated at 
reflux for 1 h. The solution was allowed to cool, filtered through Celite® and evaporated in vacuo. 
The residue was partitioned between saturated NaHCC^ (80 ml) and CHCb (80 ml), the aqueous 
layer was further extracted with CHCI3 (2 x 60 ml), washed with brine (85 ml), dried Na2S0 4  and 
evaporated in vacuo to give the title compound as a pale green solid (1.28 g, 100%) mp 85-86 °C 
(light petroleum-Et2 0 ) (Found: MH+, 343.0786. C14H19N2O4S2 requires M £ t, 343.0781); IR 
(KBr)/cm_1 v,™* 3120, 2980, 2925, 2885, 1724, 1540, 1476, 1440, 1392, 1368, 1327, 1290, 1210, 
1058, 954, 894, 876, 845, 822, 801; *H NMR (400 MHz; CDC13) 5 8.12 (2H, s, 5 and 5’-H), 5.65 
(1H, s, CH), 4.40 (2H, q, J  7.0, Ctf2Me), 3.70 (2H, dq, J  9.5, 7.0, 20C//HMe), 3.64 (2H, dq, J  
9.5, 7.0, 20CHi/Me), 1.35 (3H, t, J7.0, CH2Afe), 1.18 (6 H, app t, J7.0, 2CH2M?); 13C NMR (100 
MHz; CDCI3) 8  169.9 (C), 163.4 (C), 161.5 (C), 148.5 (C), 147.9 (C), 127.8 (CH), 118.5 (CH),
98.5 (CH), 62.4 (CH2), 61.6 (CH2), 15.1 (Me), 14.4 (Me); m/z (APcI) 343 (MFC, 100%), 297 (50).
Ethyl 2—(2-formylthiazol-4-yl)thiazole-4-carboxylate 162
Bisthiazole 161 (278 mg, 0.81 mmol) was dissolved in acetone-HClaq (2M) (8:1) (9 ml) and 
stirred at reflux for 1 h, evaporated in vacuo, and separated in H2O ( 1 0  ml) and CH2CI2 (3 x 20 
ml). The organic extracts were combined, dried (Na2SC>4) and evaporated in vacuo to give the 
title compound as a yellow solid (190 mg, 87%) mp 155-156 °C (EtOAc) (lit. 25 mp 134-135.5 
°C) (Found: M H \ 269.0053. C10H9N2O3 S2 requires M tf,  269.0049); IR (KBr)/cm_1 v™* 3423, 
3127, 3094, 2977, 2839, 2361, 1724, 1701, 1470, 1419, 1367, 1333, 1297, 1212, 1182, 1094, 
1044, 1021, 955, 901, 881, 827, 812, 787, 773, 687, 660; *H NMR (400 MHz; CDC13) 8  9.98 (1H, 
s, CH), 8.44 (1H, s, 5’-H), 8.15 (1H, s, 5-H), 4.38 (2H, q, J  7.1, OC//2Me), 1.37 (3H, t, J  7.1,
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CH2jWe); 13C NMR (100 MHz; CDC13) 8  183.3 (C), 165.9 (C), 162.0 (C), 161.2 (C), 151.1 (C),
148.3 (C), 128.5 (CH), 124.0 (CH), 61.8 (CH2), 14.4 (Me); m/z (APcI) 269 (MH+, 1 00%).
Ethyl 2-{2-formylthiazol—4—yl)thiazole-4-carboxylate (162)
EtO N^ c s n h 2XTEtO S '
Ethyl bromopyruvate (1.63 ml, 13.0 mmol) was added to a stirred solution of thiazole 160 (2.90 g, 
11.77 mmol) in EtOH (40 ml) and the mixture was heated at reflux for 2 h and evaporated in 
vacuo. The residue was dissolved in acetone-HClaq (2M) (5:2) (70 ml) and stirred at reflux for
1 .5 h, evaporated in vacuo, and separated in H2O (60 ml) and CH2CI2 (3 x 60 ml). The organic 
extracts were combined, dried (Na2SC>4) and evaporated in vacuo to give the title compound as a 
yellow solid (3.15 g, 100%) with the same spectroscopic properties.
Ethyl 2-{2-[l-(l-hydroxyethyl)]thiazol-4-yl}thiazole-4-carboxylate (163)
Methyl magnesium bromide (3.0 M in Et2 0 ) (0.77 ml, 2.31 mmol) was added dropwise to a 
solution of bisthiazole 162 (600 mg, 2.24 mmol) in diy CH2CI2 (25 ml) at 0 °C. The solution was 
warmed to RT and stirred for 18 h, saturated aqueous NH4CI (20 ml) was added and evaporated in 
vacuo. The residue was partitioned between H2O (35 ml) and CH2CI2 (50 ml), the aqueous layer 
was further extracted with CH2CI2 (2 x 40 ml), the combined organic layers were dried (Na2SC>4) 
and evaporated in vacuo. Purification by column chromatography on SiC>2, eluting with light 
petroleum-EtOAc (1:1) {Rf 0.26) gave the title compound as colourless solid (260 mg, 41%) mp 
109-110 °C (EtOAc) (Found: MH+, 285.0359. requires M fT , 285.0362); IR
(KBr)/cm_l Vmox 3422, 3106, 2975, 2925, 1734, 1654, 1560, 1541, 1298, 1216, 1098, 1017, 780; 
'H NMR (400 MHz; CDC13) 8  8.11 (1H, s, 5 -H), 8.07 (1H, s, 5’-H), 5.14 (1H, q, 76.5, CH), 4.38 
(2H, q, 77.0, OCH2Me), 2.98 (1H, bs, OH), 1.63 (3H, d, 76.5, Me), 1.36 (3H, t, 77.0, CH2Me); 
13C NMR (100 MHz; CDCI3) 8  176.7 (C), 163.4 (C), 161.5 (C), 148.0 (C), 147.9 (C), 127.8 (CH),
117.5 (CH), 68.2 (CH), 61.6 (CH2), 24.1 (Me), 14.4 (Me); m/z (APcI) 285 (M H\ 100%).
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Ethyl 2-(2-acetyIthiazol-4-yl)thiazole-4—carboxylate (164)
OH C02Et O COzEt
Method A: IBX (618 mg, 2.20 mmol) was added to DMSO (15 ml) and stirred until homogenous 
(-15 min), bisthiazole 163 (250 mg, 0.88 mmol) was added and the solution was stirred for 1 h, 
partitioned between H2O (15 ml) and CH2CI2 (40 ml). The aqueous layer was further extracted 
CH2CI2 (2 x 40 ml) and the combined organic layers washed saturated aqueous NaHCCh (40 ml), 
dried (Na2SC>4) and evaporated in vacuo. Purification by column chromatography on SiC>2 , 
eluting with light petroleum-EtOAc (1:1) (Rf 0.69), gave the title compound as a yellow solid 
(124 mg, 50%) mp 159-160 °C (EtOAc) (Found: MR", 283.0208. CnH„N20 3 S2 requires M it, 
283.0206); IR (KBr)/cm_l 3422, 3127, 3033, 1724, 1686, 1654, 1466, 1412, 1359, 1336, 
1298, 1211, 1096, 1054, 937, 772; ‘H NMR (500 MHz; CDCh) 8  8.38 ( 1H, s, 5’-H), 8.15 ( 1H, s, 
5-H), 4.39 (2H, q, J  7.1, OC7/2Me), 2.72 (3H, s, Me), 1.38 (3H, t, J  7.1, CH2Me); l3C NMR (125 
MHz; CDCh) 8  191.2 (C), 167.2 (C), 162.4 (C), 161.3 (C), 150.2 (C), 148.2 (C), 128.2 (CH),
124.1 (CH), 61.7 (CH2), 26.0 (Me), 14.4 (Me); m/z (APcI) 283 (MH*, 100%).
Method B: Mn0 2  (activate on carbon) (64 mg, 0.74 mmol) was added to a solution of bis-thiazole 
(97) (21 mg, 74 pmol) in CH2CI2 (4 ml) and stirred for 40 min. The solution was filtered over 
Celite®, washed with MeOH (15 ml) and evaporated in vacuo. Purification by column 
chromatography on SiC>2 , eluting with light petroleum-Et2 0  (1:1) (Rf 0.48), gave the title 
compound as a yellow solid (11 mg, 52%) with the same physical and spectroscopic properties.
2-(Dimethoxymethyl)thiazoIe-4-carboxamide (165)
Thiazole 96 (109 mg, 0.50 mmol) was dissolved in a saturated solution of ammonia in MeOH ( 8  
ml), the reaction was stirred in a sealed continuous microwave, irradiated at 300 watts, 60 °C, 
with cooling for 4 h. The solution was evaporated in vacuo, purification by column 
chromatography on Si0 2 , eluting with EtOAc (Rf 0.28) gave the title compound as a colourless 
solid (77 mg, 76%) mp 110-111 °C (EtOAc) (Found: MET, 203.0488. C7H„N 20 3 S requires M h t,
Meu
MeO %
203.0485); IR (KBr)/cnT' VlMX 3405, 3290, 3161, 3124, 2941, 2903, 2834, 1689, 1612, 1517, 
1495, 1370, 1358, 1327, 1285, 1187, 1095, 1054, 990, 940, 902, 812, 792, 705; 'H NMR (400
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MHz; CDCh) 8  8.12 (1H, s, 5-H), 7.19 (1H, bs, NH), 5.78 (1H, bs, NH), 5.53 (1H, s, CH), 3.35 
(6 H, s, OMe); 13C NMR (100 MHz; CDCb) 8  168.0 (C), 162.8 (C), 149.8 (C), 125.5 (CH), 99.7
(CH), 54.4 (Me); m/z (APcI) 203 (MH+, 100 %).
(2£,3^)-Beiizyl 2-(terf-butoxycarbonylamino)-3-hydroxybutanoate (179). (Boc-Thr-Bn)
Benzyl bromide (6.5 ml, 54.8 mmol) was added to a solution of Boc-Thr-OH 178 (3.0 g, 13.7 
mmol) and Et3N (2.0 ml, 14.4 mmol) in dry DMF (75 ml) at 0 °C and stirred for 3 h, allowed to 
warm to RT and stirred for 2 d. The solution was partitioned between H2O (450 ml) and Et2 0  
(300 ml), the aqueous layer was further extracted with Et2<3 (2 x 150 ml), the combined organic 
layers were washed with H2O ( 2  x 180 ml), dried (Na2S0 4), filtered and evaporated in vacuo. 
Purification twice by column chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) 
and light petroleum-Et2 0  (1:1) (Rf 0.13), gave the title compound as a pale yellow oil (2.77 g, 
65%) (Found: MFC, 310.1649. CisHmNO, requires M fT , 310.1649); [a ] D26 -12.2 (c2.15, 
CHCb); IR (film)/cm_l 3453, 2978, 2925, 1740, 1716, 1503, 1455, 1368, 1256, 1163, 1068, 
1001, 880, 850, 755, 698; 'H NMR (400 MHz; CDCb) 8  7.29 (5H, m, PhH), 5.31 (1H, d, 7  9.0, 
NH), 5.16 (1H, d, J  12.5, OC//H), 5.10 (1H, d, J  12.5, OCH/7), 4.24 (2H, 2-H and 3-H), 2.09 
(1H, d, 74.5, OH), 1.37 (9H, s, CMe3) 1.16 (3H, d, 76.5, 3-Me); 13C NMR (100 MHz; CDC13) 8
171.4 (C), 156.2 (C), 135.3 (C), 128.6 (CH), 128.5 (CH), 128.2 (CH), 80.1 (C), 68.2 (CH), 67.3 
(CH2), 58.8 (CH), 28.3 (Me), 20.0 (Me); m/z (APcI) 310 (MH+, 55%), 271 (100).
(25,31?)-Benzyl 2—(terMmtoxycarbonylamino)—3-(p-toluenesulphonyIoxy)butanoate (180). 
Boc-Thr(Ts)-Bn
TsCl (2.34 g, 12.3 mmol) was added portion wise to a solution of (Boc)-Thr-Bn 179 (1.52 g, 4.91 
mmol) in pyridine (15 ml) at 0 °C and stirred for 2 d. The solution was warmed to RT and EtOAc 
( 1 0 0  ml) was added, the solution was washed with aqueous KHSO4 solution (5% w/v) (5 x 30 ml) 
and the organic layer dried (Na2S0 4), evaporated in vacuo. Purification by column 
chromatography on Si0 2 , eluting with light petroleum-EtOAc (3:1) (Rf 0.35), gave the title
BocHN c o 2h BocHN C02Bn
BocHN C02Bn BocHN^ C02Bn
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compound26 as a colourless solid (1.03 g, 45%) mp 121-122 °C (EtOAc) (Found: MH*, 464.1737. 
C23H30NO7S requires 464.1737) [<x] D26 +50.30 (c l.15, CHC13); IR (KBr)/cm_1 3412, 
2977, 1751, 1720, 1599, 1512, 1455, 1388, 1362, 1314, 1247, 1207, 1163, 1089, 1055, 1022, 990, 
957, 940, 909, 844, 818, 777, 767, 751, 701, 6 6 6 ; 'H NMR (500 MHz; CDC13) 6  7.66 (2H, d, J  
8.2, o-PhH), 7.23-7.33 (7H, m, PhH), 5.18 (1H, d, J9.7, NH), 5.11 (1H, dq, J 2.0, 6.4, 3-H), 5.04 
(1H, d, J  12.1, OC//H), 4.81 (1H, d, J  12.1, OCHtf), 4.37 (1H, dd, J  2.0, 9.7, 2-H), 2.36 (3H, s, 
Me), 1.36 (9H, s, CMe3), 1.26 (3H, d, J6 .4 , 3-Me); ,3C NMR (125 MHz; CDC13) 8  169.1 (C),
155.6 (C), 145.0 (C), 134.9 (C), 133.6 (C), 129.9 (CH), 128.6 (CH), 128.6 (CH), 128.5 (CH), 
127.9 (CH), 80.5 (C), 78.7 (CH), 67.9 (CH2), 57.7 (CH), 28.2 (Me), 21.7 (Me), 18.2 (Me); m/z 
(ES) 464 (MET, 7%), 408 (85), 364 (100).
(Z)-Benzyl 2—(rc/t—butoxycarbonylamino)but—2-enoate (181)
T,0r  — - 1BocHN C02Bn BocHN C02Bn
Phenyl selenol (621 mg, 3.95 mmol) was added to a solution of KOH (188 mg, 3.35 mmol) in 
MeOH ( 6  ml) and stirred for 5 min, evaporated in vacuo, and dried in a vacuum dessicator for 36
h. Boc-Thr(Ts)-OBn 180 (400 mg, 0.86 mmol) was added to the residue in dry DMF under a 
nitrogen atmosphere at 0 °C and stirred for 48 h. The solution was partitioned between H20  (40 
ml) and Et20  (50 ml), the aqueous layer was further extracted with Et20  (2 x 50 ml) and the 
combined organic layers where washed with H20  (40 ml), dried (Na2S0 4 ) and evaporated in 
vacuo. Purification by column chromatography on Si02, eluting with light petroleum-EtOAc 
(1:1) (Rf 0.48), gave a colourless solid (150 mg, 60%) mp 85-86 °C (light petroleum-EtOAc) 
(lit. 27 mp 84-85 °C) (Found: M H\ 292.1540. CndfeNOt requires MH*, 292.1543); IR (KBr)/cm~ 
' 3336, 2985, 2360, 1723, 1695, 1659, 1499, 1457, 1393, 1367, 1348, 1291, 1245, 1172,
1107, 1057, 991, 907, 867, 780, 752, 700; 'H NMR (500 MHz; CDCb) 8  7.29 (5H, m, PhH), 6 . 6 6  
(1H, q, J  7.0, 3-H), 5.96 (1H, bs, NH), 5.13 (2H, s, OCH2), 1.73 (3H, d, J  7.0, 3-Me), 1.38 
(CMe3); l3C NMR (125 MHz; CDCIj) 5 164.8 (C), 135.7 (CH), 132.5 (C), 129.9 (C), 128.6 (CH),
128.5 (CH), 128.3 (CH), 80.5 (C), 78.7 (C), 67.9 (CH2), 28.2 (Me), 14.4 (Me); m/z (APcI) 292 
(MH+, 25%), 192 (100), 175 (6 8 ).
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(4S,5i?)-2,2,5-TrimethyI-3-{terr-butoxycarbonyl)oxazolidme-4—carboxylic acid (183)
/?-TsOH (5.70 g, 22.8 mmol) was added to a solution of Boc-Thr-OH 178 (15.0 g, 68.4 mmol) 
and 2,2-dimethoxypropane (84 ml, 684 mmol) in THF (500 ml) and stirred at reflux for 18 h. 
The solution was allowed to cool and evaporated in vacuo, partitioned between H2O (200 ml) and 
EtOAc (300 ml), the aqueous layer was further extracted with EtOAc (2 x 200 ml) and the 
combined organic layers were dried (Na2S0 4 ), filtered and evaporated in vacuo to give the title 
compound as a orange oil (17.35 g, 99%) (Found: MH* 260.1494, C12H22NO5 requires M ht 
260.1492); [a ] D31 -55.4 (c2.95, CHCI3); IR (film)/cm“' v™* 3468, 3016, 2983, 2936, 1725, 1700, 
1478, 1455, 1394, 1369, 1320, 1260, 1216, 1172, 1132, 1094,988,945, 856; 'H NMR (400 MHz; 
CDCb) 5 10.47 (1H, bs, OH), 4.16 (1H, dq, J  8.0, 6.0, 5-H), 3.93 (0.38H, d, J  8.0, 4-H), 3.86 
(0.62H, d, J  8.0, 4-H), 1.59 (1.86H, s, 2-Me), 1.53 (1.14H, s, 2-Me), 1.51 (1.86H, s, 2-Me), 1.48 
(1.14H, s, 2-Me), 1.42 (3.43H, s, CMe3), 1.37 (3H, d, J  6.0, 5-Me), 1.34 (5.57H, s, CMe3); l3C 
(100 MHz; CDCb) 8  171.2 (C), 175.8 (C), 152.3 (C), 150.9 (C), 95.3 (C), 94.7 (C), 81.4 (C), 80.8 
(C), 73.9 (CH), 73.5 (CH), 66.0 (CH), 66.0 (CH), 28.3 (Me), 28.2 (Me), 27.7 (Me), 26.5 (Me), 
24.8 (Me), 23.9 (Me), 18.9 (Me); m/z (APcI) 160 (M H\ 100%).
(45',5/?^’/?)-4-[(2-Hydroxypropyl)aminocarbonyI]-2^,5-trimethyl-3-(/c/1,-butoxcarb- 
onyl)oxazolidine (184)
Et3N (2.78 ml, 20 mmol) was added dropwise over 30 min to a stirred solution of oxazolidine 183 
(2.49 g, 9.68 mmol), (R)- 1 -am ino-2 -propanol (0.71 ml, 9.0 mmol) and pyBOP (5.2 g, 10 mmol) 
in dry CH2CI2 (19 ml) at 0 °C. The solution was allowed to warm to room temperature and stirred 
for a further 18 h. After concentrating in vacuo, purification by column chromatography on SiC>2, 
eluting with EtOAc (Rf 0.29), gave the title compound as a colourless solid (2.84 g, 100%), mp 
118-119 °C (light petroleum-Et2 0 ) (Found: MH+, 317.2072. C15H29N2O5 requires M ft, 
317.2071); [a ] D31 -62.0 (cl.50, CHCb); IR (KBr)/cm_l vmax 3488, 3286, 3116, 2978, 2925, 2865, 
1672, 1570, 1366, 1259, 1135, 989, 967, 945, 909, 855, 781, 765, 690; ‘H NMR (400 MHz;
BocH N ^ C 0 2H
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CDCb) 5 6.44 (1H, bs, NH), 4.22 (1H, bs, 5-H), 3.91 (1H, m, 2’-H), 3.76 (1H, d, J7 .5 , 4-H), 
3.40 (1H, bs, l ’-Z/H), 3.14 (1H, bs, l ’-H H), 2.97 (1H, bs, OH), 1.60 (3H, s, 2-Me), 1.58 (3H, s, 
2-Me), 1.44 (9H, s, CMes), l.37(3H, d ,J6 .0 , 5-Me), 1.17 (3H, d, J  6.5, 2’-Me); 13CNMR(100 
MHz; CDCb) 8  170.2 (C), 152.8 (C), 94.7 (C), 81.5 (C), 73.9, (CH), 67.9 (CH), 6 6 . 8  (CH), 47.1 
(CH2), 28.3 (Me), 27.6 (Me), 25.2 (Me), 20.2 (Me), 18.6 Me); m/z (APcI) 317 (MH+, 100%), 261 
(40).
(4S',5/?,2’/?)-4-[(2-Acetoxypropyl)aniinocarbonyl]-2,2,5-triniethyl-3-(te/*-butoxycar- 
bonyl)oxazoIidine (185)
Acetic anhydride (0.64 ml, 6.78 mmol) was added to a solution of oxazolidine 184 (714 mg, 2.26 
mmol) in dry pyridine (20 ml) and stirred for 36 h. The solution was evaporated in vacuo, 
purification by column chromatography on Si0 2 , eluting with light petroleum-EtOAc (1:1) (Rf 
0.24), gave the title compound as a colourless solid (810 mg, 73%), mp 124-125 °C (light 
petroleum-Et20) (Found: MH+, 359.2179. Ci7H3 iN20 6 requires MH*, 359.2177); [a ] D26 -34.1 
(c l.35, CHCb); IR (KBr)/cm_l v,™* 3382, 2985, 2945, 1735, 1711, 1663, 1532, 1478, 1459, 1376, 
1241, 1221, 1175, 1126, 1096, 1076, 1057, 1026, 986, 972, 954, 894, 857, 783; ‘H NMR (500 
MHz; CDCb) 5 6.36 (1H, bs, NH), 4.99 (1H, ddq, J  6.0,4.0,6.0, 2’-H), 4.22 (1H, bs, 5-H), 3.70 
(1H, d, J  6.5, 4-H), 3.55 (1H, ddd, J  14.2, 6.0, 4.0, l ’-HH), 3.37 (1H, ddd, J  14.2, 6.0, 7.0, P -  
HH), 2.05 (3H, s, Me), 1.60 (3H, s, 2-Me) 1.55 (3H, s, 2-Me), 1.49 (9H, s, CMe3), 1.42 (3H, d, J
6 .0 , 2’-Me), 1.30 (3H, d, J  6.5, 5-Me); l3C NMR (100 MHz; CDCb) 8  170.6 (C), 170.0 (C),
166.4 (C), 94.6 (C), 80.7 (C), 73.9 (CH), 69.6 (CH), 67.4 (CH), 43.8 (CH2), 28.2 (Me), 27.7 (Me),
25.0 (Me), 21.1 (Me), 18.8 (Me), 17.5 (Me); m/z (APcI) 359 (MH1, 100%), 303 (25), 259 (85).
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(45,5J?^’J?)-4-[(2-^£itf-ButyldimethyIsilyIoxy)aminocarbonyl]-2,2,5-trimethyl-3-(terf- 
butoxycarbonyl)oxazolidine (186)
OTBS
Imidazole (400 mg, 5.90 mmol), DMAP (122 mg, 1.0 mmol) and TBDMSC1 (690 mg, 4.6 mmol) 
were added successively to a solution of oxazolidine 184 (1.04 g, 3.27 mmol) in DMF (25 ml). 
The mixture was stirred at room temperature for 36 h, acidified with hydrochloric acid (1 M; 80 
ml) and extracted with Et2 0  (3 x 90 ml). The combined organic extracts were washed with H2O (3 
x 300 ml), dried (Na2SC>4) and evaporated in vacuo to give the title compound as a pale green oil 
(1.39 g, 98%) (Found: M H \ 431.2934. C2iH43N20 5Si requires M tt, 431.2936); [a ] D23 -26.4 
(c0.75, CHC13); IR (film)/cm_l 3329, 2976, 2931, 2858, 2359, 1710, 1669, 1530, 1462, 1367, 
1258, 1175, 1133, 1006, 940, 860, 837, 777; ‘H NMR (500 MHz; CDCI3) 8  6.10 (1H, bs, NH), 
4.11 (1H, bs, 5-H), 3.89 (1H, m, 2’-H), 3.69 (1H, bs, 4-H), 3.23 (2H, l ’-CH2), 1.55 (3H, s, 2- 
Me), 1.52 (3H, s, 2-Me), 1.36 (9H, s, CMe3), 1.32 (3H, d, J  6.0, 5-Me), 1.07 (3H, d, J  6.0, 2’-  
Me), 0.82 (9H, s, CMe3), 0.00 (3H, s, AfeSiMe), 0.01 (3H, s, MeSiAfe) ; l3C NMR (100 MHz; 
CDCI3) 8  169.9 (C), 151.5 (C), 94.9 (C), 80.7 (C), 77.3 (C), 74.7 (CH), 68.1 (CH), 67.2 (CH), 
46.3 (CH2), 28.3 (Me), 25.8 (Me), 21.1 (Me), 19.2 (Me), 18.0 (Me), -3.6 (Me), -4.4 (Me); m/z 
(APcI) 431 (MH*, 80%), 375 (100), 331 (75), 285 (45).
Ethyl 2-{2-[l-(l-hydroxyprop-2-yn)]thiazol-4-yI}thiazole-4-carboxyIate (193)
Ethynyl magnesium bromide (0.5 M; THF) (10.40 ml, 5.2 mmol) was added dropwise to a 
solution of bisthiazole 162 (1.0 g, 3.73 mmol) in THF (25 ml) at 0 °C, was warmed to RT whilst 
stirring 1 h. The reaction was quenched with saturated aqueous NH4CI (20 ml), evaporated in 
vacuo and partitioned between H20  (70 ml) and CH2CI2 (75 ml), the aqueous layer was further 
extracted with CH2CI2 (2 x 75 ml), dried (Na2S04) and evaporated in vacuo. Purification by 
column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (Rf 0.40), gave the 
title compound as a colourless solid (513 mg, 47%) mp 153-154 °C (EtOAc) (Found: MH*, 
295.0202. Ci2H„N 2Q,S2 requires M lf , 295.0206); IR (KBr)/cm_l Vmax 3297, 3249, 3112, 2983,
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2118, 1715, 1541, 1498, 1442, 1370, 1326, 1296, 1214, 1155, 1063, 1019, 926, 776, 758; ‘H 
NMR (500 MHz; CD3OD) 8  8.29 (1H, s, 5’-H), 8.22 (1H, s, 5-H), 5.16 (1H, s, 1” -H), 4.32 (2H, 
q, J  7.2, OC/ftMe), 3.06 (1H, s, 3” -H), 1.31 (3H, t, J  7.2, CH2Me); 13C NMR (125 MHz; 
CD3OD) 8  171.2 (C), 163.5 (C), 161.2 (C), 147.9 (C), 147.2 (C), 128.2 (CH), 118.3 (CH), 81.4
(C), 74.7 (CH), 61.2 (CH), 60.9 (CH2), 13.2 (Me); m/z (APcI) 295 (MH+, 63%). 
Ethyl 2-{2-[l-(prop-2-yn-l-oyl)lthiazol-4—yl}thiazole-4-carboxyIate (194)
IBX (302 mg, 1.08 mmol) was added to DMSO (10 ml) and stirred until homogenous (-15 min), 
bisthiazole 193 (127 mg, 0.43 mmol) was added and the solution was stirred for 2 h, partitioned 
between H2O (15 ml) and CH2CI2 (30 ml). The aqueous layer was further extracted CH2CI2 (2 x 
25 ml) and the combined organic layers washed saturated aqueous NaHCC>3 (40 ml), dried 
(Na2 SC>4) and evaporated in vacuo, to give the title compound as a yellow solid (120 mg, 95%) *H 
NMR (100 MHz; CDCI3) 5 8.47 (1H, s, 5’-H), 8.13 (1H, s, 5-H), 4.39 (2H, q, J  7.1, OC//2Me), 
3.65 (1H, s, 3” -H), 1.36 (3H, t, J7 .1 , CH2M?); 13C NMR (100 MHz; CDC13) 8  168.6 (C), 165.7 
(C), 162.0, (C), 161.2 (C), 151.1 (C), 148.22 (C), 128.8 (CH), 124.8 (CH), 84.0 (C), 77.3 (CH),
61.7 (CH2), 14.4 (Me).
2-[2-{DiethoxymethyI)thiazol—4-yl]thiazole-4-carboxylic acid (197)
LiOH monohydrate (939 mg, 22.8 mmol) was added to a stirred solution of bisthiazole 161 (1.28 
g, 3.73 mmol) in MeOH-H2 0  (5:1) (60 ml) and the solution was stirred for 18 h. After 
evaporating in vacuo, the mixture was partitioned between KHSO4 (2M; 150 ml) and EtOAc (100 
ml). The aqueous layer was further extracted with EtOAc (2 x 80 ml) and the organic extracts 
were combined, dried (Na2S0 4 ), azeotroped MeOH (3 x 40 ml) and evaporated in vacuo to give 
the title compound as a colourless solid (966 mg, 85%), mp > 315 °C (MeOH) (Found: MH+ 
315.0466. C12H 15N2O4 S2 requires MhT 315.0468); IR (KBr)/cm"' v™  3388, 3111, 2975, 2931,
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2888, 1585, 1514, 1442, 1382, 1322, 1303, 1272, 1178, 1102, 1062, 958, 892, 864, 846, 807, 783, 
714; ‘H NMR (400 MHz; SO(CD3)2) 8  8.54 (1H, s, 5-H), 7.98 (1H, s, 5’-H), 5.85 (1H, s, CH),
3.75 (2H, dq, 79.5, 7.0, 20C//HMe), 3.73 (2H, dq,79.5, 7.0, 20CH//Me), 1.25 (6 H, app t, 7 7.0, 
2CH2Afe); 13C NMR (100 MHz; SCKCDjfe) 8  170.4 (C), 164.4 (C), 160.8 (C), 157.7 (C), 148.8 
(C), 122.9 (CH), 118.8 (CH), 98.3 (CH), 62.3 (CH2), 15.5 (Me); m/z (ES) 315 (MH+, 100 %).
(2/?,2’,S,3’/?}-l-(2-{2-[2-(Diethoxymethyl)thiazol-4—yl]thiazol—4-yI}carbonyIamiiio)-3- 
((hydroxybutanoyl)amino]prop-2-yl acetate (198)
EtO N
ekM
CO2H
OAc
EtsN (1.48 ml, 10.65 mmol) was added dropwise over 30 min to a stirred solution of bisthiazole 
197 (800 mg, 2.54 mmol), TFA.H-L-Thr-aminopropanacetate (3.0 mmol) and pyBOP (1.73 g, 
3.32 mmol) in dry CH2CI2 (25 ml) at 0 °C. The solution was allowed to warm to room 
temperature and stirred for a further 4 h. Evaporated in vacuo, purification by column 
chromatography on SiC>2, eluting with MeOH-CFhCb (5% v/v) {Rf 0 .2 1 ) and tritration (Et2<3 ), 
gave the title compound as a colourless solid ( 8 8  mg, 7%), mp 150-151 °C (Et2 0 ) (Found: MH+ 
515.1627. C21H31N4O7S2 requires MhT 515.1629); IR (KBr)/cm“' v™* 3308, 2977, 2925, 1734, 
1653, 1544, 1474, 1377, 1326, 1243, 1172, 1132, 1102, 1070, 1017, 842; 'H NMR (400 MHz; 
CDC13) 8  8.35 (1H, d, 78.0, 2’-NH), 8.28 (1H, s, 5” ’-H), 8.25 (1H, s, 5” -H), 7.18 (1H, app t, 7
6.0, 3-NH), 5.88 (1H, s, CH), 5.17 (1H, m, 2-H), 4.68 (1H, dq, 76.5, 1.5, 3’-H), 4.62 (1H, dd, 7
8.0, 1.5, 2’—H), 3.91 (2H, dq,79.5, 7.0, 2<X7/HMe), 3.89 (2H, dq, 79.5, 7.0, 20CHHMe), 3.65 
(1H, ddd, 714.1, 6.0, 9.0, 3-//H), 3.46 (1H, ddd, 7  14.1, 6.5, 7.0, 3-HH), 2.18 (3H, s, Me), 1.44 
(6 H, app t, 7  7.0, 2CH2Afe), 1.39 (3H, d, 7  6.5, 3’” -Me), 1.36 (3H, d, 7  6.0, 2-Me); l3C NMR 
(100 MHz; CDC13) 8  171.5 (C), 170.9 (C), 170.2 (C), 163.0, (C), 162.2 (C), 149.6 (C), 148.4 (C),
124.4 (CH), 118.4 (CH), 98.5 (CH), 69.5 (CH), 66.3 (CH), 62.4 (CH2), 56.7 (CH), 43.7 (CH2),
21.2 (Me), 18.3 (Me), 17.6 (Me), 15.1 (Me); m/z (ES) 553 (M+K+, 45%), 537 (M+Na+, 100), 515 
(MH*, 35).
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(25,4’S,5’5)-M ethyl 2-{[2,2,5-Triinethyl-3-(ter/-butoxycarbonyl)oxazolidin—4- 
yI]carbonylamino}-3-hydroxypropanoate (199)
Boc C02H
N^CO^e
Ethyl chloroformate (7.9 ml, 80.4 mmol) was added to a solution of oxazolidine 183 (17.35 g,
67.0 mmol) and Et3N (28.0 ml, 0.2 mol) in THF (150 ml) and stirred at 0 °C for 1 h. HCl.H-Ser- 
OMe (12.47 g, 80.4 mmol) was added to the reaction and stirred at 0 °C for a further 2.5h. The 
solution was evaporated in vacuo and partitioned between aqueous KHSO4 solution (10% w/v) 
(200 ml) and EtOAc (200 ml), the aqueous layer was further extracted with EtOAc (2 x 150 ml). 
The combined organic extracts were washed sequentially with NaHCOs (150 ml) and H2O (150 
ml), dried (Na2S0 4 ), filtered and evaporated in vacuo. Purification by column chromatography on 
Si0 2 , eluting with light petroleum-EtOAc (1:1) {Rf 0.17), gave the title compound as a clear oil 
(22.95 g, 94 %) (Found: MH+, 361.1969. C.oHzMOj requires M H \ 361.1968); [a ] D26 -12.2 
(c2.15, CHC13); IR (film)/cnT‘ v™, 3432, 3337, 298, 2360, 1748, 1673, 1538, 1403, 1369, 1258, 
1212, 1175, 1135, 1081, 942, 859, 757; 'H NMR (400 MHz; CDC13) 8  6.85 (1H, d, J  6.0, NH)
4.55 (1H, m, 2-H), 4.23 (1H, m, 5’-H), 4.11 (1H, m, 3-//H), 3.80 (1H, m, 3-H//), 3.73 (3H, s, 
OMe), 3.71 (1H, m, 4’-H), 3.44 (1H, bs, OH), 1.53 (6 H, s, 2’-2Me), 1.38 (9H, s, CMe3), 1.37 
(3H, bs, 5’-Me); l3C NMR (100 MHz; CDCb) 8  171 (C), 169 (C), 152 (C), 94.7 (C), 81.6 (C),
73.6 (CH), 67.7 (CH), 61.7 (CH2), 55.5 (CH), 52.7 (Me), 28.3 (Me), 24.7 (Me), 19.0 (Me), 18.0 
(Me); m/z (APcI) 361 (MH+, 100%), 261 (60), 58 (65).
(45',4’,S',5’/?)-2-[2,2,5-Trimethyl-3—(terf—butoxycarbonyI)oxazolidin—4—yl]^4,5-dihydro-4— 
methoxycarbonyloxazoline (200)
DAST (0.38 ml, 3.06 mmol) was added dropwise to a stirred solution of oxazoldine 199 (0.92 g,
2.55 mmol) in dry CH2CI2 (45 ml) at -78 °C. The solution was stirred for 3 h and then quenched 
by the addition of KHCO3 423 mg, 3.06 mmol). After warming to room temperature, the mixture 
was extracted with saturated aqueous NaHCOs (30 ml) and CH2CI2 (3 x 35 ml). The organic 
extracts were combined, dried (Na2 S0 4 ) and evaporated in vacuo, purification by column
,NC02Me
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chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) (Rf 0.19), gave the title 
compound as a clear oil (0.76 g, 89%) (Found: MH*, 343.1863. C16H27N2O6 requires M ft , 
343.1864); [<x] D27 +36.52 (c l.15, CHCI3); IR (film)/cm ' v™, 3387, 2980, 2925, 1745, 1711, 
1664, 1519, 1474, 1438, 1389, 1263,1209, 1133, 1073, 980, 939, 921, 897, 776, 756; 'H NMR 
(400 MHz; CDCb) 8  4.76 (1H, dd, J  10.4, 9.0,4-H), 4.55 (1H, dd, J  9.0, 9.0, 5-C//H), (1H, dd, J  
10.4, 9.0, 5-CHfl), 4.06 (1H, m, 4’-H), 4.04 (1H, m, 5’-H), 3.73 (3H, s, OMe), 1.61 (3H, s, 2’-  
Me), 1.52 (3H, s, 2’-Me), 1.33 (12H, bs, CMe3 and 5’-Me); l3C NMR (100 MHz; CDCb) 8  171.0 
(C), 168.0 (C), 151.1 (C), 95.2 (C), 80.4 (C), 74.0 (CH), 69.5 (CH2), 68.3 (CH), 61.4 (CH), 52.7 
(Me), 28.2 (Me), 26.5 (Me), 24.0 (Me), 18.5 (Me); m/z (APcI) 343 (MH+, 100%), 287 (75), 261 
(55).
(25,4’5,5’Jf)-Methyl 2-{[2^,5-trimethyl-3-(te/t-butoxycarbonyl)oxazolidin-4—yl]thio-
carbonylamino}3—hvdroxypropanoate (205)
_ r  y - O '/ NI Ftor
N ,,C02Me V ° ' T  H
■ ^  ^ >AN N ^ C 0 2Me
Roc. n iBOC
Boc ^OH
Oxazoline 200 (22.94 g, 67.0 mmol) was dissolved in MeOH-EtsN (2:1) (150 ml), hydrogen 
sulphide gas was bubbled through the solution whilst stirring at RT for 5 h. The solution was 
evaporated in vacuo, purification by column chromatography on SiC>2, eluting with light 
petroleum-Et2 0  (4:1) (Rf 0.14), gave the title compound as a brown oil (11.43 g, 45%) (Found: 
MH*, 377.1741. CndbsNAsS requires M Ft, 377.1741); [<x] D28 +24.60 (cl.00, CHCb); IR 
(film)/cm_l Vmax 3468, 3354, 2980, 2925, 2361, 1746, 1711, 1518, 1438, 1378, 1263, 1207, 1173, 
1133, 1092, 982, 940, 923, 897, 858, 758; 'H NMR (400 MHz; CDCb) 8  8.45 ( 1H, d, J 6 .5 , NH),
4.72 (1H, dd, J  10.5, 8.5, 2-H), 4.55 (1H, dd, J9 .0 , 8.5, 3-7/H), 4.44 (1H, dd, J  10.5, 9.0, 3-HH),
4.07 (2H, 4’-H  and 5’-H), 3.76 (1.3H, s, OMe), 3.73 (1.7H, s, OMe), 1.60 (1.3H, s, 2’-Me), 1.58 
(1.7H, s, 2’-Me), 1.55 (1.3, s, 2’-Me), 1.50 (1.7H, s, 2’-Me), 1.40 (0.36H, s, 5’-Me), 1.36 (3.9H, 
s, CMe3), 1.33 (0.64H, s, 5’-Me),1.31 (5.1H, s, CMe3); 13C NMR (100 MHz; CDCb) 8  170.9 (C),
168.0, (C), 151.1 (C), 95.2 (C), 80.4 (C), 74.0 (CH), 69.5 (CH2), 68.3 (CH), 61.5 (CH), 53.0 (Me),
52.7 (Me), 28.3 (Me), 28.2 (Me), 26.5 (Me), 24.0 (Me), 18.5 (Me); m/z (APcI) 377 (MH+, 48%), 
343 (100).
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(4.S,4\S',5’l?)-2-[2,2,5-Triinethyl-3-(terf-butoxycarbonyl)oxazolidin-4-yl]-4,5-dihydro-4- 
methoxycarbonylthiazole (206)
DAST (0.28 ml, 2.29 mmol) was added dropwise to a stirred solution of oxazolidine 205 (661 mg,
1.76 mmol) in dry CH2CI2 (20 ml) at -78 °C. The solution was stirred for 3 h and then quenched 
by the addition of KHCO3 243 mg, 1.76 mmol). After warming to room temperature, the mixture 
was extracted with aqueous saturated NaHCC>3 (20 ml) and CH2CI2 (3 x 30 ml). The organic 
extracts were combined, dried (Na2SC>4) and evaporated in vacuo, purification by column 
chromatography on S1O2, eluting with EtOAc (Rf 0.53), gave the title compound as a brown oil 
(628 mg, 100%) (Found: MH+, 359.1636. C16H27N2O5S requires M tf , 359.1635); [a ] D26 +10.00 
(cl.60, CHCI3); IR (film)/cm_l Vmax 3351, 2980, 2936, 2359, 1699, 1623, 1520, 1478, 1438, 1376, 
1310, 1263, 1212, 1172, 1133, 1089,984, 938, 898, 756; ‘H NMR (400 MHz; CDCb) 8  4.72 (1H, 
dd, J  10.0, 9.5, 4-H), 4.55 (1H, dd.79.5, 9.0, 5-//H), 4.43 (1H, dd, J  10.0, 9.0, 5-H//), 4.07 (2H, 
4’-H  and 5’-H), 3.73 (3H, s, OMe), 1.58 (3H, s, 2’-Me), 1.50 (3H, s, 2’-Me), 1.33 (3H, s, 5’-  
Me), 1.31, (9H, s, CMe3); l3C NMR (100 MHz; CDCI3) 8  171.3 (C), 168.0 (C), 151.4 (C), 95.1 
(C), 80.4 (C), 74.0 (CH), 69.9 (CH2), 68.1 (CH), 61.4 (CH), 52.7 (Me), 28.2 (Me), 24.0 (Me),
18.2 (Me), 15.1 (Me); m/z (APcI) 359 (MH*, 100%), 303 (90), 259 (57), 215 (96).
(4S,5i?H - { 4 Methoxycarbonylthiazot-2-yl)-2,2,5-trimethyl-3~(tert-butoxycarbonyl) 
oxazolidine (207)
BrCCb (0.40 ml, 4.06 mmol) and DBU (0.6 ml, 4.01 mmol) were added dropwise to a solution of 
oxazolidine 206 (300 mg, 0.84 mmol) in dry CH2CI2 (20 ml) at -20 °C and was stirred for 18 h. 
The mixture was poured into saturated aqueous NaHCC>3 solution (25 ml) and extracted with 
CHCI3 (3 x 40 ml). The organic extracts were combined, dried (Na2SC>4) and evaporated in vacuo. 
Purification by column chromatography on SiC>2 , eluting with light petroleum-EtOAc (1:1) (Rf
0.60), gave the title compound as a colourless solid (184 mg, 62%) mp 123—124 °C (EtOAc) 
(Found: MH+, 357.1475. C16H25N2O5S requires MH*, 357.1479) [<x] D31 -67.60 (c0.55, CHCI3); IR
.,C02MeN^C02Me
,xC02Me
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(KBr)/cm_l 3098, 2890, 2943, 2911, 1708, 1479, 1457, 1436, 1366, 1301, 1258, 1219, 1153, 
1134, 1 100, 989, 931, 856, 840, 782, 754, 737; 'H NMR (400 MHz; CDCb) 8  8.08 (1H, s, 5’-H),
4.72 (1H, d, J  7.5, 4-H), 4.12 (1H, dq, J  7.5, 6.0, 5-H), 3.86 (3H, s, OMe), 1.62 (6 H, s, 2-2Me), 
1.35 (3H, d, J6 .0 , 5-Me), 1.19 (9H, bs, CMe3); l3C NMR (100 MHz; CDCb) 8  173.7 (C), 161.7 
(C), 151.3 (C), 146.3 (C), 127.6 (CH), 95.3 (C), 80.8 (C), 77.9 (CH), 66.0 (CH), 52.5 (Me), 28.1
(Me), 26.5 (Me), 25.9 (Me), 17.8 (Me); m/z (APcI) 357 (MH+, 55%), 102 (100).
(4S,5R) 4 -(4 - Methoxy carbonylthiazoI-2-yl)-2,2,5—trimethyl—3-{fer*-butoxy carbonyl) 
oxazolidine (207)
DAST (0.28 ml, 2.28 mmol) was added dropwise to a stirred solution of oxazolidine 205 (661 mg,
1.76 mmol) in dry CH2CI2 (20 ml) at -78 °C. The solution was stirred for 3 h. BrCCh (0.80 ml, 
8.13 mmol) and DBU (1.2 ml, 8.02 mmol) were added and the solution was stirred at -20 °C for 
18 h. The mixture was poured into saturated aqueous NaHCC>3 solution (40 ml) and extracted with 
CHCI3 (3 x 60 ml). The organic extracts were combined, dried (Na2SC>4) and evaporated in vacuo. 
Purification by column chromatography on SiC>2, eluting with light petroleum-EtOAc (1:1) {Rf
0.60), gave the title compound as a colourless solid (626 mg, 60%) with identical physical and 
spectroscopic properties.
(4,5',5,J?)-2-[2,2,5-Trimethyl-3—(teri-butoxycarbonyl)oxazolidin—4-yl]thiazoIe-^l- 
carboxylic acid (208)
LiOH monohydrate (1.53 g, 36.5 mmol) was added to a stirred solution of oxazolidine 207 (2.17 
g, 6.08 mmol) in MeOH-FhO (5:1) (200 ml) and the solution was stirred overnight. After 
evaporating in vacuo, the mixture was partitioned between aqueous HC1 (3M; 70 ml) and EtOAc 
(100 ml). The aqueous layer was further extracted with EtOAc (2 x 100 ml) and the organic 
extracts were combined, washed with brine (60 ml), dried (Na2SQ*) and evaporated in vacuo, 
gave the title compound as a colourless solid (2.08 g, 100%) mp 159-160 °C (EtOAc) (Found:
,C02MeN^CO^e
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MH+, 343.1321. C15H23N2O5S requires M ft , 343.1322) [<x] D22 -58.17 (cl.75, CHCI3); IR 
(K.Br)/cnT' 3106, 2975, 2925, 2865, 2725, 2634, 2544, 1715, 1687, 1509, 1489, 1458, 1375, 
1300, 1265, 1226, 1163, 1135, 1111, 1092, 1066, 1050, 985, 946, 859, 844, 775, 752, 698; 'H 
NMR (400 MHz; CDCI3) 5 8 . 6 8  (1H, bs, OH), 8.18 (1H, s, 5-H), 4.75 (1H, d, J  7.0, 4’-H), 4.12 
(1H, m, 5’-H), 1.58 (6 H, s, 2’-2Me), 1.34 (3H, d, J6 .0 , 5’-Me), 1.20 (9H, bs, CMe3); l3C NMR 
(100 MHz; CDCI3) 8 174.0 (C), 164.7 (C), 151.3 (C), 145.7 (C), 129.0 (CH), 95.4 (C), 81.0 (C),
77.8 (CH), 65.9 (CH), 28.7 (Me), 26.5 (Me), 25.9 (Me), 17.8 (Me); m/z (ES) 341 ([M-H"|, 
100%), 297 (50).
(4”S,5' ’J?)-Ethyl 3-{2-[2^,5-trimethyl-3-(terf-butyIoxycarboiiyI)oxazolidin-4-yI]thiazol- 
4-yl}-3-oxopropanoate (210)
Method A:
i.) Methyl magnesium bromide in THF (3M; 0.33 ml, 1.0 mmol) was added to a stirred 
suspension of potassium ethyl malonate (170 mg, 1.0 mmol), in dry THF (3 ml) at 0 °C. The 
mixture was stirred at 0 °C for 30 min then rapidly warmed to RT and stirred for a further 1.5 h.
ii.) Ethyl chloroformate (0.05 ml, 0.55 mmol) was added dropwise to a stirred solution of 
oxazolidine 208 (176 mg, 0.51 mmol), Et3N (0.1 ml, 0.72 mmol) in dry THF (3 ml) at 0 °C and 
stirred for 20 min. The solution from i.) was added and stirred for 3.5 h, the reaction was 
quenched with saturated aqueous NH4CI (15 ml) and evaporated in vacuo. The residue was 
partitioned between H2O (20 ml) and CHCI3 (30 ml), the aqueous layer was further extracted with 
CHCI3 (2 x 30 ml) and the combined organic extracts were washed sequentially with acetic acid 
(5% w/v; 20 ml), saturated aqueous NaHCC>3 (25 ml) and brine (20 ml), dried (Na2SC>4) and 
evaporated in vacuo. Purification by column chromatography on SiC>2, eluting with light 
petroleum-EtOAc (1:1) (R/0.70), gave the title compound as a brown oil (128 mg, 58%) (Found: 
MH*, 413.1737. C 19H29N2O6S requires MH*, 413.1741) [a ] D24 -31.0 (c2.5, CHCb); IR (film)/cnT 
1 Vmax 3115, 2979, 2935, 1740, 1704, 1631, 1479, 1366, 1258, 1219, 1136, 1091, 1035, 984, 936, 
857, 756, 6 6 6 ; 'H NMR (400 MHz; CDCb) 8  12.0 (0.4H, s, OH), 8.10 (0.6H, s, 5’-H), 7.70 
(0.4H, s, 5’-H), 5.95 (0.4H, s, 2-H), 4.7 (0.4H, bs, 4” -H), 4.6 (1H, m 5” -H), 4.2 (0.8H, q, J  7, 
OCH2Me), 4.1 (1.2H, q, J  7, OCH2Me), 4.1 (0.6H, bs, 4” -H), 4.05 (0.6H, d, J  16, 2-HH), 3.95 
(0.6H, d , J  16, 2-HH), 1.7-1.0 (18H, 2” ,2” ,5” -M e a n d  CMe3), 1.3 (1.2H, t ,  J  7, CH2Me), 1.2
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(1.8H, t, J l ,  CH2Me); ,3C NMR (100 MHz; CDC13) 5 187.5 (C), 173.4 (C), 172.4 (C), 171.2 (C),
167.5 (C), 166.6 (C), 164.8 (C), 153.4 (C), 152.3 (C), 151.3 (C), 149.6 (C), 125.9 (CH), 120.1 
(CH), 95.3 (C), 95.2 (C), 94.8 (C), 89.5 (CH), 81.2 (C), 80.7 (C), 80.5 (C), 65.9 (CH), 65.7 (CH),
62.1 (CH2), 61.6 (CH2), 61.5 (CH2), 61.2 (CH2), 60.4 (CH2), 49.0 (C), 46.9 (CH2), 41.7 (CH2),
29.1 (C), 28.1 (C), 26.5 (Me), 26.2 (Me), 26.1 (Me), 25.4 (Me), 17.6 (Me), 14.4 (Me), 14.3 (Me),
14.1 (Me), 14.0 (Me), 14.0 (Me); m/z (ES) 435 (M+Na+, 37%), 313 (100).
Method B:
i.) n-BuLi in hexanes (2.5 M; 4.0 ml, 10.0 mmol) was added dropwise to a stirred solution of 
diisopropylamine (1.40 ml, 10.0 mmol) in diy THF (10 ml) at 0 °C and stirred for 10 min. The 
solution was cooled to -78 °C and dry EtOAc (0.49 ml, 5.01 mmol) was added dropwise and 
stirred for 30 min.
ii.) Ethyl chloroformate (0.52 ml, 5.5 mmol) was added dropwise to a stirred solution of 
oxazolidine 208 (1.70 g, 4.96 mmol), Et3N (0.76 ml, 5.46 mmol) in dry THF (10 ml) at 0 °C and 
stirred for 1.5 h. The mixture was filtered and added dropwise to i.), stirred at -78 °C for lh, 
warmed to RT whilst stirring for a further 2 h, the reaction was quenched with saturated aqueous 
NaHC03 (60 ml) and evaporated in vacuo. The residue was partition between H20  (60 ml) and 
EtOAc (120 ml), the aqueous layer was further extracted with EtOAc (2 x 40 ml) and the 
combined organic layers were washed with brine (60 ml), dried (Na2S0 4 ) and evaporated in 
vacuo. Purification by column chromatography on Si02, eluting with light petroleum-Et20  (1:1) 
(R f  0.56), gave the title compound as a brown oil (333 mg, 16%), with the same spectroscopic 
properties.
(4’*S,,5,l?)-2-(2,2,5-trimethyl-3-te/,f—butoxycarbonyIoxazolidin-4-yl)thiazole-4— 
carboxamide (212)
A saturated solution of methanolic ammonia (20 ml) was added to ester 207 (160 mg, 0.45 mmol) 
and stirred at room temperature for 18 h. The mixture was evaporated in vacuo, purification by 
column chromatography on Si02, eluting with light petroleum-EtOAc (1:1) (R f  0.21), gave the 
title compound as a colourless solid (153 mg, 100%), mp 55-56 °C (EtOAc) (Found: MH+ 
342.1485. C15H24N3O4S requires MH*, 342.1482); [a ] D24 -49.0 (cl.02, CHC13); IR (KBr)/cm"‘
N .C02Me N CONH2
vmax 3465, 2979, 2925, 1701, 1591, 1458, 1367, 1308, 1261, 1173, 1135, 1089, 984, 946, 857,
158
Chapter 6 <PhSD. Thesis 2006 •ExperimentaC
757; 'H NMR (500 MHz; CDCI3) S 8.06 (1H, s, 5-H), 7.08 (1H, bs, NH//) 6.39 (0.6H, bs, N//H), 
6.26 (0.4H, bs, N//H), 4.65 (0.4H, bs, 4’-H), 4.57 (0.6H, d, J7.3, 4’-H), 4.13 (1H, m, 5’-H), 1.62 
(6 H, s, 2’-2Me), 1.36 (3H, d ,75.0 , 5’-Me), 1.12 (9H, s, CMe3); 13C NMR (125 MHz; CDCI3) 8
172.1 (C), 171.2 (C), 163.1 (C), 149.1 (C), 124.0 (CH), 95.3 (C), 81.3 (C), 77.6 (CH), 65.8 (CH),
28.3 (Me), 26.5 (Me), 25.5 (Me), 21.1 (Me) ; m/z (ES) 364 (M+Na+, 36%), 242 (100).
Phosphorous oxychloride (0.1 ml, 1.07 mmol) was added dropwise to a cold (0 °C) solution of 
thiazole 212 (153 mg, 0.45 mmol) in pyridine ( 8  ml). The solution was warmed to RT and stirred 
for 2 h and evaporated in vacuo. Purification by column chromatography on Si0 2 , eluting with 
light petroleum-EtOAc (1:1) (R/ 0.66), gave the title compound as a brown oil (112 mg, 77%) 
(Found; MH+, 324.1376. C15H22N3O3S requires MH*, 324.1376); [a ] D23 -66.38 (c0.93, CHCI3); 
IR (film)/cm_1 3020, 1703, 1369, 1215, 1135, 932, 760, 6 6 8 ; 'H NMR (400 MHz; CDCI3) 8 
7.95 (1H, bs, 5-H), 4.72 (0.5H, m, 4’-H), 4.65 (0.5H, m, 4’-H), 4.13 (0.5H, m, 5’-H), 4.10 
(0.5H, m, 5’-H), 1.65 (6 H, s, 2’-2Me), 1.40 (3H, d, J  6.0, 5’-Me), 1.96 (9H, s, CMe3); l3C NMR 
(100 MHz; CDCI3) 8  174.5 (C),173.1 (C), 152.3 (C), 151.1 (C), 130.3 (CH), 126.3 (C), 113.8 (C),
95.5 (C), 95.0 (C), 81.5 (C), 81.0 (C), 77.4 (CH), 76.7 (CH), 65.8 (CH), 65.4 CH), 28.1 (Me),
26.5 (Me), 26.2 (Me), 25.8 (Me), 17.9 (Me), 17.7 (Me); m/z (APcI) 324 ([M-H*], 3%).
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